 
PROTOCOL  
CoVP N 3006 
A randomized controlled study to assess SARS CoV-2 
infection , viral shedding , and subsequent potential 
transmission  in individuals  immunized with Moderna 
COVID -19 Vaccine  
DOCUMENT ID 38822  
Non-IND Study  
CLINICAL TRIAL SPONSORED BY  
  National Institute of Allergy and Infectious Diseases (NIAID)  
National Institutes of Health (NIH)  
Department of Health and Human Services (DHHS)  
Bethesda, Maryland, USA  
May 20, 2021 
Final  
CoVPN 3006  
Version 4.0 

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 2 of 166 Contents  
1 Overview  ................................ ................................ ................................ ........................ 5 
1.1 Protocol Team  ................................ ................................ ................................ 8 
2 Backgroun d ................................ ................................ ................................ .................. 10 
2.1 Rationale for trial concept  ................................ ................................ ............ 10 
2.2 Measures of vaccine efficacy  ................................ ................................ .......11 
2.3 Importance of understanding vaccine effects on infectiousness and 
transmissibility  ................................ ................................ ............................. 13 
2.4 Limitations of the current Phase 3 trials for addressing unanswered 
questions  ................................ ................................ ................................ .......16 
2.5 Burden of SARS -CoV -2 infection and COVID -19 disease among students
 ................................ ................................ ................................ ...................... 18 
2.6 Age and Asymptomatic Infection  ................................ ................................ 19 
2.7 Evidence for viral load as a predictor of infectiousness  ............................... 20 
2.8 Evidence for viral load as a marker of COVID -19 disease severi ty and 
clinical course  ................................ ................................ ............................... 21 
2.9 Methods for capturing transmission  ................................ ............................. 21 
2.10  Moderna COVID -19 Vaccine  ................................ ................................ ......23 
2.11  Trial desi gn rationale  ................................ ................................ .................... 24 
3 Objectives and endpoints  ................................ ................................ ............................. 28 
4 Ethical considerations  ................................ ................................ ................................ ..32 
5 IRB/EC review considerations  ................................ ................................ ..................... 34 
5.1 Minimized risks to participants  ................................ ................................ ....34 
5.2 Reasonable risk/benefit balance  ................................ ................................ ...34 
5.3 Equitable participant selection  ................................ ................................ .....35 
5.4 Appropriate informed consent  ................................ ................................ ......35 
5.5 Adequate safety  monitoring  ................................ ................................ ......... 35 
5.6 Protect privacy/confidentiality  ................................ ................................ .....36 
6 Statistical considerations  ................................ ................................ .............................. 37 
6.1 Accrual and sample size calculations  ................................ ........................... 39 
6.2 Role of the Independent Data Monitoring Committee (IDMC)  ................... 44 
6.3 Randomiza tion ................................ ................................ ............................. 45 
6.4 Statistical analyses  ................................ ................................ ........................ 45 
7 Select ion and withdrawal of participants  ................................ ................................ .....54 
7.1 Inclusion criteria for Main Cohort, Immediate Vaccination Group and 
Standard of Care Group  ................................ ................................ ................ 54 
7.2 Exclusion criteria for Main Cohort, Immediate Vaccination Group and 
Standard of Care  Group  ................................ ................................ ................ 55 
7.3 Inclusion criteria for Main cohort, Vaccine Declined Group  ....................... 56 
7.4 Exclusion criteria for Main cohort, Vaccine Declined G roup...................... 56 
7.5 Inclusion criteria for Prospective Close Contact (PCC) cohort  ................... 57 
7.6 Inclusion criteria for Case -ascertained Close Contact  (CACC) cohort  ........ 57 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 3 of 166 8 Study product  ................................ ................................ ................................ ............... 58 
8.1 Vaccine regimen  ................................ ................................ ........................... 58 
8.2 Storage, handling, preparation, and administration  ................................ ......58 
8.3 Acquisition of Moderna COVID -19 Vaccine  ................................ .............. 58 
9 Clinical procedures  ................................ ................................ ................................ ......60 
9.1 Informed consent  ................................ ................................ .......................... 60 
9.2 Pre-enrollment procedures for Main Cohort  ................................ ................ 62 
9.3 Enrollment an d vaccination visits for Main Cohort,  Immediate Vaccination 
Group  ................................ ................................ ................................ ............ 62 
9.4 Follow -up procedures for Main Cohort, Immediate Vaccination Group  .....63 
9.5 Enrollment (visit 2) and Month 2 (visit 4) Visits for Main Cohort, Standard 
of Care and Vaccine Declined Groups  ................................ ......................... 63 
9.6 Month 4 (visit 5) and Month 5 (visit 6) Visits for Main Cohort, Standard of 
Care Group and Vaccine Declined Group  ................................ .................... 64 
9.7 Procedures for Main Cohort participant diagnosed with a SARS -CoV -2 
infection during the study  ................................ ................................ ............. 65 
9.8 Enrollment and follow -up procedures for Prospective Close Contact (PCC) 
cohort  ................................ ................................ ................................ ............ 65 
9.9 Enrollment and Follow -up procedures for Case -Ascertained Close Contact 
(CACC) cohort  ................................ ................................ ............................. 66 
9.10  Visit windows and missed visits  ................................ ................................ ..67 
9.11  Discontinuing vaccination for a participant who receives a COVID -19 
Vaccine outside th e study  ................................ ................................ ............. 67 
9.12  Early termination visit  ................................ ................................ .................. 68 
9.13  Pregnancy for Main Cohort  ................................ ................................ .......... 68 
9.14 SARS -CoV -2 monitoring by schools for Main Cohort, if applicable  .......... 68 
9.15  COVID -19 symptom surveillance for Main Cohort  ................................ ....68 
9.16  Use of electronic Diary (eDiary) for Clinical Outcomes Assessments  ........ 68 
10 Laboratory  ................................ ................................ ................................ .................... 71 
10.1  CRS laboratory procedures  ................................ ................................ .......... 71 
10.2 Total blood volume  ................................ ................................ ...................... 71 
10.3  Endpoint assays  ................................ ................................ ............................ 71 
10.4  Lab assay portfolio  ................................ ................................ ....................... 72 
10.5  Exploratory studies  ................................ ................................ ....................... 72 
10.6  Specimen storage and other use of specimens  ................................ ............. 73 
10.7  Biohazard containment  ................................ ................................ ................. 73 
11 Safety Reporting  ................................ ................................ ................................ .......... 74 
11.1  FDA/CDC Vaccine Adverse Event Reporting System (VAERS)  ............... 74 
11.2  Reporting safety events to v -safe ................................ ................................ .75 
12 Protocol conduct  ................................ ................................ ................................ .......... 76 
12.1  Study termination  ................................ ................................ ......................... 76 
12.2  Emergency commu nication with study participants  ................................ ....77 
13 Version history  ................................ ................................ ................................ ............. 78 
14 Document references (other than literature citations)  ................................ .................. 84 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 4 of 166 15 Acronyms and abbreviations ................................ ................................ ........................ 86 
16 Literature cited  ................................ ................................ ................................ ............. 88 
Appendix A  Sample informed consent form for Main cohort, Immediate Vaccination and 
Standard of Care Groups  ................................ ................................ .............. 93 
Appendix B  Sample informed consent f orm for Main cohort, Vaccine Declined Group
 112 
Appendix C  Sample informed consent form for Prospective Close Contact (PCC) cohort
 135 
Appendix D  Sample informed consent form for Case -Ascertained Close Contact 
(CACC) cohort  ................................ ................................ ........................... 147 
Appendix E  Procedures for Main Cohort, Immediate Vaccination Group  .................... 159 
Appendix F  Procedures for Main Cohort, Standard of Care and Vaccine Declined 
Groups  ................................ ................................ ................................ ........ 161 
Appendix G  Procedures for Prospective Close Contact (PCC) cohort  ........................... 163 
Appendix H  Procedures for Case -Ascertained Close Contact Cohort  ............................ 164 
Appendix I  Visit windows  ................................ ................................ ............................. 165 
Appendix J  Protocol Signature Page  ................................ ................................ ............. 166 
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 5 of 166 1 Overview  
Title  
A randomized controlled study to assess SARS CoV -2 infection, viral shedding, 
and subsequent potential transmission in individuals immunized with Moderna 
COVID -19 Vaccine  
Primary objective(s)  
Primary objective 1:  
To evaluate the efficacy of Moderna COVID -19 Vaccine  against SARS -CoV -2 
infection (ie, to evaluate vaccine efficacy against infection or VE S) 
Primary objective 2:  
To evaluate the effect of Moderna COVID -19 Vaccine  on peak nasal viral load as 
a measure of infection and a proxy of infectiousness  
Study product  and route of administration  
Moderna COVID -19 Vaccine : a lipid nanoparticle ( LNP ) dispersion of a 
messenger ribonucleic aci d (mRNA ) encoding the prefusion stabilized S protein 
of SARS -CoV -2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 
comme rcially available). The Moderna COVID -19 Vaccine , also known as 
mRNA -1273, is a suspension for intramuscular injection admi nistered as a series 
of two doses (0.5 mL each) 1 month apart.  
This vaccine has been issued an Emergency  Use Authorization ( EUA ) by the US 
Food and Drug Administration (FDA) for active immunization to prevent 
COVID -19 in individuals 18 years and older .  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 6 of 166 Table 1-1 Schema  for the Main Cohort  
  Injection schedule in months  
Group  N 0 1 4 5 
Randomized  
Groups       
Immediate 
Vaccination1 Up to 
6000  Moderna 
COVID -19 
Vaccine  Moderna 
COVID -19 
Vaccine  - - 
Standard of 
Care2 Up to 
6000  - - Moderna 
COVID -19 
Vaccine3 Moderna 
COVID -19 
Vaccine3 
Observational  
Group       
Vaccine 
Decline d4 Up to 
6000  - - -4 -4 
Total  Up to 18,000   
1 Immediate Vaccination Group: participants receive Moderna COVID -19 vaccine on enrollment and 
are given recommendations to follow federal, state , and local guidelines  on COVID -19 precautions 
following vaccination, such  as masking, physical  distancing, isolation and quarantine . 
2 Standard of Care  Group:  participants  are given recommendations to follow  federal, state , and local 
guidelines  on COVID -19 vaccination  and COVID -19 precautions, such  as masking, physical  
distancing, isolation and quarantine . 
3 Vaccine will be offered if participant has not received vaccine outside of the study . 
4 Vaccine Decline d Group includes participants  who prefer not to be vaccinated . If requeste d, 
participant will be offered  vaccine if they have not received vaccine outside of the study  
Participants  
Main Cohort  (main study participants)  
Up to approximate ly 18,000 healthy v olunteers , aged 18 through 29 years , who 
will be followed  for up to 5 months after enrollment ; up to 6,000  randomized to 
Immediate Vaccin ation  Group , up to 6,000 randomized to Standard of Care 
Group , and up to 6,000  non-randomized to Vaccine Declined Group . 
Prospective Close C ontact (PCC) Cohort   
Up to  approximately  36,000 volunteers who are in frequent close physical 
proximity with main study participants  
Case-Ascertained Close  Contact (CACC) Cohort   
Approximately  3 contacts per incident case. Actual number depend ent on 
incidence ra te. Up to approximately  2250  volunteers  aged 18 years and older who 
have been in close contact  with a SARS -CoV -2 positive case from the Main 
Cohort   
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 7 of 166 Design  
Multicenter, randomized , controlled , open -label  trial augmented by an 
observational cohort  
Duration per participant  
Up to 5 months per participant for the Main Cohort and for the Prospective Close 
Contact Cohort . 1 month  per participant in Case -Ascertain ed Close Contact 
Cohort . 
Estimated total study duration  
9 months (includes  enrollment  and follow -up). 
Core operations  
CoVPN  Vaccine leadership Group/Core Operations Center, Fred Hutchinson 
Cancer Research Center ( Fred Hutch ) (Seattle, Washington, USA)  
PPD, Inc.  (Wilmington, N orth Carolina, USA )  
Statistical and Data Management Center (SDMC)  
Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutch  
(Seattle, Washington, USA)  
Laboratory Center (LC)  
Endpoint  assay laboratories   
• University of Washington Virology Laboratory ( UW-VL) (Seattle, 
Washington, USA)  
• Univers ity of Washington Virology Specialty Laboratory (UW -VSL) (Seattle, 
Washington, USA)  
• Pioneer Hi -Bred International, Inc ., a member of the Corteva Agriscience 
group of Companies (Johnston, Iowa , USA)  
• Duke University Medical C enter (Durham, North Carolina, US A) 
• CoreMedica Labs ( Lee’s Summit, Missouri, USA)  
Study sites  
Clinical research sites (CRSs) across the US  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 8 of 166 Study  monitoring  
Independent Data Monitoring Committee (IDMC)   
 
1.1 Protocol Team  
Protocol leadership  
Co-chairs Kathryn Stephenson  
Harvard University Sch ool of 
Medicine  
Beth Israel Deaconess Medical 
Center  
617-735-4556  
kstephen@bidmc.harvard.edu  
 
Audrey Pettifor  
Department of Epidemiology  
Gillings School of Global Public 
Health  
University of North Carolina  
919-966-7439  
apettif@email .unc.edu  
 
Jasmine Marc elin 
Division of Infectious Diseases  
University of Nebraska Medical 
Center  
402-559-8650  
jasmine.marcelin@unmc.edu  Protocol Lead 
Advisors  Larry Corey  
CoVPN  LOC , Fred Hutch  
206-667-6770  
lcorey@fredhutch.org  
 
Myron Cohen   
University of North Carolina  
919-966-2537  
myron_cohen@med.unc.edu  
 
James  Kublin  
CoVPN  LOC, Fred Hutch  
206-667-1970  
jkublin@fredhutch.org  
 
Statistician s Holly  Janes  
CoVPN SDMC , Fred Hutch  
206-667-6353  
hjanes@fredhutch.org  
 
Elizabeth Brown  
CoVPN  SDMC , Fred Hutch   
206-667-1731  
erbrown@fredhutc h.org  Laboratory lead  John Hural  
CoVPN  Laboratory Program  
206-667-1683  
jhural@fredhutch.org  
Protocol 
Team leader  Nicole Grunenberg  
CoVPN  LOC , Fred Hutch  
206-667-2043  
ngrunenb @fredhutch .org DAIDS Medical 
Officer  Catherin e Yen 
DAIDS, NIAID  
240-292-4783  
catherine.yen@nih.gov  
 
  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 9 of 166 Other contributors to the original protocol  
Core medical monitor  Nicole Grunenberg  
CoVPN  LOC , Fred 
Hutch  CoVPN  Physician 
consultant  Nzeera Ketter  
CoVPN  LOC , Fred 
Hutch  
Laboratory consultants  Alexander Greninger  
Robert Coombs  
Univer sity of 
Washington Medical 
Center  (UWMC)  
Keith Jerome  
Fred Hutch, UWMC   Clinical safety 
specialists  Megan Jones  
Maija Anders on 
CoVPN  LOC , Fred 
Hutch  
Laboratory center 
representatives  Nicole Espy  
Lisa Sanders   
Jen Hanke  
CoVPN  Laboratory 
Center , Fred Hutch  Clinical trials manager  Julie Hunt  
CoVPN  LOC , Fred 
Hutch  
Regulatory affairs  
associate  Megan Brandon  
CoVPN  LOC , Fred 
Hutch  Clinical data  manager s Melissa Cummings  
Vicky Kim  
CoVPN  SDMC , Fred 
Hutch  
Community Advisory 
Board (CAB) members  John Isaac  
Boston Un iversity  SDMC Associate 
Director of Operations  Jessica Andriesen  
CoVPN  SDMC , Fred 
Hutch  
Statistical research 
associate s Erika Rudnicki  
Moni Neradilek  
CoVPN  SDMC , Fred 
Hutch  SDMC Associate 
director of lab science  April Randhawa  
CoVPN  SDMC , Fred 
Hutch  
Comm unity engagement  
unit representative  Francisco E Rentas  
CoVPN  LOC , Fred 
Hutch  Data M anagemen t 
Director  Kristine Donaty  
CoVPN  SDMC , Fred 
Hutch  
Project coordinator  Kylie McCloskey   
CoVPN  LOC , Fred 
Hutch  Protocol development 
managers  Kajari Mondal  
Meg Trahey  
CoVPN  LOC , Fred 
Hutch  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 10 of 166 2 Background   
2.1 Rationale for trial concept  
The United States has the most infections and deaths from SARS -CoV -2 (the 
virus that causes Coronavirus disease 2019 [COVID -19]) of any nation in the 
world  (1). Fortunately, there is now hope that the large burden of COVID -19-
related illnes s may lessen in 2021 due to the discovery that candidate  COVID -19 
vaccines, including the Moderna  COVID -19 Vaccine , can prevent symptomatic 
COVID -19 and severe disease in adults  (2, 3) . Ongoing  Phase 3  trials are n ot 
designed  to estimate a vaccine’s efficacy against all infection s, with a cri tical gap 
being asymptomatic infections . The current trials are also  not designed to evaluate 
vaccine effects on infectiousness as measured by viral shedding or on onward 
transm ission of infection . For example, at an individual level, it is currently 
unknown if vaccinated individuals should continue to wear masks or social 
distance, or if they should be quarantined if exposed to COVID -19. At a policy 
level, it is unknown if vacci nation should be required for cert ain settings, such as 
public transit including air travel, places of employment , or school . These 
questions are  especially important given that SARS -CoV-2 is highly infectious  
compared to other respiratory illnesses such a s the flu.  Recent data also 
demonstrate that even individu als with asymptomatic  COVID -19 can have high 
titers  of nasal viral shedding  and thus  may be highly infectious . Furthermore, 
many individuals with asymptomatic infection  develop low level and transie nt 
antibodies  against SARS -CoV -2 (4), suggesting that  trials  relying on 
seroconversion as a marker  of infection may miss infections .  
While there are many populations at risk for SARS -CoV -2 infection, young 
people are particularly at risk of acquiring  and transmitting  SARS -CoV -2. 
Between August and September 2020, COVID -19 cases among young people 
aged 18-22 years increased 55% nationally (5) and during June -August 2020, 
young people aged 20-29 years  had the highest incidence of disease in the US , 
accounting  for >20% of all confirmed cases (6). Further, increases in SARS -CoV -
2 infection among younger adults in the Southern US preceded  increases among 
older adults by 4 -15 days, which confirms the importance of younger adults 
spreading infection to older, more vulnerable populations (5). At the same time, 
individuals aged 18 -29 account for a tiny  percentage (0.5%) of all deaths due to 
COV ID-19 and are very unlikely to develop severe disease (7). These reasons 
plus the congregate and social living situations of students  and that many schools 
are regu larly testing their student body make them an excellent population to 
examine . The proposed study is designed to evaluate comprehensively the vaccine 
efficacy profile of the Moderna COVID -19 Vaccine, including its effect on 
acquisition of infection includi ng asymptomatic infection, on disease and severity 
of disease, on measures of i nfectiousness, and transmission of infection.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 11 of 166 This study is a 2-arm randomized, open -label trial in adults aged 18 through 29 
years  augmented with an observational cohort  that will compare those who are 
randomized to receive the Moderna COVID -19 Vaccine up on enrollment 
(Immediate Vaccination Group ) to those who are randomized to receive the 
vaccine 4 months later ( Standard of Care Group ) and those who prefer not to be 
vaccinated (Vaccine Declined Group). The study will capture all incident 
SARS -CoV -2 infections among study participants in real time, by 
establishing real-time testing for SARS -CoV -2 on st udy and augmenting  with  
all available data from school testing or community tes ting. Study participants 
will be asked to collect daily nasal swabs, to enable ascertainment of the timing of 
acquisition and to capture the full viral load trajectory for incident infections. To 
capture secondary transmission events, very close contacts o f study  participants 
will be enrolled who may undergo  school or other community  testing  for incident 
infection over the duration of the study (‘prospective contacts’); in addition, 
diagnosis of infection among a study participant will trigger recruitment o f 
addit ional participant contacts (‘case -ascertained close contacts’). When a study 
participant tests positive based on testing of study -collected nasal swab s, school 
testing, or community testing , both prospective contacts and case -ascertained 
close conta cts wil l be asked to collect daily nasal swabs for 14 days to detect 
incident infection and also will have blood collected for serology. At the end of 
the trial, all participants in the Standard of Care and Vaccine Declined Groups 
will be offered vaccine  if they have not already been vaccinated in their 
communities . The goal of the study is to report results to inform  public policy 
including guidance on masking and physical distancing indoors.  
2.2 Measures of vaccine efficacy  
Ongoing Phase 3 COVID -19 vaccine t rials are designed with the primary 
objective to evaluate vaccine efficacy  against COVID -19 disease, written VE D, 
and defined as the multiplicative  reduction in risk of dis ease in the vaccine vs. 
placebo groups. COVID -19 disease is defined by a protocol -specified set of signs 
and symptoms of disease coincident with PCR -confirmed SARS -CoV -2 infection . 
While the reduction in risk of disease is arguably the most relevant vaccine effect  
to the individual participant, understand ing the population effect of a vac cine 
requires considering the other effects of the vaccine ( see Table 2-1) (8). The most 
fundamental  effect of a vaccine is to reduce acquisition of infection , sometimes 
referred to as ‘ vaccine efficacy against susceptibility’ , written VE S, and measured 
by the multiplicative reduction in PCR -confirmed infection in the vaccine vs. 
placebo group . A vaccine that reduces acquisition of infection will provide benefit 
to the individual  (i.e. direct effects) , as well as benefit to the population by 
reducing the number of infected and therefore potentially infectious  individuals 
who may expose and infect  unvaccinated individuals in the population  (i.e. 
indirect  effects ). Modeling studies suggest t hat COVID -19 vaccines that reduce 
acquisition are predicted to have considerably greater population impact , not only 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 12 of 166 reducing disease, hospitalizations, an d mortality, but reducing transmission of 
infection and thereby magnifying their effects (9, 10) . 
An additional potential indirect effect of a vaccine is its effect on reducing 
secondary transmission of infection, written VE I and defined as the multiplicative 
reduction in the rate of secondary transmission among v accine vs. placebo 
individuals who be come SARS -CoV -2 infected. A vaccine might reduce 
transmission through reducing the magnitude and/or duration of viral shedding, 
by reducing symptoms associated with transmission such as coughing, or by 
selectively block ing infection with less transmissible  viral strains.  Evaluating the 
effect of a COVID -19 vaccine on transmissibility is critical because a vaccine 
with high  efficacy against  COVID -19 disease but low efficacy against SARS -
CoV -2 infection  would necessarily y ield a net increase in the number of 
asymptomatic infections.  If individuals who become asymptomatically infected 
despite having received the vaccine are still infectious, and given that 
asymptomatic individuals are less likely to be dia gnosed and self -isolate, such a 
vaccine  has the potential to increase transmission and prolong the pandemic (2, 
3). 
As we prepare this study , we recognize there are other approaches to measuring 
population level benefit (eg, vaccine effect on infection and  transmissibility ). 
These approaches include : observational studies , such as those being conducted in 
Israel to examine population benefit of the vaccine  and those planned by the CDC 
to examine transmission from vaccinated individual s to household contacts in 
longitudinal cohorts ; and ancillary studies with frequent swabbing on a s ubset of 
participants in Phase 3 studies. However, none of these studies will allow for the 
rigorous capture, through daily nasal swabbing, of the early dyn amics of viral 
replication and the capture of transmission events during the acute period of 
infecti on in a randomized trial .  
All of these vaccine  salutatory  effects may depend on a variety of individual 
characteristics such as age, prior infection with SARS -CoV -2; on virological 
characteristics ; and in the case of VE I which conditions  on infection , may depend 
on clinical characteristics such as symptomatology.  
As will be discussed below in detail, the ongoing Phase 3  trials evaluate VE D and 
partially ide ntify VE S, but do not allow direct estimation of VE I. In contrast, the 
proposed study will collect data to enable evaluation of all three vaccine efficacy 
parameters  in the participant population . Importantly, the use of an open -label 
Standard of Care Grou p as opposed to a blinded placebo arm , implies that the 
various effects e valuated will  capture not only biological vaccine effects, but also 
potential behavioral effects associated with  vaccin ation , including potential 
behavioral disinhibition . Behavioral effects most plausibly influence exposure and 
therefore infection, but knowledge of va ccine receipt is viewed as less likely to 
influence disease, viral load, and secondary transmission.  
CoVP N 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 13 of 166 Table 2-1 Population m easu res of vaccine efficacy that will be evaluated using the proposed 
study , where a Standard of  Care Group  will be used instead of placebo  
Efficacy measure  Definition  
Vaccine efficacy against 
SARS -CoV -2 infection 
(VE S) The multiplicative reduction in SARS -CoV-2 infection as 
measured by PCR of nasal swabs, vaccine vs. placebo  
Vaccine efficacy against 
COVID -19 disease (VE D) The multiplicative reduction in symptomatic COVID -19*, 
vaccine vs. placebo  
Vaccine efficacy against viral 
replication (VE VL) The r eductio n in SARS -CoV -2 viral burden as measured by 
PCR of nasal swabs, vaccine vs. placebo  
Vaccine efficacy against 
transmission (VE I) The multiplicative reduction in rate of SARS -CoV -2 
transmission from infected individuals on the vaccine arm 
relative to the pl acebo arm  
*Defined by a protocol -specific set of signs and symptoms defined in Section  3. 
2.3 Importance of understanding vaccine effects on infectiousness and 
transmissibility  
The most effective way for a vaccine to prevent onward  transmission of infection 
is to prevent acquisition o f infection. Vaccine efficacy against infection, VE s, is a 
measure of this effect (8). However, a vaccine that does not completely block 
acquisition of infec tion may still reduce onward transmission among  indivi duals 
who become infected despite having received the vaccine , as measured by VE I (8, 
11). As discussed above, understanding the effect of a COVID -19 vaccine on  
transmission is critical because a vaccine with high  efficacy against  COVID -19 
disease but low efficacy against SARS -CoV -2 infection  would necessarily yield a 
net increas e in the number of asymptomatic infections. If individuals who become 
asymptomaticall y infected despite having received the vaccine are still infectious, 
and given that asymptomatic individuals are less likely to be diagnosed and self -
isolate, such a vacci ne has the potential to increase transmission and prolong the 
pandemic (2, 3) .  
If a COVID -19 vaccine did reduce infectiousness, mathematical modeling 
suggests that much greater population impact could be achieved. Deterministic 
compartmental models fit to data from King County, Washington and envi sioning 
vaccine rollout starting De cember 1, 2020 to 18% of the adult population 
proportionally across age groups, suggest that while a vaccine that reduces 
COVID -19 disease by 90% and SARS -CoV -2 infection by 10% reduces total 
infections in 2021 by 18.1% a nd deaths by 27.5%, if the vaccine additionally 
reduces infectiousness by 50% the impact on infections would more than double 
(to 49.3% reduction) and deaths would be cut in half (to 50.9% reduction) (Swan 
and Dimitrov  et al, in preparation ; Figure 2-1).  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 14 of 166  
Figure 2-1 COVID -19 vaccine that reduces infectiousness by 50% has greater impact on 
infections and deaths.  Deterministic compartmental model calibrated to King County, WA 
stratifie d by age, SARS -CoV-2 infection status, COVID -19 treatment status and vaccination. 
800,000 doses vaccine (for 18% of population) starting Dec 1, 2020, allocated proportionally across 
age groups. Absent vaccination, 20%  of infections are asymptomatic; asympt omatic infections are 
28% less infectious than symptomatic infections, but more transmissible due to lower rates of 
diagnosis and quarantine. Both vaccines reduce COVID -19 disease by 90% and SARS -CoV-2 
infection by 10 %. While one vaccine (light blue) does not reduce infectiousness among individuals 
who become infected, the other vaccine (dark blue) reduces infectiousness by 50%. As a result, it 
achieves a much greater reduction in both infections and deaths. (Swan, Dim itrov et al , in 
preparation) . 
In the co ntext of limited vaccine supply, mathematical modeling also suggests 
that optimal allocation of vaccine depends on how well a vaccine reduces 
infectiousness. Take, for instance, a d eterministic  compartmental  model cal ibrated 
to Washington State  that uses t he following assumptions: that, absent vaccination, 
40% of infections are asymptomatic , asymptomatic infections confer equal 
immunity and are equally infectious , and that there is sufficient vaccine supply for 
30% of the population. For a vaccine that redu ces COVID -19 disease by 90% but 
has no effect on infection or infectiousness, the limited supply of vaccine should 
be allocated to older adults who have a high burden of disease in order to 
minimize deaths and peak ho spitalizations ( Figure 2-2). However, if the vaccine 
also reduces infectiousness by 60%, minimizing peak hospitalizations is achieved 
by allocating limited vaccine to the young, while minimizing deaths still requires 
vaccinating older adults. These results again highlig ht the critical importance of 
understanding vaccine effects on acquisition and infectiousness in order to make 
policy decisions.  

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 15 of 166  
Figure 2-2 Deterministic  compartmental  model calibrated to Washington State ( 7.6M people), 
reflecting US demographics.  Model assumes  4.56M doses vaccine (for 30% of population) 
assuming  10% of the population is previous ly infected and immune and there are 1000 current 
infections.  Absent vaccination, 40% of infections are asymptomat ic; asymptomatic infections confer 
equal immunity (for at least 6 mo. duration) and are equally infectious. (Matrajt et al , in preparation)  
Non-human primate (NHP) data also suggests that elimination of viral shedding 
by a COVID -19 vaccine is not guarantee d. Table 2-2 shows the comparison of 
NHP data between candidate COVID -19 vaccines in current Phase 3 trials. While 
most of the vaccines were shown to prevent viremia within the lower respiratory 
tract (bronchoalveolar lavage fluid) , and thus improve markers of disease severity, 
three out of the four platforms tested did not eradicate nasal viral shedding in all 
cases.  

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 16 of 166 Table 2-2 Comparison of NHP data between Janssen Ad26, Moderna RNA, AstraZeneca 
ChimpAdOx1 and Novavax COVID -19 vaccines  
 Ad26  
One dose  
1 x1011 mRNA  
(4 weeks 
post-dose 2)  AstraZeneca/Oxford 
2.5x1010 
0, 4 week s Novavax  
2 doses 
(0,21)  
5 mcg, 50 
mcg 
Pseudovirus 
neut ralization  
(GMT)  408 1,862  5 – 40 
boost 10 - 160 No 
Live viru s assay  113 3,481   16,026  
Spike protein  15,000  
(not 
shown)  36,186 
(AUC)   335,017  
Lung BAL 
protection  Complete  Complete at 
day 7  75% both prime and 
boost  Complete  
Nasal protection  5/6 (83%)  7/8 0% Complete 
(12/12)  
T-cell immune 
response  Some 
CD8  No CD8+  T 
cells Not reported  CD4 and 
CD8  
Finally, not understanding relative infectivity is a huge gap in translating vaccine 
use to public health messaging. The demonstration of reduced infectivity may 
reduce vaccine hesitancy. Public health, medical personnel and organizations may 
embrace vacci nation, as well as users, if the vaccine both provides individual as 
well as family/community benefit. For individuals, knowing that a vaccine 
reduces infectivity to household and personal contacts is often a prime motiva tor 
for vaccination. Data from this  trial can facilitate this messaging as well as help 
decision -making among individuals about interactions with household members 
and attending work and school.  
2.4 Limitations of the current Phase 3 trials for addressing unan swered 
questions  
Currently, none of  the current Phase 3 vaccine efficacy trials will enable robust 
estimation of vaccine effects on infectiousness. The primary objectives for all 
trials are to evaluate vaccine efficacy ( VE) against COVID -19 disease. Second ary 
objectives include evaluating V E against seroconversion using infrequent 
serology (every 1 -6 months over 1 year, with more frequent sampling over the 
first 3 months), but this will not fully capture all infections including those that 
are asymptomatic . Estimates based on acute infection  cohorts (12) suggest that 
12-50% of asymptomatic infections might be missed using this sampling, leading 
to an unknown magnitude and direction of bias in the estimate of VE S. Dat a from 
Long et al. found  that 40% of individuals with asymptomatic RT-PCR confirmed 
SARS -CoV -2 infections  were IgG negative at 8 weeks after the acute phase of 
infection ( Figure 2-3) (4). Further, i t has been observed that asymptomatic cases 
have lower IgG titers across all antigens (including NP) ( Figure 2-4) (13). In 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 17 of 166 current trials, i nfectiousness  is not captured robustly among those who become 
infected; viral load (VL) is only measured for those who are symptomatic and 
only after the onset of symptoms. Data from the Moderna trial where nasal swabs 
were collected at the time of vaccine administration on days 0 and 28 among all 
participants suggest that the vaccine may reduce the level of nasal carriage of 
virus  (14). However, one time point does not robustly capture the full viral 
dynamics of infection, in particular , asymptomatic infe ctions. The data are  
suggestive that the vaccine may reduce viral carriage  (15). The level of viral 
shedding prior to the onset of symptoms , when most transmission occurs (16), 
will not be captured for any infected participants. Importantly, no d ata in current 
trials  are collected on onward transmission of infection and therefore VE I cannot 
be evaluated directly.   
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 18 of 166  
Figure 2-3 40% of asymptomatic individuals were IgG negative by 8 weeks post -acute 
infection (Long et al. (4). 
 
Figure 2-4 Asymptomatic Patients with COVID -19 have Lower IgG Titers Across Multiple 
Antigens Among Italian Medical Staff N>600  (13). 
2.5 Burden of SARS -CoV-2 infection and COVID -19 disease  among 
students  
The study will be conducted among eligible adults 18 through 29 years of age 
including students enrolled in post-secondary educational institutions  (eg, 
universities, vocational and technical col leges ) because these are ideal locations 
for studying SARS -CoV -2 transmission clusters. Large numbers of cases of 
COVID -19 have been reported on numerous campuses throughout the US as 
colleges and universities re-opened in fall 2020 . More than 397,000 cases were 
counted at 1, 800+ colleges and universities in fall 2020  (17, 18) . Over the time 
period July -December 11th , 2020,  more  than 85 colleges and Universiti es had 
more than 1 ,000 cases . Among these 49 campuses the cumulative attack rate from 
July to October was on average 6.2%.  These estimates are somewhat uncertain 
given the fact that the number of reported cases for some schools includes faculty, 

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 19 of 166 staff and graduate students;  however, the number of such individuals is very small 
in comparison to the number of undergraduates.  
Among 15 Association of American Universities ( AAU ) universities , and using 
data from the start of semester through September 18, 2020,  there was an 
estimated 3.7% 1 -month attack rate. The attack rate appeared to decline  over time ; 
it was 1.7% over September 19 to October 20, 2020.  Attack rates may be 
underestimated because the denominator is assumed to be all undergraduates, 
whereas some  schools had only a subset of students on campus.  These statistics 
suggest that a conservative assumption of SARS -CoV -2 incidence among US 
university  students for Fall semester 202 0 is 6%. A conservative incidence 
assumption for Spring and Summer 2021 semesters , anticipating  potential 
improvements in testing, contact tracing, social distancing measures, as well as 
vaccine rollout to priority populations outside the universit ies, is therefore 3-6%.  
The outbreaks of SARS -CoV-2 infection at college campuses have been reported 
to be associated with students residing in high density housing, socializing off 
campus, and not following social distancing guidelines  (19). In the US, it is 
estimated that 45 percent of young adults aged  18-22 years were enrolled in 
colleges and universities in 2019  (16). As such, much of the increase in cases this 
summer and fall are attributed to college students. The coll ege campuses are 
associated with a high rate of SARS -CoV -2 infection and resulting asymptomatic 
carriage due t o huge impulse to socialize as well as no fear of severe disease 
among the young students.  
2.6 Age and Asymptomatic Infection  
For this study, participants will be enrolled who are 18 through 29 years of age. 
This age range is chosen because of the high inciden ce of asymptomatic infection 
in this population. A considerable body of data suggest that SARS -CoV -2 can be 
spread by indi viduals with and without symptoms  (20-23). VL data among 
individuals with acute SARS -CoV -2 infection also indic ate that peak VL usually 
occurs before disease onset  (22, 24) . This suggests that there is a substantial 
transmission potential before symptom onset. According to the latest Centers for 
Disease C ontrol and Prevention ( CDC ) estimate 40% of SARS -CoV -2 infections 
are asymptomatic  (25). Available data indicate that younger individuals appear 
more likely to remain asymptomatic following infection  than older individuals  
(26, 27) . A recent study done in the UK showed about 80% of children  between 
10-19 years of age remain  asymptomatic (28). As infected young students  are less 
likely to show clinical symptoms, the number of  clinical  cases reported among 
young populations would be lower, but the asymptomatic young students could 
still be capable of transmitting the virus to others  (29). 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 20 of 166 2.7 Evidence for viral load as a pr edictor of infectiousness  
Math ematical  modelling in human immunodeficiency virus ( HIV) and 
herpesviruses and now COVID -19 suggests a significant percentage of 
transmission occurs from high peak VL which in all these diseases is during the 
asymptomatic peri od. Models by Josh Schiffer and Ashish G oyal suggest that a 
person has a 50% chance of infection with exposure to 107 SARS -CoV -2 RNA 
and <5% chance of infection with exposure to 105 SARS -CoV -2 RNA  (Figure 
2-5) (21). The model by  Goyal et al (21) suggests that vaccine reduction in peak 
VL may reduce infectiousness . A 0.6 log reduction corresponds to ~50% VE I and 
a 2.5 log reduction to ~90% VE I (Figure 2-6). This suggests collecting nasal 
swab s every oth er day would be required to measure the vaccine effect on peak 
VL and area under the VL curve . Asymptomatic and pre -symptomatic cases of 
SARS -CoV -2 appear to play an important role in the onward transmission of the 
virus.  
 
Figure 2-5 SARS -CoV-2 transmission probability as a function of shedding. A.  Optimal 
infectious dose (ID) response curve (infection risk = Pt) and transmission dose (TD) 
response curve (transmission risk = Pt * Pt) curves for SARS -CoV-2. Transmission 
probability is a product of two probabilities, contagiousness and infectiousness.  B-D. Three 
simulated viral shedding curves. Heat maps represent risk of transmission at each s hedding 
timepoint given an exposed contact with an uninfected person at that time .  

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 21 of 166  
Figure 2-6 Vaccine efficacy  against infectiousness versus the change in peak viral load . 
Model by Goy al et al  (personal co mmunication) .  
2.8 Evidence for v iral load as a marker of COVID -19 disease severity and 
clinical course  
Beyond infectiousness, there is a growing body of evidence su pporting a linkage 
between VL and COVID -19 disease outcome. Two Phase 2/3 trials of monoclonal 
antibodies for COVID -19 treatment in outpatient settings found that VL at 
enrollment and early after intervention was associated with future clinical 
outcomes and disease course (30, 31) . In the BLAZE -1 trial of in travenous 
infusion of the LY -CoV555 antibody, on day 7 post -infusion the frequency of 
hospitalization among patients with a high VL (Ct value of less than 27.5) was 
12% (7 of 56 patients), as compared to 0.9% (3 of 340 patients) amon g those with 
a lower VL . Numerous observational studies have also identified associations 
between VL and clinical outcomes (32). The highest quality evidence comes from 
large cohort studies. In a large hospitalized cohort, Pujadas et al (33) estimated a 
highly significant 7% increase in mortality per log10 incre ase in VL at admission, 
after adjusting for other factors associated with clinica l outcomes (p = 0.0014, 
multivariate Cox model). Chen et al (34) confirmed this finding in a larger cohort 
of patients admitted to th ree New York City hospitals. These data suggest that VL 
at and soon after the time of symptom onset may be a useful measure of disease 
severity.  
2.9 Methods for capturing transmiss ion  
Reducing transmission is key to ending/controlling the COVID -19 pandemic . Due 
to vaccination, the number of asymptomatic individuals might increase as 
vaccine -induced immune responses may lead to VL reduction. However, it is still 
to be discovered whether those individuals will continue to shed and transmit 

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 22 of 166 virus to others . Henc e, it is important to identify secondary transmissions from  
study participants to est imate secondary infections rates by arm  and to validate 
VL as a surrogate for transmission risk.  Onward  transmission of SARS -CoV -2 
infection from study participants  can be  identified  in combination with  sequence -
analysis and phylogenetics methods (35).  
Estimating vaccine efficacy in reducing transmission (VE I), requires me asuring 
transmission of SARS -CoV -2 from vaccinated and unvac cinated individuals to 
others (36, 37) . Measuring transmission of infected individuals to uninfected 
individuals is challenging, especially for transient infections where it may be 
more difficult to ascertain which  infection occurred first. For example, beca use 
HIV is not transient and per -exposure transmission is low, resulting in a 
potentially long time period of exposure, transmission can be studied in sero -
discordant sexual partnerships. In a transient infection , ideally both members of 
the transmission p air are monitored before either is infected so that timing and 
direction of transmission can be easily determined. Prospectively following a 
cohort of vaccinated and unvaccinated individuals and their close conta cts to 
observe whether infection is transmit ted from study participants to close contacts, 
or from contacts to study participants, based on frequent testing of both allows for 
better quantification of the temporality of events regarding infection transmiss ion, 
if it occurs. To do this, Datta et al. propose augmenting a randomized, controlled 
vaccine trial with a cohort of close contacts of trial participants. Both trial 
participants and the contact cohort are followed prospectively for acquisition, 
allowing  for estimation of VE I. Another approach to capturing transmission 
events is a case ascertainment design (38, 39) . Under this design, contacts of 
index cases are enrolled and tested as the cases emerge over time. A  similar case 
ascertainment design was used for a recent household study for SARS -CoV -2 
prevention. In the HCQ PEP trial, which was a household -randomized, double -
blind, controlled trial of hydroxychloroquine postexposure prophylaxis to prevent 
acquisition  of SARS -CoV -2 among close contacts recently exposed to persons 
diagnosed with SARS -CoV -2 infection, individuals were self -referred from 
infected individuals and enrolled online and all study procedures were done 
remotely including infor med consent and dai ly self -nasal swabbing for 14 days 
(40). A case -ascertained approach is more resource -efficient than a prospective 
contact approach which requires enrollment of a large number of contacts, most 
of whom w ill not bec ome infected nor have an infected index case in the main 
study. Because contacts are only identified and tested after index case diagnosis, 
the case -ascertained approach also enables assessment of secondary transmission 
in contacts not participa ting in fre quent, prospective testing programs. However, 
the case -ascertained approach has the potential to miss or misclassify transmission 
events given the gap between diagnosing an index case and identifying, enrolling, 
and testing a contact. Index case s may also experience stigma when identifying 
contacts at the time of diagnosis, as opposed to when identifying contacts 
prospectively and before infection. The feasibility of recruiting and retaining 
contacts  of young adults , and of classifying transmission events a mong contacts, 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 23 of 166 using the prospective and case -ascertained designs has yet to be evaluated and 
compared.  
This study will employ both the augmented and case ascertainment approaches to 
studying transmission through e nrollment of two contact cohorts, a Prospe ctive 
Close Contact (PCC) cohort and a Case -Ascertained Close Contact (CACC) 
cohort. The PCC Cohort will be identified at enrollment as close and sustained 
contacts of main study participants (eg, roommates or co -workers). Participants in 
the PCC cohort may undergo routine screening for SARS -CoV -2 infection as part 
of their attendance at their school or location of  employment, which may allow 
the participant and study team to receive real -time clinical diagnosis of COVID -
19 during the study . Additionally, w hen a positive case is identified for a main 
study participant, the participant (‘index case’) will identify and refer their recent 
close contacts for enrollment into the CACC cohort. For both cohorts, infection 
diagnosis of the associated main study parti cipant will trigger intensive short term 
sample collection (with a potential delay for the CACC cohort due to the need for 
informed consent and enrollment) including sera followed by daily nasal swabs 
for 14 days. Assessment of viral sequences, viral load trajectories, antibody 
detection and epidemiologic information from the infected participant and any 
positive close contacts in the PCC or CACC will aid in identifying transmission 
events between the participant an d the contact. Details of the enrollment a nd 
procedures for both contact cohorts are described below.  
2.10 Moderna COVID -19 Vaccine  
This trial will utilize vaccine obtained under EUA by  the US Government’s 
COVID -19 Vaccine Response  and allocated for this trial . Participants may also 
access Moderna COVI D-19 EUA vaccine via other sources  (see Section 8.3). 
2.10.1  Clinical  studies  of Moderna COVID -19 Vaccine   
Table 2-3 Summary of clinical  studies  
ClinicalTrials.go
v Identifier  Study 
number  Phas e N Dose 
groups  Route  Schedule  Reference  
[STUDY_ID_REMOVED]  P101  1 120 25, 50, 
100, or 
250 mcg  IM M0, M1  (41, 42)  
[STUDY_ID_REMOVED]  P201  2 600 50 or 100 
mcg IM M0, M1  (14, 15, 43)  
[STUDY_ID_REMOVED]  P301  3 30,351  100 mcg  IM M0, M1  (14, 15, 43)  
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 24 of 166 2.10.2  Potential risks of Moderna COVID -19 Vaccine  
Risks associated with receipt of the Moderna COVID -19 Vaccine are descri bed in 
the “Fact Sheet For Healthcare Pro viders Administering Vaccine (Vaccination 
Providers) Emergency Use Authorization (EUA) Of The Moderna COVID -19 
Vaccine To Prevent Coronavirus Disease 2019 (COVID -19)”, available at 
https://www.modernatx.com/covid19v accine -eua/. 
2.11 Trial design rationale  
We ar e proposing a 2-arm randomized , controlled , open -label trial, augmented 
with an observational cohort . Individuals  indifferent to receipt and timing of 
COVID -19 vaccination will be randomized to immediate vaccination  at Months 0 
and 1, or standard of care  with vaccination given  at Months 4 and 5 , if not 
received off -study previously . Individuals who prefer not to be vaccinated will be 
enrolled in an observational ‘Vaccine Declined’ group ; all these individuals are 
considered part of the ‘Main cohort’  (Figure 2-7). The design also includes  two 
cohorts  of contacts of main study cohort participants  – the Prospective Close 
Contact (PCC) c ohort and the Case -Ascertained Close Contact  (CACC)  cohort – 
to allow capture of secondary transmissio n events .  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 25 of 166  
Figure 2-7 Main cohort study design  
Participants in the main study will self -collect nasal swabs daily in order to 
capture all incident SARS -CoV -2 infection events over 4 months of follow -up 
and to capture the full course of viral shedding  – from onset of infection to viral 
clearance  – among  those with both asymptomatic and symptomatic infection .  
To minimize participant burden and maximize study efficiency, as many study 
procedures as possible wi ll be conducted remotely (not requiring an in -person 
visit) and electronically, such as initial s creening and consent. Participants 
diagnosed with SARS -CoV -2 infection will complete daily e -diaries to capture 
symptoms.  
Given that primary analyses will be c onducted among baseline seronegative 
participants, the rate of baseline SARS -CoV -2 seropositivity will be monitored 
operationally with an operational target of no more than  10% for the main study 
cohort . 
2.11.1  Dose  and schedu le 
The latest information  regarding Moderna COVID -19 Vaccine  dose and 
administration  instructions  can be found at  
https://www.modernatx.com/covid19vaccine -eua/. 

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 26 of 166 For this study, v accine will be  administered  at D1 and D29  for the immediate 
vaccination arm, and at D 113 and D141 for the Standard of Care Group (if they 
have not been vaccinated outside the study) . Vaccine will also be offered to the 
Vaccine Declined Group at D113 and D141 . 
2.11.2  Choice of Standard of Care Group   
There is no licensed SARS -CoV -2 vaccine currently available to serve as a 
reference control . Currently, there are  several SARS -CoV -2 vaccines available in 
the US under Emergency Use Authorization (EUA) , including the Moderna 
COVID -19 Vaccine being used in thi s study . Accordingly, a  Standard of Care 
Group has been chosen as an inter nal control. No placebo will be used , and 
participants will not be blinded to randomization assignment. The open -label 
design has been chosen  primarily to achieve operational efficiency and to 
minimize resource utilization . Main study p articipants will be asked throughout 
the study about the timing and type of any outside  vaccination , and contacts in the 
PCC and CACC will be queried about COVID -19 vaccine receipt . Main study 
participants receiving outside vaccination will remain on -study and follow the 
same  study procedures after vaccination . Section 6.4.3.1  describes how the 
analysis of vaccine efficacy will take into account outside vaccination . 
Randomized p articipants will not be blinded to randomization assignment. The 
open -label design has been chosen primarily to achieve operational efficiency and 
to minimize resource utilization. With an open -label design, differences between 
the randomized arms in study endpoints including SARS -CoV -2 infection , viral 
load, and secondary tra nsmission will capture not only biological effects of 
vaccination, but potentia lly behavioral effects  influencing exposure , including 
adherence to study procedures . This is most relevant for the SARS -CoV -2 
infection endpoint : if participants who are random ized to  immediate vaccination 
engage in more risk -taking behavior and thus experience higher exposure to 
SARS -CoV -2 relative to participants randomized to delayed vaccination, ie, there 
is behavioral disinhibition, this will  be captured in the estimate of vaccine  
efficacy  against infection : the biological reduction in incidence of SARS -CoV -2 
infection attributable to vaccination will be offset by an increase in incidence due 
to higher exposure . Therefore , the measure of vaccine efficacy against infection 
that is estimated in this study is in truth  a measure of effectiveness. However, we 
retain  the terminology “vaccine efficacy ” for simplicity.  Section 6.4.3.1  discusses 
this i ssue in greater detail, including how the statistical an alysis will attempt to 
control for potential imbalances in SARS -CoV -2 exposure between treatment 
arms  when evaluating vaccine efficacy , and how both efficacy and effectiveness 
measures will be evaluat ed and compared . We note that endpoints measured after 
diagnosis of SARS -CoV -2 infection, including SARS -CoV -2 viral load and 
secondary transmission, are viewed as much less likely to be influenced by 
participant behavior and knowledge of vaccine receipt . 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 27 of 166 2.11.3  Rationale for  Vaccine Declined Group  
A cohort of indivi duals who prefer not to receive COVID -19 vaccination and 
decline randomization will be enrolled as a second internal control group  in 
addition to the Standard of Care  arm. The purpose of this  group is to provide 
supplementary information on study endpoints , including SARS -CoV -2 
incidence, SARS -CoV -2 viral load, and secondary transmission, absent COVID -
19 vaccination . The ‘Vaccine Declined’ group will be enrolled concurrently with 
the randomize d study participants, and at the same study sites , and in this fa shion 
variability in the endpoints due to space and time will be minimized. Section 6.4 
and the Stat istical Analysis Plan will detail methods that will be used to control 
for other potential differences between participants who are randomized versus 
those in the Vaccine Declined group.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 28 of 166 3 Objectives and endpoints  
Primary Objectives  Prim ary Endpoints  
1. To evaluate the efficacy of Moderna 
COVID -19 Vaccine against SARS -CoV -2 
infection (ie, to evaluate vaccine efficacy 
against infection  or VE S). SARS -CoV -2 infection diagnosed by PCR 
among participants who were SARS -CoV -2 
seronegative at enrollment  
2. To evaluate the effect of Moderna 
COVID -19 Vaccine on peak nasal viral 
load as a measure of infection and a proxy 
of infectiousness  Peak vir al load in  nasal samples from participants 
diagnosed with SARS -CoV -2 infection among 
participants who were SARS -CoV -2 seronegative 
at enrollment  
Secondary Objectives  Secondary Endpoints  
1. To evaluate the impact of Moderna 
COVID -19 Vaccine on secondary 
transmission of SARS -CoV -2 infection, 
using data for the Prospective Close 
Contact (PCC) cohort and Case -
Ascertained Close Contact (CACC) cohort 
(ie, to evaluate vaccine efficacy against 
infectiousness or VE I) Number of adjudicated * secondary transmission 
events in PCC and CACC cohorts  from main 
study participants who were SARS -CoV -2 
seronegative at enrollment .  
*based on  questionnaire -based epidemiologic 
data, antibody and viral dynamics, and viral 
sequence data  
2. To evaluate the efficacy of Moderna 
COVID -19 Vaccine to prevent 
serologically confirmed SARS -CoV -2 
infection  SARS -CoV -2 antibodies to the nucleocapsid 
protein post visit 3 (month 1), among 
participants who were SARS -CoV -2 
seronegative at enrollment  
3. To evaluate vaccine e fficacy against 
COVID -19 dise ase, (ie, to evaluate VE D) 
using weekly e -diaries and confirmatory 
PCR testing  SARS -CoV -2 infection confirmed by PCR 
among participants who were SARS -CoV -2 
seronegative at enrollment, coincident with the 
following symptoms:  
• at least TWO of the following 
systemic symptoms: Fever (≥ 38ºC), 
chills, myalgia, headache, sore 
throat,  
OR 
at least ONE of the following signs/symptoms: 
cough, shortness of breath or difficulty 
breathing, new olfactory or taste disorder, 
clinical or radiogr aphical evidence of 
pneumonia , thromboembolic event, myocardial 
infarction, myocarditis, chilblains, or multi -
inflammatory syndrome  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 29 of 166 4. To evaluate vaccine effect on additional 
measures of magnitude of viral load over 
time, e.g. area under the viral load curv e, 
duration of shedding, and time to log10 
viral load above 105 copies/mL  
 Summary measures of the viral load curve, all 
evaluated among participants diagnosed with 
SARS -CoV -2 infection who were SARS -CoV -2 
seronegative at enrollment:  
• Transmission potential endpoint, defined as 0 
for an individual without SARS -CoV -2 
infection, and peak log10 viral load, for an 
individual with SARS -CoV -2 infection  
• Area under log10 viral load curve (AUC)  
• Duration of viral shedding  (viral load above 
assay limit of detection)  
• Area under log10 viral load cur ve above 105 
copies/mL  
• Duration of viral shedding above 105 
copies/mL  
• Time from enrollment to viral load above 105 
copies/mL  
 
5. To evaluate  vaccine efficacy against 
SARS -CoV -2 infection, the vaccine effect 
on viral load, and the vaccine effect on 
secondary transmission  in all enrolled 
participants without regard to baseline 
SARS -CoV -2 serostatus  • SARS -CoV -2 infection diagnosed by PCR 
[Primary endpoint 1]  
• Peak log10 viral load in nasal samples from 
participants who are diagnosed with SARS -
CoV -2 infection [Prim ary endpoint 2]  
• Number of secondary transmission events in 
the PCC and CACC [Secondary endpoint 1]  
6. To evaluate the immunogenicity of the 
vaccine  Magnitude and response rate of immune 
responses to vaccination measured at Months 0, 
and 2 stratified by basel ine SARS -CoV -2 
serostatus as measured by binding antibody and 
neutralization assays in the case-cohort 
immunogenicity  set 
7. To evaluate imm une responses 1 month 
post-second vaccination as correlates of 
risk of SARS -CoV -2 acquisition, viral 
load, secondary i nfection, and COVID -19 
disease among vaccine recipients in the 
Immediate Vaccination Group Magnitude and response rate of immune 
responses  to vaccination in the Immediate 
Vaccination Group and measured at Months 0 
and 2, stratified by baseline SARS -CoV -2 
serostatus, as measured by binding antibody and 
neutralization assays in the case -cohort 
immunogenicity set  
8. To evaluate vaccine efficacy against 
asymptomatic SARS -CoV -2 infection  SARS -CoV -2 infection by PCR or periodic  
serology among participants seronega tive for 
SARS -CoV -2 at baseline  and without any prior 
reporting of symptoms that led to confirmation 
of a CO VID-19 disease endpoint  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 30 of 166 9. To evaluate vaccine efficacy against 
SARS -CoV -2 infection  and COVID -19 
disease and  the vaccine effect on viral 
load and secondary transmission  among 
participants who received all planned 
immunizations at the designated 
immunization visits within specific visit 
windows  Endpoints evaluated among participants who 
were SARS -CoV -2 seronegative at enrollment  
• SARS -CoV -2 infection d iagnosed by PCR 
[Primary endpoint 1]  
• Peak log10 viral load in nasal samples from 
participants who are diagnosed with SARS -
CoV -2 infection [Primary endpoint 2]  
• Number of secondary transmission events in 
the PCC and CACC [Secondary endpoint 1]  
• SARS -CoV -2 infection coincident with 
signs and sympto ms of COVID -19 listed 
under Secondary endpoint 3  
10. To evaluate the association between 
measures of the magnitude of viral load 
over time and secondary transmission of 
SARS -CoV -2 infection, among 
individuals with incide nt SARS -CoV -2 
infection in each treatme nt group, i.e. to 
conduct analyses aimed at evaluating viral 
load measures as surrogates of secondary 
transmission  • Peak log10 viral load [Primary endpoint 2] 
and other viral load summaries [Secondary 
endpoints 4]  
• Numb er of secondary transmission events in 
the PCC cohort and CACC cohort 
[Secondary endpoint 1 ] 
11. To evaluate vaccine effects on peak viral 
load and on secondary transmission of 
SARS -CoV -2 infection separately among 
individuals with asymptomatic vs. 
symptomati c SARS -CoV -2 infection  • Peak log10 viral load [Primary endpoint 2] 
and other viral load summaries [Secondary 
endpoints 4]  
• Number of secondary transmission events in 
the PCC cohort and CACC cohort 
[Secondary endpoint 1]  
• SARS -CoV -2 infection diagnosed using 
PCR, with and without signs and symptoms 
of COVID -19 listed under Secondary 
endpoint 3  
Exploratory Objectives  
1. To evaluate the associations between demographic and clinical factors and secondary 
transmission of SARS -CoV -2 infection  and COVID -19 disease , among individuals with incident 
SARS -CoV -2 infection in the main study cohort  and their contacts in the PCC and CACC  
2. To assess if and how vaccine efficacy against SARS -CoV -2 infection, transmission and COVID -
19 disease depends on baseline demographic, cl inical, socio -economic indicators, and/or 
behavioral characteristics of study participants  
3. To assess if and how vaccine efficacy against SARS -CoV -2 infection and COVID -19 disease 
depends on genotypic or neutralization phenotypic characteristics of SARS -CoV -2 (sieve 
analysis)  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 31 of 166 4. To further evaluate immunogenicity of the vaccine, additional immunogenicity assays may be 
performed such as antibody (Ab) Avidity and Fc Receptor function assays, based on the CoVPN 
Laboratory Center assay portfolio  
5. To conduct analyse s related to furthering the understanding of SARS -CoV -2, immunology, 
vaccines, and clinical trial conduct  
CoVPN 3006  Version  4.0 / May 20, 2 021 
CoVPN 3006_v4.0_Final.docx  / Page 32 of 166 4 Ethical considerations  
It is critical that universally accepted ethical guidelines are followed at all sites 
involved in the conduct of clinical tria ls. The COVID -19 Prevention Network 
(CoVPN) have addressed ethical concerns in the following ways :  
• CoVPN  trials are designed and conducted to enhance the scientific 
knowledge base necessary to find a preventive vaccine, using methods that 
are scientifical ly rigorous and valid, and in accordance with International 
Council for Harmonisation  of Technical Requirements for Pharmaceuticals 
for Human Use  (ICH)  and/or other Good  Clinical Practice (GCP) guidelines.  
• CoVPN  scientists and operational  staff incorporate th e philosophies 
underlying major codes (44-46), declarations, and other guidance documents 
relevant to human subjects research into the design and conduct of SARS -
CoV -2 vaccine clinical trials.  
• CoVPN  scientists and operational staff are committed to substantive 
community input —into the planning, conduct, and follow -up of its research —
to help ensure that locally appropriate cultural and linguistic needs of study 
populat ions are met.   
• The CoVPN provides training so tha t all participating sites similarly ensure 
fair participant selection, protect the privacy of research participants, and 
obtain meaningful informed consent. During the study, participants will have 
their wel lbeing monitored, and to the fullest extent possi ble, their privacy 
protected. Participants may withdraw from the study at any time.  
• Prior to implementation, CoVPN trials are rigorously reviewed by scientists 
who are not involved in the conduct of the tria ls under consideration.  
• CoVPN trials are reviewed  by local and national regulatory bodies and are 
conducted in compliance with all applicable national and local regulations.  
• The CoVPN designs its research to minimize risk and maximize benefit to 
both study  participants and their local communities. For ex ample, CoVPN 
protocols provide enhancement of participants’ knowledge of SARS -CoV -2 
and SARS -CoV -2 prevention, as well as counseling, guidance, and assistance 
with any social impacts that may result from res earch participation. CoVPN 
protocols also include  careful medical review of each research participant’s 
health conditions and reactions to study products while in the study.  
• CoVPN research aims to benefit local communities by directly addressing the 
health  and SARS -CoV -2 prevention needs of those communi ties and by 
strengthening the capacity of the communities through training, support, 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 33 of 166 shared knowledge, and equipment. Researchers involved in CoVPN trials are 
able to conduct other critical research in their  local research settings.  
• The CoVPN values the ro le of in -country Institutional Review Boards (IRBs), 
Ethics Committees (ECs), and other Regulatory Entities (REs) as custodians 
responsible for ensuring the ethical conduct of research in each setting.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 34 of 166 5 IRB/E C review considerations  
US Food and Drug Administ ration (FDA) and other US federal regulations 
require IRBs/ECs /REs  to ensure that certain requirements are satisfied on initial 
and continuing review of research (Title 45, Code of Federal Regulations (CFR),  
Part 46.111(a) 1 -7; 21 CFR 56.111(a) 1 -7). The f ollowing section highlights how 
this protocol addresses each of these research requirements. Each CoVPN  
Investigator welcomes IRB/EC /RE questions or concerns regarding these research 
requirements.  
5.1 Minimized risks to participants  
45 CFR 46.111 (a) 1 and 21 CFR 56.111 (a) 1: Risks to subjects are 
minimized.  
This protocol minimizes risks to participants by (a) correctly and promptly 
informing participants about risks so that they can join in partnership with the  
researcher in recognizing and reporting harms; ( b) respecting local/national blood 
draw limits; (c) performing direct observation of participants postvaccination and 
reporting  information regarding side effects to the FDA/CDC Vaccine Adverse 
Event Reporti ng System (VAERS ) per EUA guidance ; (d) having st aff properly 
trained in administering study procedures that may cause physical harm or 
psychological distress, such as blood draws, vaccinations, COVID -19 testing and 
counseling; and ( e) providing safety mon itoring.  
5.2 Reasonable risk/benefit balance  
45 CFR 4 6.111(a) 2 and 21 CFR 56.111(a) 2 : Risks to subjects are 
reasonable in relation to anticipated benefits, if any, to subjects, and 
the importance of the knowledge that may reasonably be expected to 
result.  
In all public health research, the risk -benefit rat io may be difficult to assess 
because the benefits to participant s in prevention protocols  are not as apparent as 
they would be in treatment protocols, where a study participant may be ill and 
may have exhau sted all conventional treatment options. However,  this protocol is 
designed to minimize the risks to participants while maximizing the potential 
value of the knowle dge it is designed to generate.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 35 of 166 5.3 Equitable participant  selection  
45 CFR 46.111 (a) 3 and 21 CFR 56.111 (a) 3: Subject selection is 
equitable  
This protocol has specific inclusion and exclusion criteria for investigators to 
follow in admitting participants into the protocol. Participants are selected 
because of these criteria and not because of pos itions of vulnerability or privilege. 
Investigato rs are required to maintain screening and enrollment logs to document 
volunteers who screened into and out of the protocol and for what reasons.  
5.4 Appropriate informed consent  
45 CFR 46.111 (a) 4 and 5 and 21 CFR 56.111 (a) 4 and 5: Informed 
consent is sough t from each prospective subject or the subject’s 
legally authorized representative as required by 45 CFR 46. 116 and 
21 CFR Part 50 ; informed consent is appropriately documented as 
required by 45 CFR 46. 117 and 21 CFR 50.27  
The protocol specifies that infor med consent must be obtained before any study 
procedures are initiated and assessed throughout the trial (see Section 9.1). Each 
site is provided training in informed consent by the CoVPN  and is required to 
have  a Standard Operating Procedure (SOP) on the informed consent process . The 
CoVPN  requires a signed consent document for documentation, in addi tion to 
chart notes or a consent checklist . 
5.5 Adequate safety monitoring  
45 CFR 46.111 (a) 6 and 21 CFR 56.111 (a) 6 : There is adequate 
provision for monitoring the data collected to ensure the safety of 
subjects.  
Vaccination  providers are required to report to VAERS the certain  adverse events 
after COVID -19 vaccination, under Emergency Use Authorization (EUA)  and 
encou raged  to report  adverse events  to Moderna TX 
|(https://www.cdc.gov/vaccines/covid -19/vaccination -provider -support.html , see 
Section 11). Additionally , the use of v-safe will be recommended to vaccine 
recipients  (https://www.cdc.g ov/coronavirus/2019 -
ncov/vaccines/safety/vsafe.html , see Section 11), and  an Independent Data 
Monitoring Committee (IDMC)  will periodically review s tudy data.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 36 of 166 5.6 Protect privacy/confidentiality  
45 CFR 46.111 (a) 7 and 21 CFR 56.111  (a) 7: There are adequate 
provisions to protect the privacy of subjects and maintain the 
confidentiality of data.  
Privacy refers to an individual’s right to be free from unaut horized or 
unreasonable intrusion into his/her private life and the right to con trol access to 
individually identifiable information about him/her. The term “privacy” concerns 
research participants or potential research participants as individuals whereas the 
term “confidentiality” is used to refer to the treatment of information abou t those 
individuals. This protocol respects the privacy of participants by informing them 
about who will have access to their personal information and study data (see 
Appendix A , Appendix B , Appendix C  and Appendix D  ). The privacy of 
participants is protected by a ssigning unique identifiers in place of the 
participant’s name on study data and specimens. In the United States, rese arch 
participants in CoVPN protocols are protected by a Certificate of Confidentiality 
from the US NIH, which can prevent disclosure of st udy participation even when 
that information is requested by subpoena. Participants are told of the use and 
limits of the certificate in the study consent form.  In addition, each staff member 
at each study site in this protocol signs a n Agreement on  Confid entiality and Use 
of Data and Specimens with the CoVPN. In some cases, a comparable 
confidentiality agreement process may be acceptable.  Each study site participating 
in the protocol is required to have a standard operating procedure on how the staff 
membe rs will protect the confidentiality of study participants.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 37 of 166 6 Statistical considerations  
With an overall goal of accruing  48,000 person -months div ided evenly between 
vaccinated and unvaccinated follow -up time, w e anticipate enrolling up to 18 ,000 
participants . Up to  12,000 participants  will be randomized 1:1 to Immediate 
Vaccination Group  (at Months 0 and 1) or Standard of Care Group , with 
vaccination given  at Months 4 and 5  if not received off -study previo usly. Up to a n 
additional 6,000 participants will be enrolled into the Vaccine Decline d Group 
and will also  be offered vaccine at Months 4 and 5.  Operational monitoring of 
SARS -CoV -2 incidence, retention , outside COVID -19 vaccination, adherence to 
study procedures, and enrollment and tes ting of contacts in the PCC and CACC – 
pooled over main study participant groups -- will guide the choice of total number 
randomized and tota l number in the Vaccine Declined Group. Guidelines will be 
specified in the study SAP.  
Primary analyses of vaccine efficacy against infection ( VE S) and of the vaccine 
effect on viral load (ΔVL) will be conducted among all main study participants 
SARS -CoV -2 seronegative at enrollment . These analyses will be  supported by 
analyses in  the “Day 29 Negative Set”--the set of participants without PCR -
confirmed infection on or prior to Day 29 —that only  count SARS -CoV -2 
infection events diagnosed post -Day 29 ; see Table 6-1 for a full d efinition of the 
various analysis sets for the study. Secondary analyses will  be conducted among 
all participants who receive both immunizations , ie, the Per-Protocol Set . 
Immunogenicity assessment will be done i n the Case -Cohort Immunogenicity 
Set—a subsample of the participants randomized to immediate vaccination and  
sampled on the basis of SARS -CoV -2 infection status and baseline characteristics 
that will be fully described in the study SAP.  
The FAS  differs fro m a full Intention -to-Treat set by excluding randomized 
volunteers who do not enroll. The exclusion of these individuals is justified 
because the effects of the vaccine  are unlikely to influence such exclusion. 
Because of the brief length of time between r andomization and e nrollment  
(ideally these will be on the same day ), we expect almost all randomized 
volunteers to be in the FAS.  
All primary and secondary analyses will be done according to  enrollment group , 
ie, Immediate Vaccination  Group , Standard of Ca re Group , or Vacci ne Declined  
Group .   
Main study participants will be tested using real-time PCR testing of swabs, and 
these  data will be used to identify SARS -CoV -2 infection events for primary 
analysis.  Some main study participants may also receive SARS -CoV -2 testing 
through university testing systems, or through outside providers , and  will be 
asked to report any positive test results to the study team . Any positive SARS -
CoV -2 test result s for main study participants  – based on  PCR testing of study 
swabs  or based on other testing systems  indicative of acute infection – will trigger 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 38 of 166 swabbing of contacts in the PCC and enrollment and swabbing of contacts in the 
CACC.  Secondary analyses of vaccine efficacy will include SARS -CoV -2 
infection events diagnosed th rough any testing system  – either by PCR testing of 
study swabs or through outside testing.  
The two contact cohorts – the PCC and the CACC  – will both be used for 
analyses of the vaccine effect on secondary transmission, as described below.  
The study is “t ime-driven”, ie, the primary analysis will occur when all 
participants have completed the 4 months follow -up. The number of primary 
endpoint infection events that accrue in the study is random and will depend on 
the level of SARS -CoV -2 incidence in each ar m. 
Table 6-1 Study Analysis Sets and Definitions  
Analysis Set  Definition  Analyses  
Full Analysis Set (FAS)   Main Study participants who enroll in the  study   Primary  efficacy 
analyses * 
Day 29 Negative (D29 -) 
Set Participants in the FAS without PCR -confirmed 
infection on or before Day 29¥ Primary efficacy 
analyses * 
Per-Protocol (PP)  Set Participants in the D29- set who received all planned 
immunizations at the designated immunization visits 
within specific visit w indows  Secondary efficacy 
analyses * 
Day 29 Negative  
Transmission Set (D29-TS) Participants in the D29- set and their contacts  in the 
Prospective and Case Ascertained Contact Cohorts  Primary a nalyses 
of secondary 
transmission * 
Case -Cohort 
Immunogenicity S et (ccIS)  Subset of the FAS that is  randomly sampled  for 
measurement of  immunological markers and fully 
described in study SAP   Immunology 
marker analyses  
*These analysis sets include participants without regard to baseline SARS -CoV -2 status. However, 
primary  
efficacy analyses will condition on baseline SARS -CoV -2 seronegativ e status . 
¥ Note that Day 29 is the second vaccination visit (visit 3) for participants on the Immediate 
Vaccination Group . The SAP will specif y the definition of Day 29 for participa nts in the Standard of 
Care Group and in the Vaccine Declined Group. 
Table 6-2 Assumptions underlying study power/sample size calculations, unless otherwise 
specified. Parameters and their assumed values pertain t o participants in the main study cohort.  
Parameter    Assumption    
Enrollment      Uniform enrollment over 4 weeks    
Baseline seroprevalence  in main 
study and  PCC  and CACC   10% of enrolled participants are baseline SARS -CoV -2 seropositive. 
This parameter i s monitored and controlled operationally (see 
Section  6.3)   
Per-protocol  rate  98% of enrolled participants are in the per -protocol  set   
Loss to follow -up rate in the main 
study , the PCC  and the CACC   5% of participants are lost to follow -up over 16 weeks at a constant 
rate   
SARS -CoV -2 incidence absent 
vaccination   Exponential (constant rate) over 16 weeks; primary assumption 
is 4% over 16 weeks   
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 39 of 166 Secondary transmission 
rate among susceptible contacts  
absent vaccination   15% transmission rate  based on  (47-49) 
Vaccine efficacy (VE) against 
SARS -CoV -2 infection and 
transmission    Constant after 14 days post -first vaccination (calculations do not 
depend on earlier VE); level is  varied      
Contact  enrollment   For the PCC:  60% of main study participants enroll contact(s) and 
the average number of contacts  enrolled  is 2  
For the CACC: 75% of main study participants enroll contact(s) and 
the average number of contacts enrolled is  3  
6.1 Accrual and sample size calculati ons 
Sample size calculations were  performed assuming that 48 ,000 person -months of 
follow -up will accrue, evenly divided between vaccinated an d unvaccinated 
follow -up time  and subject to a small 5% loss-to-follow -up rate . This person -time 
may come entirely from 12,000  participants randomized to Immediate 
Vaccination Group versus  Standard of Care Group  and followed for 4 months (16 
weeks), or, if there is insufficient unvaccinated follow -up among those 
randomized to Standard of Care, it will be supplemented w ith unvaccinated 
follow -up for p articipants in the Vaccine Declined Group. The power calculations 
apply, regardles s of where  the unvaccinated follow -up comes from . For this 
reason, w e refer to the two groups being compared as “ vaccinated” and 
“unvaccinated ”, where the former group consists of  participants  randomized to 
immediate vaccination and the latter group may in clude both participants  
randomized to Standard of Care Group and participants  enrolled in the Vaccine 
Declined Group (see Figure 2-7). 
Power calculations also focus ed conservatively on numbers of infections that 
accrue post -Day 29 , although as mentioned above, primary analyses will be 
conducted both in the FAS, counting all follow -up and infection events post -
enrollment;  and in the Day 29 negative set, counting only follo w-up and infection 
events post -Day 29.  
With 48,000 person -months of follow -up, evenly divided between vaccinated and 
unvaccinated follow -up, there is  a high probability that a sufficient number of 
post-Day 29 infection  events, ie , SARS -CoV -2 infections among baseline 
seronegative participants in the D29 - set and diagnosed after Day 29 , will accrue 
to adequately power analyses addressing both primary objectives as well as key 
secondary objectives . Specifica lly, with 24,000 person -months of vaccinated 
follow -up and 24,000 person -months of unvaccinated follow -up, under a 4% 
SARS -CoV -2 incidence absent vaccination over 16 weeks (a conservative 
assumption for US college campuses, see Section 2.5, and supported by 
unpublished modeling within the CoVPN ), assuming VE S = 50% and other 
assumptions laid out in Table 6-2, a total of 225 post-Day 29 infection  events will 
occur across vaccinated and unvaccinated groups  with probability 0. 5 and 214 
events will occur with probability 0.8 .  
CoVPN 3006  Vers ion 4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 40 of 166 Table 6-3 shows the expected number of post-Day 29 infection  events  in the main  
study cohort  overall and in the vaccinated  group , as the assumed incidence absent  
vaccination  varies . As shown , the design ensures a  sufficient number of post-Day 
29 infection  event s to address a variety of objectives that condition on post-Day 
29 infection . For example, with 4% SARS -CoV -2 incidence absent vaccination , 
75 post-Day 29 i nfection  events are expe cted in the vaccinated  group  for immune 
correlates analyses.  
Table 6-3 Expected number of post -Day 29 infection  events , available for secondary 
analyses that condition on event status. Calculations assume  24,000 person -months of 
vaccinated follow -up and 24,000 person -months of unvaccinated follow -up and other assumptions 
in Table 6-2, VES = 50%, and varying 16-week incidenc e of SARS -CoV-2 infection absent 
vaccination . 
16-Week SARS -CoV -2 
Background 
(unvaccinated) Incidence   Post-Day 29  Infection  Events  
Vaccinated and Unvaccinated 
Group s Combined  Vaccinated Group   
1.5%  86 28 
2% 143 47 
3% 170 56 
3.5%  198 66 
4% 225 75 
The study  provides high power to evaluate the vaccine effect on acquisition 
(VE S). Figure 6-1 shows the power of the study to detect a given level of VE S, 
reject ing H0: VE S ≤ 30%, based on a 1 -sided 0.025 -level log -rank test and as a 
function of the SARS -CoV -2 incidence absent vaccination . With 4% 16 -week 
incidence, the study has 90% power to detect any VE S > 57%; with 3% incidence, 
VE S > 60% can be detected with 90% power.   
The proposed study also provides adequate precision with which to estimate VE S. 
Table 6-4 shows that, with 225 post -Day 29 infection events, the approximate 
95% confidence interval (CI) about an estimated 50% VE S is (36.9%, 60.4%) . 
More precise inference is obtained under higher VE S and higher post -Day 29 
infection totals.  
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 41 of 166  
 
Figure 6-1 Power to detect varying vaccine efficacy (VE) against SARS -CoV-2 infection as a 
function of inciden ce absent vaccination over 16 weeks. Simulation -based power calculations 
assume 24,000 person -months of vaccinated and 24,000 person -months of unvaccinated f ollow -
upand other assumptions listed in  Table 6-2. Power based on 1 -sided 0.025 -level log -rank test and 
1,000 simulations.  
Table 6-4 Approximate 95% confidence interval around a given estimated VES against SARS -
CoV-2 infection, comparing vaccinated and unvaccinated groups  as a function of the 
number of post -Day 29   infection  events in the vaccinated and unvaccinated groups . 
Calculations assume 24,000 person -months of follow -up in each group and other assumptions in 
Table 6-2. 
Number of post-Day 29 
infection  event s Approximate 95% CI for 
estimated  VE = 50%   Approximate 95% CI for 
estimated  VE = 70%   
200 (36.0%, 60.9%) (60.7%, 77.2%) 
225 (36.9%, 60.4%)  (61.1%, 76.9%) 
250 (37.7%, 59.9%)  (61.6%, 76.6%) 
6.1.1  Power and precision for evaluating the vaccine effect on VL  
Emerging data on acute SARS -CoV -2 infection suggest that with an expected 225 
post-Day 29 infection events, the vaccine effect on mean peak log10 viral load 
among post-Day 29 infection events can be estimated with adequate precision. 
Specifically, assuming  that peak log10 viral load is normally dist ributed with a 
1.8 standard deviation in both treatment  groups , and assuming 50% VE S, a 1-log 
reduction in mean peak viral load can be detected with 96.9% power given 225 
post-Day 29 infection  events ; power remains high ( 93.5%) with 70% VE S. Table 
6-5 shows power to detect a 1 -log reduction in peak log viral load as a function of 
the assumed standard deviation in log peak v iral load which is allowed to vary 
between 1.0 and 2.5. The standard deviation in peak log viral load in a coho rt of 

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 42 of 166 68 individuals associated with the National Basketball Association who were 
diagnosed with acute SARS -CoV -2 infection was 1.4 to 1.8, depen ding on the set 
of samples included in the analysis  (50). Emerging data from the HCQ -PEP study 
of ~100 acutely infected household members of recently diagnosed COVID -19 
cases  suggests a standard deviation in peak  log viral load in the range of 2.0 -2.2, 
depending on the set of samples included [data not published]. Table 6-6 shows 
the approximate 95% CI about an estimated 1 -log reduction in mean peak log 
viral load, demonstrating the precision that is obtained with 225 post-Day 29 
infection events . Modest precision is ob served with a 1 -1.8 standard deviation  in 
the endpoint , with lower precision under a higher standard deviation ; precision is 
also lower under increasing  VE S. 
Table 6-5 Power to detect a 1 -log reduction in mean peak log viral load comparing post-Day 
29 infection event s between vaccinated and unvaccinated  groups , as a function of the 
assumed standard deviation in peak log viral load in both groups and the assumed level of 
VE against SARS -CoV-2 infection. Simulation -based power calculations assum e 225 post-Day 
29 infecti on events across vaccinated and unvaccinated  groups. Power based on 1 -sided 0.025 -
level t -test and 1,000 simulations . 
Std. dev. in peak log viral 
load VE S = 50%  VE S = 70%  
1 100%  100%  
1.5 99.6%  97.8%  
1.8 96.9%  93.5%  
2 95.6%  86.5% 
2.5 79.9%  68.7%  
Table 6-6 Approximate 95% confidence interval around an estimated 1 -log reduction in 
mean peak log viral load comparing post -Day 29  infection events between vaccinated and 
unvaccinated  groups , as a function of the assumed standard deviation in peak log viral load 
in both groups and the assumed level of vaccine efficacy against SARS -CoV-2 infection . 
Calculations assume 225 post-Day 29 infection  events across vaccinated and unvaccinated  
groups.  
Std. dev. in peak log viral 
load VE S = 50%  VE S = 70%  
1 (0.72, 1.28)  (0.68, 1.31)  
1.5 (0.57, 1.41)  (0.51, 1.46)  
1.8 (0.50, 1.50)  (0.44, 1.57)  
2 (0.46, 1.57)  (0.36, 1.61)  
2.5 (0.29, 1.65)  (0.20, 1.74)  
6.1.2  Power for evaluating the vaccine effect on secondary transmission  
The study has adequate power to evaluate vaccine efficacy against secondary 
transmission, based on analyses that are conducted among post-Day 29 infection 
events  in the Main study cohort and their contacts in the PCC and CACC, ie , 
based on con ditional analyses , as long as VE against SARS -CoV -2 infection is 
low. As demonstrated in Figure 6-2, if there is high vaccine efficacy against 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 43 of 166 SARS -CoV -2 infection , power is low to evaluate secondary transmission using a 
conditiona l analysis. I n this case, an unconditional analysis of VE against 
secondary transmission  is planned and is expected to be more powerful, and also 
more appropriate given that it reflects that infections bloc ked have no 
transmission potential.    
We performe d simulation -based calculations to explore the power to evaluate VE 
against secondary transmission  based on a conditional analysis  that compares 
secondary transmission events among contacts of vaccinated an d unvaccinated 
main study participants . In additio n to the assumptions in Table 6-2, we assumed : 
equal  infection surveillance in the PCC and CACC ; that PCC contacts acquire 
infection from outside sources (other than the index case) at the same rate as the 
Standard of Care Group ; that only baseline seronegative contacts and those in the 
PCC not infected by outside sources are at risk of secondary transmission;  that the 
number of secondary transmission events among at -risk contacts follows a 
Poisson distribution  in each arm, with VE against secondary transmission 
reducing the event rate proportionally given vaccination . A one -sided 0.025 -level 
likelihood ratio t est based on  a Poiss on regression model was used to evaluate VE 
against secondary transmission. As shown in Figure 6-2, the study has 90% power 
to detect a 59% reduction  in secondary transmission if VE S = 50%; a higher  69% 
reduction in secondary transmission is detectable if VE S = 70%. Table 6-7 helps 
explain the power  results : it shows the amount of statistical information on which 
the analysis  is based , ie, the median number of post-Day 29 infection  events and 
associated secondary transmission events in the vaccinated and unvaccinated 
groups . With 50% VE S and 50% VE against seco ndary transmission, we expect  
15 secondary transmission events in the vaccinated group  and 59 in the 
unvaccinated group ; the limited number of events  is due to the “transmission 
cascade” whereby under our assumptions only some SARS -CoV -2 infected 
participa nts enroll contacts into the PCC and CACC, only some contacts are 
susceptible and retained, and the transmission rate is low  (15%).   
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 44 of 166  
Figure 6-2 Power to detect varying vaccine efficacy against secondary tr ansmission as a 
function of vaccine efficacy against SARS -CoV-2 infection. Simulation -based power 
calculations assume 24,000 person -months of vaccina ted follow -up and 24,000 person -months of 
unvaccinated follow -up and other assumptions listed in  Table 6-2. Power based on 1 -sided 0.025 -
level likelihood ratio test unde r Poisson regression model  and 1,000 simulations.  
Table 6-7 Number of post -Day 29 infection  events and associated  secondary tr ansmission 
events in the vaccinated and unvaccinated groups , under varying VE against SARS -CoV-2 
infection and varying VE against secondary transmission, under other assumptions laid out 
in Table 6 -2, and based on 1,000 simulations . 
 VE S = 50%  VE S = 70%  
VE against 
secondary 
transmission  Median no. post-Day 29 
infection events , 
Vaccinated vs. 
Unvaccinated Groups  
(IQR)  Median no. secondary 
transmissions , 
Vaccinated vs. 
Unvaccinated Groups  
(IQR)  Median no. post-Day 
29 infection events , 
Vaccinated vs. 
Unvaccin ated Groups  
(IQR)  Median no. secondary 
trans missions , 
Vaccinated vs. 
Unvaccinated Groups  
(IQR)  
VE = 0%  76 (70 -82)  
vs. 150 (142 -158) 29 (25 -34)  
vs. 59 (53 -66) 45 (41 -50)  
vs. 149 (141 -158) 18 (14 -21)  
vs. 59 (53 -65) 
VE = 40%  76 (70 -81)  
vs. 150 (142 -158) 18 (15 -21)  
vs. 59 (53 -64) 45 (41-50)  
vs. 149 (142-158) 11 (8-13)  
vs. 59 (53 -65) 
VE = 50%  76 (70 -82)  
vs. 150 ( 143-159) 15 (12-17)  
vs. 59 (53 -66) 45 (41 -50)  
vs. 150 ( 142-158) 9 (7-11)  
vs. 59 (53 -65) 
VE = 60%  76 (70-82)  
vs. 150 (142 -158) 12 (9 -14)  
vs. 58 (52 -65) 45 (41 -50)  
vs. 151 (143 -159) 7 (5-9)  
vs. 59 (53 -65) 
VE = 70%  75 (70 -81)  
vs. 150 (142 -158) 9 (7-11)  
vs. 58 (52 -65) 46 (41-50)  
vs. 150 (142-159) 5 (4-7)  
vs. 59 (53-65) 
6.2 Role of the Independent Data Monitoring Committee (IDMC)   
The stu dy IDMC  will provide study oversight and ensure that the study is on -
target to meeting its objectives in a timely fashion . The IDMC  will receive 
summaries of study progress  throughout the study . Given  the short duration of the 
study and the considerable pr ior data establishing safety and efficacy of the 

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 45 of 166 vaccine, and the status of the EUA vaccine, there will be no pre -specified interim 
monitoring boundaries for VE or non -efficacy.  The IDMC  will make 
recommendations to protocol chairs and lead advisors . The s et of metrics, 
operational targets for them, and potential remedial actions will be laid out in full 
in the IDMC  Charter .  
6.3 Randomization  
A participant’s randomization assignment will be computer generated and 
provided to the CRS study staff through a Web -based randomization system.  
Randomization will be stratified . The randomization will be done in blocks to 
ensure balance among contempora neously evaluated Immediate  Vaccination and 
Standard of Care arms within levels defined by study site and type of resi dence . 
6.4 Statistical analyses  
This section describes the final study analys es which will  occur after the last main 
study participant has completed the Month 4 visit. All data from enrolled 
participants will be analyzed according to the initial group  assignme nt regardless 
of how and when  in-study and outside -study vaccinations are received. Follow -up 
and endpoints that accrue  post-outside -study -vaccination will be censored for 
primary and secondary analyses. In the rare instance that a participant receives 
study vaccination at the wrong time, the Statistical Analysis Plan (SAP) will 
address how to analyze the data. A nalys es are modified intent -to-treat in that 
individuals who are randomized but not enrolled do not contribute data and hence 
are excluded. Because  of the brief length of time between randomization and 
enrollment , few such individuals are expected.  
The SAP will spec ify how data from the Vaccine Declined group will contribute 
to assessing primary and secondary objectives. Wherever possible, analyses w ill 
limit to data collected on randomized participants, and will entail comparing 
outcomes between those randomized to Immediate Vaccination or Standard of 
Care. However, if operational data on enrollment, retention, adherence to study 
procedures suggest t hat there wil l be insufficient unvaccinated follow -up for the 
Standard of Care Group to permit a specific analysis , data from the Standard of 
Care Group will be combined with data from the Vaccine Declined Group, with 
methods fully pre -specified in the SAP . 
Analyses fo r primary endpoints will be performed using SAS and R. All other 
descriptive and inferential statistical analyses will be performed using SAS, 
StatXact, or R statistical software.  
In general, no  formal multiple comparison adjustments will be e mployed for 
multiple secondary endpoints. However, multiplicity adjustments will be made for 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 46 of 166 certain immunogenicity assays, as discussed below, when the assay endpoint is 
viewed as a collection of hypotheses (eg, testing multiple peptide pools to 
determine  a positive r esponse).  
6.4.1  Analysis variables  
The analysis variables defined for all partici pants in the main study cohort consist 
of baseline participant characteristic s, longitudinal measures of risk of infection , 
SARS -CoV -2 infection  and seroconversion  and COVID -19 dise ase status,  and 
immun e response biomarkers . For individuals diagnosed with SARS -CoV -2 
infection, post -infection variables will include various summaries of VL, the full 
genome sequence of the infecting virus, and the infection status of and 
relationship to each of their contacts enrolled in the PCC and CACC . For contacts 
enrolled in the PCC and CACC , variables consist of baseline participant 
characteristics, SARS -CoV -2 infection and seroconversion status, risk factors  
around time of exposure to  main study participant (if infected) and relationship to 
the referring main study participant.   
6.4.2  Baseline comparability  and comparability over study follow -up 
Groups of main study participants  will be compared with respect to  baseline 
participant  characte ristics using descriptive statistics.  
Given th at the study is open -label, and the associated potential for differences 
between randomized arms with respect to  retention, compliance with study 
procedures, ascertainment of endpoints, and variables a ssociated  with exposure to 
SARS -CoV -2, these measures will be compared between randomized arms over 
time using methods fully described in the SAP.  Given that participants self -select 
into the Vaccine Declined Group, similar methods will be used to evaluate 
potentia l differences between this group and thos e randomized to Immediate 
vaccination or Standard of Care. Imbalances between groups will influence the 
analysis choices as described below . 
6.4.3  Vaccine efficacy (VE) analyses  against SARS -CoV-2 infecti on 
The time origi n for all analyses of SARS -CoV -2 infection is enrollment . We 
define the time of diagnosis of the SARS -CoV -2 infection endpoint as the 
collection time of the first daily swab with a positive PCR test. T he time of 
diagnosis of lab -confirmed clinical COVID -19 disease  is the first time of reported 
qualifying COVID -19 symptoms that occurs simultaneous ly or after the diagnosis 
of the SARS -CoV -2 infection endpoint. The time of diagnosis of  asymptomatic 
SARS -CoV -2 infection is the collection time o f the first sampl e with a positive  
PCR  test result or seroconversion without any prior or subsequent reporting of 
symptoms that led to confirmation of a COVID -19 disease  endpoint. The time of 
diagnosis of SARS -CoV -2 seroconversion is the collection time of  the first 
sample  seropositive for SARS -CoV -2, for participants SARS -CoV -2 seronegative 
at baseline ; the SAP will specify criteria for defining seroconversion (re -infection) 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 47 of 166 for individuals SARS -CoV -2 seropositive at baseline . The failure times of 
particip ants never observ ed to be diagnosed with a given clinical endpoint will be 
right -censored at the date of last contact at which endpoint status was assessed or 
study termination. The failure times of participants reporting receipt of COVID -
19 vaccination ou tside the study w ill be right -censored at the date of first outside 
vaccination.  
6.4.3.1  Primary VE Analysis  
For the primary analysis, Cox proportional hazards regression will be used to 
estimate vaccine efficacy against SARS -CoV -2 infection among baseline SARS -
CoV -2 seronegative participants , as measured  by one minus the hazard ratio (HR) 
in the Immediate Vaccin ation vs. Standard of Care arms . This analysis that 
restricts attention to randomized participants will be supported by a co-primary 
analysis that combines data from the Standard of Care arm with data from the 
Vaccine Decline d Group. An additional supporti ve analysis will restrict to  the 
D29- set, counting only infection events diagnosed post -Day 2 9. These analyses 
supporting the primary objectives of the study will be detai led in the SAP. To 
improve precision  when comparing randomized groups , and to avoid bias when 
including non -randomized participants,  primary analyses  will adjust for a n SAP-
specified set of “risk” variables , or a composite risk score based on them, that are  
potentially associated with SARS -CoV -2 exposure  including demographics and 
behaviors captured using the risk assessment tool. Inference will be based on  a 2-
sided score -based CI and 2-sided score -test for H0: VE = 0% with a type 1 error 
rate of 0.05 , alth ough primary interest is in estimation as opposed to hypothesis 
testing  and the study is designed  to ensure  that the lower limit for the CI will lie 
above 30% with high probability  under VE > 60%.The baseline hazard function 
in the Cox model will be strati fied by study site and randomization stratum , which 
improves precision  of the  VE estimate and accounts for the fact that SARS -CoV -2 
infection  incidence may vary widely across study sites. Description of the risk 
variables under consideration and of the der ivation of a risk score based on them 
will be described in the study SAP.  
The potential impacts of the open -label and observational  aspect s of the study 
design will be factored into  the choice of efficacy analysis. If there is evidence of 
differential rete ntion of study participants across groups , or differential adherence 
to study procedures affecting ascertainment of endpoints such as collection of 
daily swabs, the analyses will ad just for the differential censoring distribution 
across groups - as well as  potentially informative censoring - as described in the 
study SAP. At a minimum, these analyses will be performed as sensitivity  
analyses , complementing the primary analyses describe d above.   
Variables captured using the risk assessment tool and potentially  associated with 
exposure will be compared across groups  over study follow -up. If there is 
evidence that their distributions differ between groups  over time, sensitivity 
analysis wi ll additionally adjust for time -dependent exposure -related variables.   
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 48 of 166 The proportional hazards assumption will be evaluated using methods of 
Grambsch and Therneau (51).  
6.4.3.2  Secondary VE Analyses  
The primary analysis of VE again st SARS -CoV -2 infection  will be repeated in the 
FAS and D29- sets but including baseline seropositive participants  [Secondary 
Objective 5]; and in the PP set  [Seconda ry Objective 9]. The same methods  also 
apply to evaluating VE against seroconversion [Seco ndary Objective 2] and VE 
against COVID -19 disease [Secondary Objective 3]. Additional secondary VE 
analyses will be conducted where the time of SARS -CoV -2 infection diagnosis is 
defined as the earli est of the first positive SARS -CoV -2 test result based on  either 
PCR testing of nasal swabs or external SARS -CoV -2 testing . 
While the primary analysis of VE against SARS -CoV -2 infection will censor the 
follow -up time of participants  who receive outside COVID -19 vaccination at the 
time of first outside vaccination, a secondary analysis will be performed that 
includes infection events and person -time that accrue following outside 
vaccination with the Moderna COVID -19 Vaccine . Participan ts receiving outside 
vaccination other than Moderna COVID -19 Vaccine will continue to be censored 
at the time of outside vaccination. A time -varying Cox model will be used for 
inference , per methods in the study SAP.  
The asymptomatic SARS -CoV -2 infection e ndpoint  [Secondary Endpoint 8] is 
defined by the PCR tests of daily swabs and serolog ic diagnostic testing schedule 
at month 0, 2, and 4. The occurrence of a COVID -19 disease  event is a competing 
risk because the occurrence of COVID -19 disea se precludes the possibility of 
occurrence of a subsequent asymptomatic SARS -CoV -2 infection  event . 
Therefore, VE against asymptomatic SARS -CoV -2 infection  will be assessed 
using methods accounting for COVID -19 dise ase as a competing risk. The SAP 
will provid e details.  
Vaccine efficacy against the infection  and disease endpoints as measured by the 
reduction in the cumulative incidence of the endpoint by Month 4, will also be 
evaluated  using the Nelson -Aalen estimator of cumulative incidence . This 
analysis does n ot rely on the proportional hazards assumption and has a simple 
interpretation that lends itself  to understanding of population effects . 
6.4.4  VL analyses  
Primary analyses of the vacc ine effect on VL will focus on the primary VL 
endpoint, peak log10 viral load, and will condition on SARS -CoV -2 infection  
status. Peak log10 viral load will be estimated by the observed maximum log10 
viral load measure ; secondary VL analyses will employ pa rametric models to 
estimate VL at peak. The mean observed log10 viral load will  be compared 
between the Immediate Vaccination and Standard of Care arms . This analysis that 
restricts attention to randomized participants will be supported by a co -primary 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 49 of 166 analysis that combines data from the Standard of Care arm with data from the 
Vacci ne Decline d Group. Both analyses will use methods that adjust for baseline  
covariates and covariates at the time of SARS -CoV -2 infection diagnosis, per the 
study SAP. The covariate adjustment is used to control for potential  post-
randomization selection bi as and lack of compar ability between randomized 
participants and those in  the observed cohort, whereby SARS -CoV -2 infected 
participants in the vaccinated and unvaccinated groups  are not comparable in 
ways that are associated with the VL endpoint. Important ly, this bias occurs when 
there are  factors that modify VE against SARS -CoV-2 infection and that are 
associated with the VL endpoint . An additional supportive analysis will restrict to 
SARS -CoV -2 infections in the  D29- set. Full details around the analysis  plan will 
be specified in the study SAP.   
Secondary analyses of vaccine effects on VL will consider a set of other summary 
measures of the VL curve, each of which have merits for further characteriz ing 
the vaccine effect. These include  a model -based esti mate of peak log10 viral load, 
duration of detection of virus  [estimated e mpirically or alternatively based on a 
model fit to the viral load curve] , area under the log viral load curve [AUC] 
calculated using the trapezoidal rule, and area under the portion  of the log viral 
load curve over 105 viral copies/mL . Some mathematical m odeling studies 
provide evidence of transmission potential for VL above this threshold (21), but 
there is considerable uncertainty and therefore other thresholds will be 
considered. Analysis methods will be the same as for the prim ary VL endpoint 
above.  
In addition, the above  VL endpoints will be evaluated using  unconditional 
analys es, ie, not conditioning on SARS -CoV -2 infection status , among all 
enrolled main study participants. Participants not diagnosed with SARS -CoV -2 
infection  will have an endpoint  value defined for analysis, typically a value of 
zero. The ‘transmission potential’ endpoint [Secondary endpoint 4] is one such 
endpoint that is defined unconditionally. The merit of unconditional  analyses is 
that they are not subjec t to potential post-randomization selection bias. A 
disadvantage of the unconditional analyses is that they may have lower statistical 
power.   
An additional  VL endpoint  that will be studied is a censored event -time variable, 
time to VL above 105 copies/mL. This endpoint is def ined for all enrolled main 
study participants and will be analyzed using the same methods used to evaluate 
VE against SARS -CoV -2 infection, but onl y counting infections once VL is 
above 105 copies/mL. Additional methods of analysis that allow for the 
uncer tainty in the level of virus that is associated with transmission will be 
considered.   
Sensitivity analyses for VL will include data from all SARS -CoV -2 infected 
participants diagnosed based on PCR testing of study swabs or based on outside 
testing.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 50 of 166 The st udy SAP will  detail the secondary analysis approaches  for the VL 
endpoints . 
6.4.5  Secondary transmission analyses  
6.4.5.1  Identifying ‘adjudicated transmission e vents’  
An expert adjudication committee will examine and make a primary 
determination to identify ‘ adjudicate d transmission events’ from a main study 
participant diagnosed with infection (‘index case’) to a contact in the PCC or 
CACC diagnosed  with SARS -CoV-2 infection. Note that the close contact could 
also be a main study participant in theory, although this is  unlikely given the 
relatively small proportion of each community  that will be recruited to the main 
study. The adjudication committee will operate  under a charter that lays out a pre -
specified set of criteria for defining  the occurrence and direction of t ransmission 
and will be blinded to the enrollment group  of all study participants  and contacts . 
The endpoint definition will include criteria that need to be met regarding the 
temporal relationship (eg, evidence that person B’s infection occurred after per son 
A’s infection, evidence of compatible incubation period), epidemiologic link 
(evidence of close contact during person A’s infecti ous period), and relatedness of 
their SARS -CoV -2 viruses.  
The adjudication committee will be provided with all relevant dat a from the study 
to deduce transmission  events  from potential transmission pairs . A potential 
transmission pair is a post-baseline  SARS-CoV -2- infected main study index case 
and their identified contact (s) in the PCC or CACC who have positive SARS -
CoV -2 test results within a pre specified period (eg, two weeks ) of the index case 
diagnosis . This will include the type, frequency, and magnitude (eg, duration  and 
setting)  of contact between the index case and contact based on risk assessment 
questionnaires given  to the index case and the contact; the timing of diagnosis of 
infection by PCR for  the index case and the contact  (defined as  the date of 
specimen collection) ; the VL trajectories , serology , and symptomatology  for the 
index case and the contact; and summa ries of the viral sequences for the index 
case and the contact including the number of nucleo tide differences in the 
sequences and any cluster ing and results of phylogenetic analyses  (see Section 
6.4.5.3 ). Adjudi cation of all potential transmission events will occur within a 
short time frame at the end of the study to ensure decisions are being made using 
the same background research on transmission  and to ensure that the adjudication 
can take into account all SAR S-CoV -2 infect ion events captured in the main study 
cohort and both contact cohorts . Primary analyses of the vaccine effect on 
secondary transmission will rely on the determination of this committee and use 
the adjudicated transmission events and ou tcomes in statistical models . These 
same primary analyses will also only include main stud y participants diagnosed 
with infection through PCR testing of study swabs . However, sensitivity analyses 
will incorporate  data from  the full set of main study participants diagnosed with 
infection either through outside  testing or through PCR testing of swabs collected 
through the study  per methods described in the SAP . 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 51 of 166 6.4.5.2  Analyses of the vaccine effect on secondary transmission  
Primary analyses of vaccine efficacy  against seco ndary transmission will include 
adjudicated  transmission events collected from  both the PCC and CAC C. Both 
conditional and unconditional analyses will be performed. Conditional analyses 
will compare the expected number  of adjudicated  transmission events be tween 
index cases in the Immediate  Vaccination  Group vs. Standard  of Care Group . This 
analysis that restricts attention to randomized participants will be supported by a 
co-primary analysis that combines data from the Standard of Care Group  with 
data from the Vaccine Decline d Group. An additional supportive analysis will 
restric t to SARS -CoV -2 infection events in the  D29- set. These primary analyses 
will use Poisson regression , where goodness of fit tests will be used to determine 
whether an overdispersed P oisson  or other alternative distribution s fit the data 
better , per the stu dy SAP . Analyses using the observ ational  cohort cannot assume 
balanced mixing with suscep tible contacts between vaccinated and unvaccinated 
groups  and will adjust for number and type  of contacts.  The SAP will specify the 
baseline p articipant characteristics and measurements  available at the time of 
SARS -CoV -2 infection  diagnosis that are potentially associated with secondary 
transmission  to be included as covariates. The conditional a nalysis may have 
greater power than an unconditional analysi s, eg, under low VE against SARS -
CoV -2 infection. However, it  is subject to the post -randomization selection bias , 
as discussed in relation to the viral load endpoint. In general, it will be biase d if 
there are factors that modify VE against SARS -CoV -2 infection that are also 
associated with onward transmission; or if factors associated with onward 
transmission are modifiers of VE against infection.  
A secondary analysis of this endpoint will measu re vaccine  efficacy against  
secondary transmission as the percent reduction in the expected number of 
adjudicated transmission events linked to  a participant in the Immediate 
Vaccination  Group  relative to the Standard of Care Group . In contrast to the 
prim ary transmission analysis  that con ditions on the main study participant being 
infected , all main study participants will contribute to the analysis including those 
who do not become infected  to reflect the fact t hat SARS -CoV -2-uninfected 
participants  do no t transmit to others and therefore have 0 transmission  events . 
Let N = number of adjudicated transmission events for a given index case which 
is assumed to follow  a zero -inflated Poisson distribution with the mean of the 
non-zero point mass component  is 𝜇𝑒(𝑉𝛾) , where V indicates randomization 
assignment ( 1 Immediate Vaccination ; 0 Standard of Care). Further let 𝛽 denote  
the log hazard ratio from a Cox proportional hazards model for infection time . 
Then the ratio of  the expected number of adjudic ated transmission events linked 
to a participant in the Immediate Vaccination  Group  relative to the Standard of 
Care Group  can be expressed as  
𝑒𝜃=𝑒𝛾𝑒𝛽, 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 52 of 166 where 𝜃 is a measure of the vaccine’s impact on total onward transmission 
(transmission  from participants in main study) and 𝑒𝜃 is the relative reduction in 
the proportion of adjudicated transmission events  in the Immediate Vaccination  
Group  relative to the Standard of Care Group . This is analogous to the product 
estimator in the proporti onal means model (53, 54) . Note that this formulation 
assumes the time between detection in the index case participant and infection of 
a contact is ignorable.  Covariate -adjusted approaches will be  detailed in the SAP.  
The analysis tha t restricts attention to randomized participants will be supported 
by an analysis that combines data from the Standard of Care Group  with data 
from the Vaccine Decline d Group.  
The unconditional  analysis retains high power even if there  are few breakthrough 
infections in the Immediate Vaccination Group due to high VE against infection . 
It also  properly  reflects that a vaccine is successful at reducing secondary 
transmission if it either meaningfully reduce s acquisition or reduces onward 
transmission from infected participants . Moreover, by avoiding conditioning on 
SARS -CoV -2 infection, it avoids the post -randomization selection bias issue .  
6.4.5.3  Processing and phylogenetic analysis of SARS -CoV-2 viral sequence d ata 
A central sequencing facilit y will obtain whole -genome sequences from all 
infected participants in the main study cohort and all infected participants in the 
PCC and CACC , based on the nasal swab with the highest viral load (see Section 
10.3.2 ). Details ab out the sequencing platform and methodology for QC processes 
will be included in the study SAP. This will include the creation of a global 
alignment, which will b e used for the isolation of genes and the sequence analyses 
of local regions.  
A first step in the analysis of the sequence data will be to determine, for each pair 
of sequences among infected participants or contacts within a given study 
community , which a re identical. Data from Gen Bank, Global Initiative on Sharing 
Avian Influenza Data ( GISAID ), and other public databases suggest that we can 
expect limited variability in genetic sequences, especially those from a single 
common ancestor and constrained within a single study community over a 4 -
month time period. Consensus -based whole genomes that differ by more than two 
nucleotides can reasonably be ruled out as being transmission events.  
A second step will be to conduct distance -based analyses of the sequences, 
including phylogenetic analysis, to identify potential lineages of infecting viral 
strains, infection clusters, and potentially linked transmissions. Phylogenetic 
analyses will also include ‘background’ SARS -CoV -2 sequences with 
geographical or temporal relevance from publicly available databases, such as 
GenBank and GISAID. The background sequences will help root the tree and give 
the tree structure and may lend insight into the identification of clusters and into 
potential transmission  events  during the adjudication process . 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 53 of 166 Details about the phylogenetic and other sequence analyses, inclu ding the tree -
building methods and evolutionary models to be used, as well as approaches to 
incorporating data from multiple reads, will be available in the study SAP.  
6.4.6  Immunogenicity analys es 
6.4.6.1  Vaccine immunogenicity  
Immunogenicity will be characterized for th e immediate vaccination group only , 
using data from the Case -Cohort Immunogenicity Set (ccIS). Data from 
quantitative immunogenicity assays will be summarized using positive response 
rates and geometric means with 95% CIs, for each time point for which an 
assessment is performed. Data from qualitative (ie, yielding a positive or negative 
result) assays will be summarized by tabulating the frequency of positive 
responses for each assay at each timepoint that an assessment is performed. 
Analyses focus on the Month 2 time point , the Day 1 time point, and the change 
in marker response between the two time points. The analyses will evaluate 
immunogenicity in all immediate vaccination arm participants and separately in  
subgroups defined by basel ine SARS -CoV -2 seros tatus. The SAP will describe 
the complete set of immunogenicity analyses.  
6.4.6.2  Immune response marker correlates of risk  
A separate Trial Marker SAP will describe the statistical methods and data 
analysis implementations for assessing immun e response markers a s correlates of 
the SARS -CoV -2 infection and peak log viral load  study endpoints, as well as 
various types of correlates/surrogates of protection.  
An unblinded statistical analysis by treatment assignment of a primary 
immunogenicity en dpoint may be perfor med when all participants have 
completed the Month 2  visit and data are available for analysis from at least 80% 
of these participants. Similarly, an unblinded statistical analysis by treatment 
assignment of a secondary or exploratory i mmunogenicity endpoi nt may be 
performed when all participants have completed the corresponding 
immunogenicity visit and data are available for analysis from at least 80% of 
these participants. The CoVPN  Laboratory Center  will review  the analysis report 
prior to distribution t o the protocol chairs, NIAID , study product  developer, and 
other key CoVPN  members and investigators. Reports for distribution or 
presentation should use PubIDs and not PTIDs for individual responses.  
Distributio n of reports will be limited to those with a  need to know for the 
purpose of informing future trial -related decisions. The CoVPN  leadership must 
approve any other requests for CoVPN  immunogenicity analyses prior to the end 
of the scheduled follow -up visits . 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 54 of 166 7 Selection and withdrawal of participants  
Participants will be  generally  healthy adults who comprehend the purpose of the 
study and have provided written informed consent. Volunteers will be recruited 
and screened; those determined to be eligible, based o n the inclusion and 
exclusion criteria, will  be enrolled in the study. Final eligibility determination will 
depend on information available at the time of enrollment , medical history  
questionnaire , physical examinations , and answers to self -administered an d/or 
interview questions . 
Investigators shou ld always use good clinical judgment in considering a 
volunteer’s overall fitness for trial participation. Some volunteers may not be 
appropriate for enrollment even if they meet all inclusion/exclusion criteria.  
Medical, psychiatric, occupational, or othe r conditions may make evaluation of 
safety and/or immunogenicity difficult, and some volunteers may be poor 
candidates for retention.  
Determination of eligibility, taking into account all inclusion and exclusion 
criteria, must be made within 56 days prior to enrollment unless otherwise noted 
below . 
7.1 Inclusion criteria  for Main Cohort , Immediate Vaccination Group  and 
Standard of Care Group  
General and Demographic Criteria  
1. Age of 18 through 29 years . 
2. Willingness to be followed  for the planned duration of the s tudy. 
3. Agrees to allow  study staff to access school  SARS -CoV -2 testing  data and 
outcome s, if applicable .  
4. Ability and willingness to provide informed consent . 
5. Assessment of understanding : volunteer demonstrates understanding of this 
study ; completes a quest ionnaire with demonstration of understanding of all 
questionnaire items answered incorrectly . 
6. Willing to be randomized to either immediate vaccination or standard of 
care group  and comply with planned study procedures . 
7. Agrees not to enroll in another study  of an investigational research agent  until 
the end of the study . 
8. Access to device and internet  for completion of study procedures .  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 55 of 166 7.2 Exclusion criteria  for Main Cohort , Immediate Vaccination Group and 
Standard of Care Group  
General  
1. Acutely ill 72 hours  prior to or at screening . Volunteers  meeting this criterion 
may be rescheduled within the relevant window periods. Participants with minor 
illnesses can be enrolled at the discretion of the investigator.  
2. Blood products , systemic immunoglobulins , or monoclonal  antibodies (including 
against SARS -CoV -2) received within 90 days before first vaccination.  
3. Investigational research agents  received within 30 days before first vaccination . 
4. Self-reporte d known history of SARS -CoV -2 infection . 
Vaccines and other Injection s 
5. Prefers to receive COVID -19 vaccination immediately . (These volunteers to be 
referred to community resources for vaccination).  
6. Prior administration of a coronavirus  (SARS -CoV -2, SARS -CoV , MERS -
CoV) vaccine or current/planned simultaneous participation in  another 
interventional study to prevent or treat COVI D-19. 
Immune System  
7. Immunosuppressive medications  received within 168 days before first 
vaccination  (not exclusionary : [1] corticosteroid nasal spray; [2] inhaled 
corticosteroids; [3] topical corticost eroids for mild, uncomplicated dermatologic 
condition ; or [4]  a single course of oral/parenteral prednisone or equivalent  at 
doses < 60 mg/day and length of therapy < 11 days with completion at le ast 30 
days prior to enrollment ). 
Clinically  significant med ical conditions  
8. Clinically significant medical condition , physical examination findings, or past 
medical history with clinically significant implications for current health. A 
clinically significant condition or process includes but is not limited to:  
• A process that would affect the immune response  (well-controlled human 
immunodeficiency virus infection is allowed) , or 
• Any condition specifically listed among the exclusion criteria below.  
9. Any medical, psychiatric, occupational, or other condition  that, in th e 
judgment of the investigator, would interfere  with, or serve as a contraindication 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 56 of 166 to, protocol adherence, assessment of safety or reactogenicity, or a volunteer’s 
ability to give informed consent . 
10. Bleeding disorder  (eg, factor deficiency, coagulopathy, or platelet disorder 
requiring special precauti ons). 
11. Asplenia : any condition resulting in the absence of a functional spleen . 
12. History of angioedema or anaphylaxis , including to vaccines or vaccine 
components  (not exclusionar y: angioedema or anaphylaxis wit h known  trigger 
and no episodes within five yea rs.). 
13. History of generalized urticaria  within past five years . 
7.3 Inclusion criteria for Main cohort, Vaccine Declined Group  
General and Demographic Criteria  
1. Age of 18 through 29  years . 
2. Ability and willingness to  provide informed consent.  
3. Prefers not to receive COVID -19 vaccine . 
4. Willingness to be followed  for the planned duration of the study . 
5. Assessment of understanding : volunteer demonstrates understanding of this 
study ; completes a questionnaire with demonstrat ion of understanding of all 
questionnaire items answered incorrectly . 
6. Access to device and internet  for completion of study procedures .  
7.4 Exclusion criteria for Main cohort , Vaccine Declined Group  
1. Prior administration of a coronavirus  (SARS -CoV -2, SARS -CoV,  MERS -
CoV) vaccine  or current/planned simu ltaneous participation in another 
interventional study to prevent or treat COVID -19 (participation in  studies o f 
other investigational research agents allowed) . 
2. Any medical, psychiatric, occupational, or other cond ition  that, in the 
judgment of the investigator, would interfere with, or serve as a contraindication 
to, protocol adherence, or a volunteer’s ability to give informed consent.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 57 of 166 7.5 Inclusion criteria for Prospective Close Contact (PCC) c ohort  
1. Age of 18 years or older, at the time of signing the informed consent . 
2. Willing and able to provide informed consent . 
3. Expected to be in frequent  close physical proximity  with Main Cohort  
participant  during the study . 
4. Willing to share results of SARS -CoV -2 testing . 
5. Access to  device and internet  for completion of study procedures . 
7.6 Inclusion criteria for Case -ascertained Close Contact (CACC) c ohort  
1. Age of 18 years or older , at the time of signing the informed consent . 
2. Willing and able to provide informed consent . 
3. Access to device and internet  for completion of study procedures . 
4. Willing to share results of SARS -CoV -2 testing . 
5. Had close contact  with  Main Cohort participant  with known PCR -confirmed 
SARS -CoV -2 infection  (eg, index case).  Close contacts  will have had exposure 
to the index participant , generally  within 72 hours of an  index diagnosis , and may 
include individuals that meet any of the following guidelines : 
• Prolonged close physical proximity with Main Cohort participant within a 
residence/vehicle/enclosed space without mai ntaining  social distance , 
• Medical staff, first responders, or other care persons who cared for the index 
case without appropriate personal protecti ve equipment . 
Further information on the definition of close cont act can be found in the CoVPN 
3006  Study Specific Procedures ( SSP). 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 58 of 166 8 Study product  
The protocol schema is shown in Table 1-1.  
Definitions of on -study and outside of study COVID -19 vaccination:  
• On-study: occurred as directed by the protocol procedures (i.e. procedures 
occurring within the visit windows) with Modern a COVID -19 vaccine for the 
cohort to which the participant has been randomized or assigned  
• Outside of study: any COVID -19 vaccination that was administered at a time 
outside of protocol -specified vi sit windows for the cohort to which the 
participant has be en randomized or assigned   
Moderna COVID -19 Vaccine  provided via the US Government  study -allocated 
supply can only be administered to CoVPN 3006 study participants in an on -study 
manner. Exceptions may be made for Main Cohort study participants who become 
infected with SARS -CoV -2 after enrollment . Such exceptions require  approval of 
CoVPN 3006 Protocol leadership . 
8.1 Vaccine regimen  
Immediate Vaccination Group  
Treatment 1 (T1):  Moderna COVID -19 Vaccine  in 100 mcg dose  given as 0.5  
ml IM into the deltoid muscle on Day 1 and Day 29.  
Standard of Care Group  and Vaccine Declined Group who accept  
vaccine offer at M4  
Treatment 2 (T2):  Moderna COVID -19 Vaccine  in 100 mcg dose given as 0.5 
ml IM into the deltoid muscle on Day 1 13 and Day 141. 
8.2 Storage, handling, preparation , and administration  
Vaccin ation  providers  will refer to EUA vaccine instructions accessed  and 
updated at https://www.modernatx.com/covid19vaccine -eua/. 
8.3 Acquisition of Moderna COVID -19 Vaccine  
Emergency use authorized  Moderna COVID -19 Vaccine  will be provided by 
Moderna , Inc. through the US Government COVID -19 Vaccine Response  and 
allocated for this trial . Participants may also access Moderna COVID -19 EUA 
vaccine via other sources  for on -study vac cinations if the administration fee is 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 59 of 166 either paid for by the study or is not billed to any party. Examples of how 
vaccinations may be administered to study participants include the following : 
• At the CRS using study -allocated vaccine supply  
• At a non -CRS loc ation using study -allocated vaccine supply with 
administration fees funded by the study  
• At a pharmacy administering  EUA  Moderna COVID -19 vaccine via Federal 
Retail Pharmacy Partnership (FRPP) supply with administration fees funded 
by the st udy  
Please s ee the  CoVPN 3006 SSP  for additional examples and details .  
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 60 of 166 9 Clinical procedures  
Procedures are in place so that study visits may be conducted remotely, such as 
via phone, text message, email , or other electronic means, in lieu of, or in 
comb ination with, in -person visits at the clinical research site. Furthermore, some 
visit procedures may be conducted outside the CRS (see CoVPN 3006  SSP for 
additional details).  
The schedule s of clinical procedures are shown in Appendix E , Appendix F , 
Appendix G  and Appendix H . 
9.1 Informed consent  
Informed consent is the process of working with participants so that they fully 
understand what will and may happen to them  while participating in a research 
study.  The CoVPN  informed consent form documents that a participant (1) has 
been informed about the potential risks, benefits, and alternatives to participation, 
and (2) is willing to participate in a CoVPN  study. Informe d consent encompasses 
all written , verbal , and elec tronic  study information CRS staff provide to the 
participant, before and during the trial. CRS staff will obtain informed consent of 
participants according to the CoVPN 3006 SSP . 
If any new information is  learned that might affect the participants ’ decisi ons to 
stay in the trial, this information will be shared with trial participants. If 
necessary, participants will be asked to provide  revised informed consent forms.  
9.1.1  Screening consent form  
Without a gener al screening consent, screening for a specific stud y cannot take 
place until the site receives protocol registration from NIAID or its designee . 
Some CRSs have approval from their IRB/EC and any applicable RE  to use a 
general screening consent form that al lows screening for an unspecified SARS -
CoV -2 vaccine trial. In this way, CRS staff can continually screen potential 
participants and, when needed, proceed quickly to obtain protocol -specific 
enrollment consen t. Sites conducting general screening or prescre ening approved 
by their IRB/EC and any applicable RE  may use the results from this screening to 
determine eligibility for this protocol, provided the tests are conducted within the 
time periods specifi ed in t he eligibility criteria.  
9.1.2  Protocol -specific conse nt forms  
The protocol -specific consent  forms describe the study products to be used and all 
aspects of protocol participation, including screening and enrollment procedures . 
Sample protocol -specific consent  forms for the Main cohort  are located in  
Appendix A  and Appendix B . A sampl e protocol -specific consent form for the 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 61 of 166 PCC  cohort is located in  Appendix C . A sample protocol -specific consent form 
for the CACC  cohort  is loca ted in Appendix D . 
The consent for ms for the PCC and CACC cohort s may be managed centrally by 
the CoVPN . This will allow for a streamlined approach to consenting these 
individuals , given the  referral mechanism to participate in the study, in addition to 
the remote nature of their study par ticipation. In this instance, the  centralized 
consen ts and consenting process will be approved by the IRB/EC  at the protocol -
level .  
For consent forms that the CoVPN does not manage centrally, e ach CRS is 
responsible for developing protocol -specific consent form (s) for local use, based 
on the sample protocol -specific consent form s. The consent form (s) must be 
developed in accordance with requirements of the following:  
• CRS’s IRB/EC  and any applica ble RE s 
• CRS’s institution  
• Elements of informed consent as described in Title 45, CFR Part 46 and Title 
21 CFR, Part 50, and in ICH E6(R2), Good Clinical Pract ice: Consolidated 
Guidance 4.8  
Study sites are strongly encouraged to have local community represe ntatives  from 
the target p opulation  review their sites -specific consent forms. This review should 
include, but should not be limited to, issues of cultural competence, local 
language considerations, and the level of understandability.  
The sample informed c onsent form (s) include (s) instructions for developing 
specific content . 
9.1.3  Assessment of Understanding  
Study staff are responsible for ensuring that participants fully understand the 
study before enrolling them. This process involves reviewing the informed 
consent form with the partic ipant, allowing time for the participant to reflect on 
the procedures and issues presented, and answ ering all questions completely.  
An Assessment of Understanding is used to document the participant ’s 
understanding of key concepts  in this study . Participants must demonstrate  
understanding of all questions answered incorrectly. This process and the 
participant’s understanding of the key concepts is to be recorded in the eConsent . 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 62 of 166 9.2 Pre-enrollment procedu res for Main Cohort   
Screening may occur over the course of several contacts/visits, up to and 
including before enrollment . All inclusion and exclusion criteria must be assessed 
within 56 days before enrollment, unless otherwise specified in the eligibilit y 
criteria (or below in this se ction).  Screening results will be reviewed with the 
volunteer.  
After the appropriate informed consent has been obtained and before enrollment, 
the following procedures are performed:  
• Participant will  download  the electronic d iary ( eDiary ) application to th eir 
smartphone or tablet and complete an optional application training . Participant 
will use eDiary to enter data . Data collection  will include : 
▪ Medical history questionnaire  
▪ Volunteer demographics in compliance with the NIH Policy on Reporting 
Race and E thnicity Data: Subjects in Clinical Research, Aug. 8, 2001 
(available at http://grants.nih.gov /grants/guide/notice -files/NOT -OD-01-
053.html ) 
▪ Baseline SARS -CoV -2 infection ri sk information  
• Discussion of the eDiary entries  done  by the participant  with the site staff  
• Review  of materials for  possible self -collection of blood by the participant  
9.3 Enrollment and vaccination visits  for Main Cohort , Immediate 
Vaccination Group  
Once a v olunteer has consented to trial participation and is found to meet all 
eligibility criteria (see Sections 7.1 and 7.2), the CRS requests the randomization 
assignment  via a Web -based randomization sy stem. Enrollment is simultaneous 
with rando mization . In general, t he time interval between randomization and 
completion of all study activities for Visit 2 should not exceed approximately 7  
working days . However, c ircumstances may require a participant’s v isit to be 
changed. This may exceed the 7-day randomization time limit  recommendation . 
At vaccination visits , the following procedures are performed before 
vaccination : 
• COVID -19 symptom check , both vaccination visits  
• Specimen collection  (only at first vacc ination  visit, see Appendix E ) 
CoVPN 3006  Version  4.0 / May 20, 202 1 
CoVPN 3006_v4.0_Final.docx  / Page 63 of 166 Following completion of all procedures in the preceding list , and if results 
indicate that vaccination may proceed, vaccination is prepar ed and administered  
per Moderna EUA Fact She et and Full Prescribing Information for Vaccination 
Providers that can be accessed at https://www.modernatx.com/covid19vaccine -
eua/).  
Additionally , the participants will be : 
• Reminded to enter information in eDia ry throughout the study   
• Provided with  a supply of nasal swabs and shown how to swab both nostrils  
9.4 Follow -up procedures for Main Cohort , Immediate Vaccination Group  
The following procedures are performed during  follow -up per schedule in 
Appendix E : 
• Partic ipants r eminded to enter information in eDiary throughout the study  (see 
Section  9.16) 
• Nasal swab collection by participant  
• Blood collection by CRS  staff, phlebotomist,  or participant   
• End of study questionnaire  
9.5 Enrollment  (visit 2)  and Month 2 ( visit 4 ) Visits  for Main Cohort, 
Standard of Care and Vaccine Declined  Group s 
Randomi zation applies to  Standard of Care participants  only: Once a volunteer 
has consented to trial participation and is found to meet all elig ibility criteria (see 
Sections 7.1 and 7.2), the CRS requests the randomization assignment  via a Web -
based randomization system.  Enrollment is simultaneous with randomization . 
In general, t he time i nterval between randomization and completion of all study 
activities for Visit 2 should not exceed approximately 7  working days . However, 
circumstances may require a participant’s visit to be changed. This may exceed 
the 7-day randomization time limit  recommendation.  
For Vaccine Declined par ticipants : Once a volunteer has consented to trial 
participation and is found to meet all eligibility criteria (see Sections 7.3, and 7.4) 
they are considered enrol led. 
For Standard of Care and Vaccine Declined  participants : before leaving the 
clinic, the participants will be : 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 64 of 166 • Reminded to e nter information in eDiary  throughout the study   
• Provided with a supply  of nasal swabs and shown how to swab both nostrils  
At vis its 2 and 4 , the following procedure s are performed per schedule in 
Appendix F : 
• eDiary entries by participant (see Section 9.16) 
• Nasal swab collection by participant  
• Blood collection b y CRS staff, phlebotomist, or participant  
9.6 Month 4  (visit 5) and Month 5 (visit 6) Visit s for Main Cohort, 
Standard of Care  Group  and Vaccine Declined Group  
For those participants who have not received a COVID -19 vaccine outside 
the study  and who request va ccination:  
At vaccination visits  the following procedures are performed before 
vaccination : 
• COVID -19 symptom check , both visits   
• Specimen collection  (only at Month 4  visit, see Appendix F ) 
Following completion of all procedures in the preceding list , and if results 
indicate that vaccination may proceed, vaccination is prepared and administered , 
per Moderna EUA Fact Sheet and Full Prescribing Information for Vaccination 
Providers that can be accessed at https://www.modernatx.com/c ovid19vaccine -
eua/).  
• End of study questionnaire  at Month 5 (Visit 6)  
For participants who have already received COVID -19 vaccination  outside of 
study prior to Month 4 (Visit 5) visit or who decline vaccination, the following 
procedures are performed at Vi sit 5; Visit 6 will not occur (see  Appendix F ):  
• Specimen collection   
• End of Study questionnaire  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 65 of 166 9.7 Procedures for Main Cohort participant diagnosed with a SARS -CoV-
2 infection during the study  
If a participant is diagno sed with a  SARS -CoV -2 infection  during the course of 
the study, CDC guidelines on administration of vaccination will be followed.  
Main Cohort participants who are clinically diagnosed with SARS -CoV -2 
infection (from any test result indicative of acute inf ection ) are referred to as 
clinically diagnosed index cases. They will be instructed to isolate per local 
guidelines and the following procedures will be performed:  
• eDiary collection of daily symptoms of COVID -19 and assessment of whether 
clinical care was  sought or  hospitalization occurred  (via self -report  and/or 
request for medical records) through an eDiary for a period of 1 4 days or until 
symptoms have resolved , whichever is longer  
• Daily nasal swabbing continued per schedule of procedures (see  Appendix E ) 
• Blood collection by phlebotomist or participant  for SARS -CoV -2 clinical 
serology  
• Close contacts identification (see Section 9.9) 
Following resolution of the isolation  period, participants wil l continue scheduled 
study visits. Follow -up duration for participants diagnosed with moderate or 
severe COVID -19 disease may be adjusted in consultation with the CRS (eg, to 
avoid interference with participant initiation of SARS -CoV -2 treatment).  
9.8 Enrollm ent and follow -up procedures for Prospective Close Contact 
(PCC)  cohort   
Upon enrollment, p articipants from the Main Cohort  will be asked to invite  
individuals with whom  they will be in frequent close physical proximity  during 
the study  to join the PCC cohort (See Section 7.5 and CoVPN 3006 SSP for 
additional information on PCC  cohort ). New PCC contacts may also be added 
during the study . 
Prospective close  contacts will be given  referral codes and information about  how 
to enroll in the study as part of the PCC  cohort . If they choose to enroll and sign 
an informed consent , they will be asked to:  
• provide access to  their routine SARS -CoV -2 testing reports , if applicable  
• enter data weekly  through eDiary  (see Section 9.16) 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 66 of 166 If a PCC  cohort  participant or the Main Cohort  participant to whom  he/she is 
connected  is diagnosed with a SARS -CoV -2 infection  during the course o f the 
study, the  PCC  cohort  participant  will be instructed  to perform the following 
procedure s (see  Appendix G ): 
• eDiary collection of daily symptoms of COVID -19 and assessment of whether 
clinical care was sought or hospitalization occurred  (via self -report  and/or 
request for medical records) through an  eDiary for a peri od of 1 4 days or until 
symptoms have resolved , whichever is longer  
• provide nasal swab for 14 days  
• self-collect blood samples on day 1 and day 29, relative to the notification of 
infection  
For Main Cohort  participants who are also PCC  cohort participants  related to a n 
index case  in another Main cohort participant , the following procedures in 
addition to those listed in  Appendix E  may be performed : 
• one additional blood collection (self -collection)  as soon as po ssible  following 
the report of the index case  
• eDiary collection of information  regarding exposure to the Index case  
• eDiary collection of daily symptoms of COVID -19 and assessment of  whether 
clinical care was sought or hospitalization occurred  (via self -report  and/or 
request f or medical records) through an eDiary for a period of 1 4 days or until 
symptoms have resolved , whichever is longer  
See CoVPN 3006 SSP for additional information on PCC  cohort.  
9.9 Enrollment and Follow -up procedures for Case -Ascertained Close 
Contact (CACC)  cohort 
Participants from the Main Cohort  who are  clinically diagnosed with SARS -CoV -
2 (referred to as the Index case) during the study will be asked to contact any 
individuals with whom they have been in close contact within about 72 hours of  
the date of the  SARS -CoV -2 diagnosis test . See Section 7.6 and CoVPN 3006 
SSP for additional information on case-ascertained c lose contac ts. 
Potential CACC  cohort participants  will be given  referral codes and information 
about how to enroll in  the study as part of the CACC  cohort, if they choose to, 
and sign an informed consent.  
Once a volunteer has consented to be a part of CACC  cohort, the following 
procedures will be performed  (see Appendix H ): 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 67 of 166 • eDiary collection o f information  regarding exposure to the Index case  
• eDiary collection of daily symptoms of COVID -19 and assessment of whether 
clinical care was sought or hospitalization occurred  (via self -report  and/or 
request for medical records) through an eDiary for a p eriod of 1 4 days or until 
symptoms have resolved , whichever is longer . 
• Outcomes of SARS -CoV -2 test ing performed by the school  or other facilities  
• Nasal swab self-collection from day 1 -14 
• Blood collection by participant for SARS -CoV -2 clinical serology at day 3 
and at day 2 9 
If a CACC  participant is diagnosed with a SARS -CoV -2 infection  during the 
course of the study , they will be instructed to track daily symptoms of COVID -19 
through an eDiary for a period of 1 4 days or until symptoms have resolved , 
whichev er is longer .  
For Main Cohort participants who are also CACC  cohort  participants , the 
follow ing procedures in addition to those listed in  Appendix E  may be performed:  
• one additional blood collection (self -collection)  as soon as  possible  
• eDiary c ollection o f information regarding exposure to the Index case   
• eDiary collection of daily symptoms of COVID -19 and assessment of whether 
clinical care was sought or hospitalization (via self -report  and/or request for 
medical records) occurred  through an eDiary for a period of 1 4 days or until 
symptoms have resolved , whichever is longer . 
9.10 Visit windows and missed visits  
Visit windows are included in Appendix I . The procedures for documenting 
missed visits and out  of window visits are described in CoVPN 3006  SSP.   
9.11 Discontinuing vaccination for a part icipant who receives  a COVID -19 
Vaccine outside the study  
In the event a participant receives an EUA or licensed COVID -19 vaccine outsi de 
the study , an individual participant’s  study vaccinations will be permanently 
discontinued . Participants should be counseled on the importance of continuing 
with the study and strongly encouraged to participate in follow -up visits and 
protocol -related p rocedures per the protocol for the remainder of the trial, unless 
medically contraindicated.   
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 68 of 166 9.12 Early termination visit  
In the event of early participant termination, site staff should consider if final 
specimen collection is appropriate .  
9.13 Pregnancy  for Main  Cohort  
For Main cohort participants who have been vaccinated, p regnancies and 
pregnancy outcomes will be reported via the FDA/CDC Vaccine Adverse Event 
Reporting System (VAERS)  (see Section  11.1).  
9.14 SARS -CoV-2 monitoring by schools  for Main Cohort , if applicable  
For p articipating schools  that have SARS -CoV -2 monitoring plans in place , 
monitoring will typically provide approximately  twice weekly SARS -CoV -2 
testing for enrolled Main Cohort participants . For any positive test result, t he 
institution will inform the student  (initiating isolation ), will provide the SARS -
CoV -2 test results  to the students , and will carry out contact tracing  if applicable . 
Participants will be instructed to report positive test result s via the eDiary.   
9.15 COVID -19 symptom surveillance  for Main Cohort  
Participants will be monitored for symptoms of COVID -19 throughout the course 
of the study via a weekly eDiary. These symptoms will be used to establish 
whether a participant meets criteria for COVID -19 disease as defined  by 
Secondary Endpoint 4.  If a part icipant has symptoms consistent with COVID -19, 
they will be encouraged to seek testing and clinical care through their local testing 
and care facilities. Results of testing will be reported throu gh the eDiary and 
participants who have positive test results  will follow procedures described in 
Section 9.7. 
For Immediate Vaccination Group only: due to the overlap of symptoms that can 
result from vaccination and symptoms o f COVID -19, monitoring will begin 7 
days following the first study product administration. Symptom monitoring will 
be paused 7 days  following the second product administration.  
9.16 Use of electronic Diar y (eDiar y) for Clinical Outcomes Assessments  
At the time  of consent, participants must confirm they will be willing to complete 
an eDiary  collection of study data (see below for details of data to be collected) . 
The eDiary will be completed  using an  application downloaded to their 
smartphone  or tablet . This stu dy will utilize the Medidata Patient Cloud 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 69 of 166 Application as the eDiary software. This application allows for real -time data  
collection directly  from participants.  
After participants have signed the informed consent , all participant s will be 
instructed  to downl oad the eDiary application on their personal smartphone  or 
tablet . The eDiary application has a self -training component, enabling immediate 
use. The site staff will perform any retraining as necessary.  
For Main Cohort  participants ,  
Study participants will  record data in the eDiary throughout the study  as described 
in Appendix E  and Appendix F , following the prompts provided for data 
collection . eDiary data collection areas  may include:  
• Medical history  questionnaire  
• Volunteer demographics  
• Risk assessment for SARS -CoV -2 infection (see Appendix E  and Appendix F ) 
• Surveillance for symptoms of COVID -19 (see Section 9.15) 
• Self-collection  of samples (eg , nasal swabs)  (see Appendix E  and Appendix F ) 
• Outcomes of SARS -CoV -2 testing performed by the school  or other facilities  
(see Appendix E  and Appendix F ) 
• COVID -19 symptom tracking  upon incide nt diagnosis of SARS -CoV -2 
infection , including assessments of whether clinical care was sought or 
hospitalization occurred  via self -report  and/or request for medical records (see 
Section 9.7) 
Additionally , participants will be reminded through the eDiary  of the need to 
continue practices for reducing  acquisition and transmission  of SARS -Cov-2 
regardless of t heir vaccination status.  
For Prospective Close Contact (PCC) cohort participants ,  
PCC  participants record data in the eDiary  as described in Appendix G, following 
the prompts provided for data collection . eDiary data collection  areas may 
include:  
• Collection of demographic  information  
• Collection of information regarding exposure to the main study participant  
• Outcomes of SARS -CoV -2 testing performed by the school  or other facilities  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 70 of 166 • Self-collection of samples (eg, nasal swabs) (se e Appendix G ) 
• COVID -19 symptom tracking upo n incident diagnosis of SARS -CoV -2 
infection  in PCC or main study participant, including assessments of whether 
clinical care was sought or hospitalization occurred  via self -report  and/or 
request for medical records  
• Recording of any COVID -19 vaccines rece ived outside of the study  
For Case -Ascertained Close Contact (CACC) cohort  participants ,  
CACC  participants will record data in the eDiary  as described in Appendix H , 
following the prompts provided for data collection . eDiary data collection areas 
may include:  
• Collection of demographic  information  
• Collection of information regarding exposure to the Index c ase 
• Outcomes of SARS -CoV -2 testing performed by the school or other facilities  
• COVID -19 symptom tracking , including assessments of whether clinical care 
was sought or hospitalization occurred  via self -report  and/or request for 
medical records  
• Self-collect ion of samples (eg, nasal swabs) (see  Appendix H ) 
• Recording of any COVID -19 vaccines received outside of the study  
CoVPN 3006  Versio n 4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 71 of 166 10 Laboratory  
10.1 CRS laboratory procedures  
The CoVPN 3006  SSP and other study materials  provide further guidelines for 
operational issues concerning the clinic s and laborat ories . These documents  
include special considerations for phlebotomy and guidelines for general 
specimen collection , specimen labeling  and specimen processing . 
Tube types for blood collection are specified in CoVPN 3006  SSP. 
Of note, al l assays described below , with the exception of SARS -CoV -2 PCR,  are 
performed as research assays to evaluate the ability of the SARS -CoV -2 virus  to 
induce immune responses in the context of the participants’ genetic background 
and are not appr oved for use in medical care. Results from these research assays 
are not  made available to participants or medical professionals to guide treatment 
decisions.  
10.2 Total blood volume  
Required blood collections  per visit are shown in Appendix E , Appendix F , 
Appendix G  and Appendix H . The total blood volume drawn for each participant 
will not exceed 500 mL in any 56 -day (8 -week) per iod.  
10.3 Endpoint assays  
10.3.1  SARS -CoV-2 PCR  
Real-time reverse transcription polymerase chain reaction (RT -PCR) assays to 
detect SARS -CoV -2 will be run on nasal samples collected from study 
participants. After RNA extraction, specimens will be analyzed by a labor atory 
developed test u sing the World Health Organization’s E/RdRp primer set, the 
N1/N2 primer set from the Centers for Disease Control and Prevention, or tests 
from Hologic (Panther Fusion), DiaSorin (Simplexa), or Roche (cobas). Novel 
methods to detect S ARS -CoV -2 may also be used if applicable.  
10.3.2  SARS -CoV-2 viral sequencing  
Genome sequencing of SARS -CoV -2 virus may be performed on nasal samples 
from study participants using a metagenomic approach. RNA from positive 
specimens is converted to a cDNA library b y reverse transcriptio n and the library 
is sequenced. Resulting consensus sequences are assembled against a SARS -CoV -
2 reference genome.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 72 of 166 10.3.3  Neutralizing antibody assay (nAb)  
SARS -CoV -2–specific nAb assays may be performed on serum samples from 
study particip ants. The assay will t est neutralization of S -pseudotyped and/or full-
genome recombinant viruses as measured by a reduction in luciferase (Luc) 
reported gene expression after infection in ACE -2 positive cells.  
10.3.4  Binding antibody multiplex assay (BAMA)  
SARS -CoV-2 specific total Ig G and IgM  binding antibodies may be assessed in 
serum samples. In addition, SARS -CoV -2–specific serum IgA and  IgG subclass 
(IgG1, IgG2, IgG3, and IgG4) antibodies may also be assessed.  Epitope 
specificity by ACE -2 blocking assay and responses to endemic co ronavirus 
proteins may also be assessed.  
10.3.5  Antibody avidity (BioLayer Interferometry and BAMA avidity index)  
SARS -CoV -2-specific polyclonal serum antibody and IgG subclass avidity may 
be measured using BAMA with the addition of a d issociation step to calcula te the 
antibody avidity index (BAMA -AI). BLI and/or SPR technologies may also be 
used to measure antibody avidity.  
10.3.6  Fc-Mediated Antibody Function  
Additional assays to measure SARS -CoV -2-specific  antibody Fc functions  may 
be perfo rmed  (ie, antibody dependen t cellular cytotoxicity  [ADCC ], antibod y-
dependent  cellular  phagocytosis  [ADCP] , antibody -dependent neutrophil 
phagocytosis [ADNP],  binding antibody FcR array , and S-protein -Expressing Cell 
Antibody Binding Assay [SECABA ]). 
10.4 Lab a ssay portfolio  
Additional a ssays may be performed per the Laboratory Center assay portfolio, 
which includes immune assessments such as those for cellular, humoral, and 
innate immune responses , and  host genetics. The assay portfolio  will be updated 
periodically to include new assays  and adjust qualification levels of existing 
assays . 
10.5 Exploratory studies  
Samples may be used for other testing and research related to furthering the 
understanding of SARS -CoV -2 immunology, virology, or va ccines. In addition, 
cryopreserved samples may be us ed to perform additional assays to support 
standardization and validation of existing or newly developed methods.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 73 of 166 10.6 Specimen storage and other use of specimens  
The CoVPN  stores specimens from all study part icipants indefinitely, unless a 
participant requests  that specimens be destroyed or if requir ed by IRB/EC, or RE.  
Other use of specimens is defined as studies not covered by the protocol or the 
informed consent form s for the study ( see Appendix A , Appendix B , Appendix C , 
and Appendix D ). 
This research may relate to SARS -CoV -2, vaccines, coronaviruses , the immune 
system, and other dise ases. This could include genetic testing and, potentially, 
genome -wide studies. This research is done only to the extent authorized in each 
study site’s informed consent form, or as otherwise authorized under applicable 
law. Other research  on specimens (“other use”) will occur only after review and 
approval by the CoVPN , the IRB/EC of the researcher requesting the specimens, 
and the IRBs/ECs/REs of the CRSs if required.  
As part of consenting for the study, participants document their initial decision to 
allow or not allow their specimens to be used in other research, and  they may 
change their decision at any time. The participant’s initial decision about other 
use of their specimens, and any later change to that decision, is recorded by their 
CRS in a Web -based tool that documents their current decisions for other use of 
their specimens. The CoVPN will only allow other research to be done on 
specimens from participants who allow such use.  
CRSs must notify CoVPN  Regulatory Affairs if institutional or local 
governmental requirements pose a conflict with or impose restriction s on 
specimen storage or other use of specimens.  
10.7 Biohazard containment  
The transmission of blood -borne pathogens can occur through contact with  
contaminated needles, blood, and blood products, and the transmission of SARS -
CoV -2 and other respiratory pathog ens may occur through contact with 
contaminated respiratory droplets, aerosols, and other biological materials. 
Appropriate precautions will be  employed by all personnel in the collection,  
shipping , and handling of all specimens for this study, as currentl y recommended 
by local health authorities, the CDC , the NIH , or other applicable agencies.  
All dangerous goods materials, including Biological Substances, Category A or 
Category B, must be transported according to instructions detailed in the 
International  Air Transport Association Dangerous Goods Regulations.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 74 of 166 11 Safety Reporting   
11.1 FDA/CDC Vaccine Adverse Event Reporting System (VAERS)  
The Vaccine Ad verse Event Reporting System (VAERS ) is co-managed by the 
U.S. CDC and FDA and serves as the reporting mechanism for adverse events 
occurring from licensed and EUA vaccines, including the Moderna  COVID -19 
vaccine being used in this trial. VAERS accepts and  analyzes reports of adverse 
events (AEs) after a person has received a vaccination. It is accessed at 
https://va ers.hhs.gov/reportevent.html . 
Risks associated with receipt of the Moderna COVID -19 Vaccine and AE 
reporting  requirements are described in the “Fact Sheet For Healthcare Providers 
Administering Vaccine ( Vaccination  Providers) Emergency Use Authorization 
(EUA) Of The Moderna COVID -19 Vaccine To Prevent Coronavirus Disease 
2019 (COVID -19)”, available at https://www.modernatx.com/co vid19vaccine -
eua/. 
All v accination  providers , including those at the CRS, are required to report to 
VAERS the following adverse ev ents after COVID -19 vaccination, under 
Emergency Use Authorization (EUA), and other adverse events if later revised by 
CDC  |(https://www.cdc.gov/vaccines/covid -19/vaccination -provider -support.html  
and https://vaers.hhs.gov/faq.html ): 
• Vaccine administration  errors, whether or not associated with an adverse 
event (AE)  
• Serious AEs regardless of causality. Serious AEs per FDA are def ined as:  
▪ Death;  
▪ A life -threatening AE;  
▪ Inpatient hospitalization or prolongation of existing hospitalization;  
▪ A persistent or sign ificant incapacity or substantial disruption of the ability 
to conduct normal life functions;  
▪ A congenital anomaly/birth defec t; 
▪ An important medical event that based on appropriate medical judgement 
may jeopardize the individual and may require medical or  surgical 
intervention to prevent one of the outcomes listed above.  
• Cases of Multisystem Inflammatory Syndrome  
• Cases of COVID -19 that result in hospitalization or death  
CoVPN 30 06 Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 75 of 166 CRS vaccination providers are encouraged to report to VAERS any additional 
clinically s ignificant AEs following vaccination, even if they are not sure if 
vaccination caused the event; and are to  report any additio nal select AEs and/or 
any revised safety reporting requirements per FDA’s conditions of authorized use 
of vaccine(s) throughout th e duration of any COVID -19 Vaccine being authorized 
under an EUA.    
CRS vaccination providers  will complete and submit reports to VAERS online at 
https://vaers.hhs.gov/reportevent.html. Further assistance with reporting to 
VAERS is accessed by calling 1 -800-822-7967. The reports should include the 
words “Moderna COVID - 19 Vaccine EUA” in the descr iption section of the 
report.  
As indicated in the “Fact Sheet For Healthcare Providers Administering Vaccine 
(Vaccination Providers) Emergency Use Authorization ( EUA) Of The Moderna 
COVID -19 Vaccine To Prevent Coronavirus Disease 2019 (COVID -19)”, 
vaccina tion providers  (including those at the CRS)  are encouraged, to the extent 
feasible, to report adverse events to Moderna . 
11.2 Reporting safety events to v -safe 
An addit ional source of VAERS reports will be through a program administered 
by the CDC known as v -safe (https://www.cdc.gov/coronavirus/2019 -
ncov/vaccines/safety/vsafe.html). V -safe is a smartphone -based opt -in program 
that uses text messaging and web surveys fro m CDC to check in with vaccine 
recipients for health problems following COVID -19 vaccination.  The system also 
will provide telephone follow -up to anyone who reports medically significant 
(important) adverse events. Responses indicating missed work, inabili ty to do 
normal daily activities, or that the recipient received care from a doctor or other 
healthcare professional will trigger the VAERS Call Center to reach out to the 
participant and collect information for a VAERS report, if appropriate . CRS 
vaccinat ion providers will encourage the study participants receiving the Moderna 
COVID -19 vaccine to use  v-safe. 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 76 of 166 12 Protocol conduct  
This protocol and all actions and activities connected with it will be conducted in 
compliance with the principles of GCP (ICH E6 (R2)), and according to NIAID  
and CoVPN  policies and procedures as specified in the CoVPN 3006 SSP , NIAID  
Clinical Research Policies and Standard Procedures Documents including 
procedures for the following:  
• Protocol registration, activation, and implementatio n; 
• Informed consent, screening, and enrollment;  
• Study participant reimbursement;  
• Clinical and safety assessments;  
• Safety monitoring and reporting;  
• Data collection, documentation, transfer, and storage;  
• Participant confidentiality;  
• Study follow -up and close -out; 
• Unblinding of staff and participants;  
• Quality control;  
• Protocol monitoring an d compliance;  
• Specimen collection, processing, and analysis ; 
• Exploratory and a ncillary studies  and sub -studies , and  
• Destruction of specimen s. 
Any policies or procedures that  vary from NIAID  and CoVPN  standards or 
require additional instructions (eg, instru ctions for randomization specific to this 
study) will be described in the CoVPN 3006  SSP. 
12.1 Study termination  
NIAID reserves the right to term inate or curtail a clinical study for any reason, 
including but not limited to the following (reference: 
https://grants.nih.gov/grants/guide/rfa -files/RFA -AI-12-012.html  ): 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 77 of 166 • risk to subject  safety  
• the scientific question is no longer relevant or the objecti ves will not be met 
(ie, slow accrual)  
• failure to comply with GCP, U.S. Federal regulations, or Terms and 
Conditions of Award  
• occurrence of unforeseen drug safety issues or data from preclinical studies 
indicate  a presence of unanticipated toxicity  
• risks t hat cannot be adequately quantified  
• ethical concerns raised by the local community or local medical care/health 
care authorities  
• failure to remedy deficiencies identified through site monitoring  
• substandard data  
• reaching a major study endpoint substantiall y before schedule with persuasive 
statistical significance.  
This study may also be terminated early by the determination of the FDA , the 
United States Department of Health and Human Services Office for Human 
Research Protections (OHRP). In addition, the co nduct of this study at an 
individual CRS may be terminated by the determination of the IRB/EC and any 
applicable RE.  
12.2 Emergency communication with study participants  
As in all clinical research, this study may ge nerate a need to reach participants 
quickly t o avoid imminent harm, or to report study findings that may otherwise 
concern their health or welfare  and their willingness to remain on study . 
When such communication is needed, the CRS will request that its IR B/EC and 
any applicable RE expedite review of  the message. If this review cannot be 
completed in a timeframe consistent with the urgency of the required 
communication, the site can contact the participant without IRB/EC approval if 
such communication is ne cessary to avoid imminent harm  to the study p articipant. 
The CRS must notify  the IRB/EC and  any applicable RE  of the matter as soon as 
possible.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 78 of 166 13 Version history  
The Protocol Team may modify the original version of the protocol. 
Modifications are made to CoVPN  protocols via clarification memos, letter s of 
amendmen t, or full protocol amendments.  
The version history of, and modifications to, Protocol CoVPN 3006  are described 
below . 
Protocol history and modifications  
Date: May 20, 2021  
Protocol version: Version 4.0  
Protoco l modification: Full Protocol Amendment 3  
Item 1  Revised in Title page, Section 1, Overview, Section 2, Background, Section 
6, Statistical considerations, Section 7.1, Inclusion criteria for main cohort, 
Appendices A, C, and D, Sample informed consent form s, and Appendices 
E-H, Procedures: definition of Main cohort participant expanded to include 
non-student adults aged 18 through 29  
Item 2  Revised throughout the protocol: delayed  vaccination group renamed 
standard of care group  
Item 3 Added in Section 1, O verview, Section 2, Background, Section 6, 
Statistical considerations, Section 7.1 and 7.2, Inclusion and Exclusion 
criteria for Main Cohort, Immediate Vaccination and Standard o f Care 
groups, Section 7.3, Inclusion criteria for Main cohort, Vaccine Declin ed 
group, Section 7.4, Exclusion criteria for Main cohort, Vaccine Declined 
Group, Section 9, Clinical procedures, Appendix B, Sample informed 
consent form for Main cohort, Vacci ne Declined Group, Appendices A, C 
and D, Sample informed consent forms, and A ppendix I, Visit windows: 
new observational group, “Vaccine Declined” group, of up to 6000 
participants  
Item 4  Added in Section 7.2, Exclusion criteria for Main Cohort, Immediate  
Vaccination Group and Standard of Care Group: exclusion for volunteers 
who pr efer to be vaccinated immediately  
Item 5  Revised in Section 1, Overview and Appendices A, C, and D, Sample 
informed consent forms: number of potential participants in close conta ct 
cohorts increased  
Item 6  Updated in Section 1, Overview: increased estimate d total study duration 
from 7 months to 9 months  
Item 7  Clarified in Section 2.10, Moderna COVID -19 Vaccine, and Section 8.3, 
Acquisition of Moderna COVID -19 Vaccine: participant s may also access 
Moderna COVID -19 EUA vaccine via other sources  
Item 8  Revise d in Section 3, Objectives and endpoints and Section 6, Statistical 
considerations: inclusion of all SARS -CoV -2 infection events in analysis 
for primary endpoints and secondary e ndpoints 1 -5 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 79 of 166 Item 9  Revised in Section 3, Objectives and endpoints, explorator y objective 1: 
expanded to main study cohort  
Item 10  Revised in Section 7.1, Inclusion criteria for Main Cohort, Immediate 
Vaccination Group and Standard of Care Group: timing of  completion of 
assessment of understanding  
Item 11  Revised in Sections 7.1, 7. 3, 7.5, and 7.6, Inclusion criteria for all groups: 
access to device and internet is needed for completion of study procedures  
Item 12  Added in Section 8, Study product: definiti ons of on -study and outside of 
study vaccination  
Item 13  Clarified in Section 8, Study product: study allocated vaccine can only be 
administered to study participants  
Item 14  Added in Section 8.3, Acquisition of Moderna COVID -19 Vaccine: 
participants can a ccess Moderna COVID -19 EUA vaccine via other sources 
for on -study vaccinations  if the administration fee is either paid for by the 
study or is not billed to any party  
Item 15  Deleted from Section 9.3, Enrollment and vaccination visits for Main 
Cohort, Imme diate Vaccination Group and Section 9.6, Month 4 (visit 5) 
and Month 5 (visit 6) Visits for Main Cohort, Standard of Care Group and 
Vaccine Declined Group: parenthetical reference to temperature in COVID -
19 symptom check  
Item 16  Added in Section 9, Clinica l Procedures, and Appendix F, Procedures for 
Main Cohort, Standard of Care and  Vaccine Declined Groups: end of study 
questionnaires as procedures  
Item 17  Added in Section 9.1.2, Protocol -specific consent forms: consent forms for 
close contact cohorts may b e managed centrally by the CoVPN  
Item 18  Clarified in Section 9.15, COVID -19 symptom surveillance for Main 
Cohort: symptom overlap between COVID -19 and vaccination is only 
applicable to Immediate Vaccination Group  
Item 19  Corrected in Appendix A, Sample in formed consent form for the Main 
cohort, Immediate Vaccination and Standard of  Care Groups, Appendix C, 
Sample informed consent form for Prospective Close Contact (PCC) cohort 
and Appendix D, Sample informed consent form for Case -Ascertained 
Close Contact (CACC) cohort: frequency of eDiary entries.  
Item 20  Added in Appendix A, Sampl e informed consent form for the Main cohort, 
Immediate Vaccination and Standard of Care Groups: we may ask Main 
cohort participants to provide contact information for potential c lose 
contact cohort volunteers  
Item 21  Clarified in Appendix A, Sample informe d consent form for the Main 
cohort, Immediate Vaccination and Standard of Care Groups: Month 4 will 
be the last study visit for Standard of Care participants who receive 
COVID -19 vaccine outside the study prior to Month 4  
Item 22  Added in Appendix A, Sampl e informed consent form for the Main cohort, 
Immediate Vaccination and Standard of Care Groups: the risk of delaying 
COVID -19 vaccination  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 80 of 166 Item 23  Added in Appendix C, Sample info rmed consent form for Prospective 
Close Contact (PCC) cohort and Appendix D, S ample informed consent 
form for Case -Ascertained Close Contact (CACC) cohort: new section 
“Risks of COVID -19” 
Item 24  Deleted from Appendices A, C and D, Sample informed consent forms: 
sentence that states we will not share your name or identifying informa tion 
with the CoVPN  
Item 25  Clarified in Appendix A, Sample informed consent form for the Main 
cohort, Immediate Vaccination and Standard of Care Groups: benefits of 
COVID -19 vac cination  
Item 26  Added in Appendices A, C, and D, Sample informed consent form s: 
participants will be prompted to scan the barcode on nasal swabs  
Item 27  Updated in Appendices A, C, and D, Sample informed consent forms: 
recommendation to follow federal, state, and local guidelines for SARS -
CoV -2 prevention  
Item 28  Updated in Appendi ces A, C, and D, Sample informed consent forms: 
contact information for Advarra IRB  
Item 29  Updated in Appendix A, Sample informed consent form for the Main 
cohort, Im mediate Vaccination and Standard of Care Groups: Moderna 
COVID -19 Vaccine, risks and numb er of vaccinated people  
Item 30  Updated Title page and Section 13, Version history: contents of this 
amendment  
Item 31  Throughout the protocol: minor editorial changes , clarifications, and 
corrections  
Date: April 12, 2021  
Protocol version:  3.0 
Protocol mod ification:  Full protocol amendment 2  
Item 1  Added in Section 1, Overview  and Section 6, Statistical considerations : 
Clinical Research Sites (CRSs) that can participate in the study expanded to 
include non -university affiliated CoVPN Clinical Research Sites  (CRSs)  
Item 2  Revised in Section 1, Overview , Section 2, Background , Section 6, 
Statistical considerations , Section 7.1, Inclusion criteria for main cohort , 
Section 9, Clinical procedures , and Appendix A, Sample informed consent 
form for the Main cohort : definition of participant expanded to include 
students enrolled in any post -secondary educational institution  
Item 3  Revised in Section 1, Overview , Section  2, Background , Section 6, 
Statistical considerations, Section 7.3 , Inclusion criteria for Prospecti ve 
Close Contact (PCC) cohort, Section 9 , Clinical procedures, and 
Appendices A, B, D, E, F: University SARS -CoV -2 testing is not required  
Item 4  Revised in  Section 9.3 , Enrollment and vaccination visits for Main Cohort, 
Immediate Vaccination Group , Sectio n 9.5,  Enrollment (visit 2) and visit 4 
(Month 2) for Main Cohort, Delayed Vaccination Group  and Appendix H, 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 81 of 166 Visit windows : maximum recommended time between  randomization and 
completion of Visit 2 activities increased from 4 days to 7 days  
Item 5  Clarified  in Section 2, Background , Section 6, Statistical considerations , 
and Section 9.7, Procedures for Main Cohort participant diagnosed with a 
SARS -CoV-2 infection during the study : any SARS -CoV -2 test result 
indicative of acute infection (on or off study) obt ained from a Main cohort 
participant will trigger “index -case” activities  
Item 6  Clarified in Section 2, Background , Section 6.4.3, Vaccine  efficacy (VE) 
analyses against SARS -CoV-2 infection , Section 7.1, Inclusion criteria for 
main cohort , Section 9, Clinical procedures , Appendix A, Sample informed 
consent form for Main cohort , and Appendix B, Sample informed consent 
form for Prospective Cl ose Contact (PCC) cohort : participants can choose 
to obtain an EUA or licensed COVID -19 vaccine outside the study  
Item 7 Added to Section 3, Objectives and endpoints : 2 endpoints for the duration 
of viral shedding specified in corresponding secondary objec tive 4  
Item 8  Clarified in Section 6, Statistical considerations, 7th paragraph:  primary 
analysis occurs when partici pants complete 4 months of follow -up 
Item 9  Clarified in Table 6 -1, Study analysis sets and definitions : Day 29 is visit 3 
for immediate va ccination arm and will be define in Statistical analysis plan 
(SAP) for delayed vaccination arm  
Item 10  Revised in Se ction 6.3, Randomization : randomization evaluated within 
levels defined by study site and type of residence  
Item 11  Clarified in Section 6. 4.3.1, Primary VE Analysis : rationale for choice of 
analysis  
Item 12  Revised in Section 6.4.5.2, Analyses of the vacc ine effect on secondary 
transmission : details of the derivation  
Item 13  Revised in Section 7.2, Exclusion criterion #1 for Main Cohort: removed 
febrile assessment  
Item 14  Clarified in Section 2.10, Moderna COVID -19 Vaccine , and Section 8.3, 
Acquisition of Moderna COVID -19 Vaccine : Moderna COVID -19 Vaccine 
provided under EUA and allocated for this trial  
Item 15  Corrected in Section 9, Clinical procedures : CRS staff will obtain informed 
consent of participants according to the COVPN 3006 SSP  
Item 16  Corrected  in Appendix A, Sample informed consent form for Main cohort: 
blood will be collected 3 times for delayed vaccination arm  
Item 1 7 Added to Appendix B, Sample informed consent form for Prospective 
Close Contact (PCC) cohort: COVID -19 care is not paid for by  the study  
Item 18  Added to Appendices A, B, C, Sample informed consent forms : information 
regarding employee/family member part icipation  
Item 19  Added to Appendices A, B, C, Sample informed consent forms : terms of 
use for data collection via web -based app  
Item 20  Deleted in Appendix B,  Sample informed consent form for Prospective 
Close Contact (PCC) cohort, and Appendix C, Sample informed consent 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 82 of 166 form for Case -Ascertained Close Contact (CACC) cohort, item 8: text 
referring to vaccine receipt  
Item 21  Added to Appendix H, Visit windows for CACC: upper allowable window 
for blood specimen collection  
Item 22  Added changes per Protocol v  2.0, Letter of Amendment 1  
Item 23  Updated Title page and Section 13, Version history : contents of this 
amendment  
Item 24  Updat ed Section 1.1, Protocol team : deletion of Site Principal Investigator 
representative  
Item 25  Throughout the protocol: minor editorial changes, clarifications, and 
corrections  
Date: March 10, 2021  
Protocol version: Version 2.0  
Protocol modification: Letter  of Amendment 1  
Item 1  Added in Section 10.1, CRS laboratory procedures , Appendices A, B, and 
C, Sample informed consent forms : return of SARS -CoV -2 nasal swab 
testing results to participants  
Item 2  Added to Section 1.1, Protocol team : Jasmine Marcelin, co -chair and 
Jeffrey L Carson, Site Principal Investigator representative  
Date: February 26, 2021  
Protocol version: 2.0 
Protocol modification: Full protocol amendment 1  
Item 1  Revised in Section 3, Objective and Endpoints, Section 6, Statistical 
consideratio ns, Section 9, Clinical procedures , Appendix A, Sample 
informed consent form for the main cohort , and Appendices D and E, 
Procedures for the main cohort : Month 3 visit removed for both Main 
cohort groups, M1 visit removed for delayed vaccination group of M ain 
cohort, and Month 1 blood collection removed for immediate v accination 
group of Main cohort  
Item 2  Added in Section 1, Overview : 2 new endpoint laboratories  
Item 3  Updated in Section 1.1, Protocol team : team members  
Item 4  Deleted Section 6.1, Accrual restrictions : no accrual restrictions for this 
study  
Item 5  Revi sed in Section 6.4, Statistical analyses : minor clarifying text revisions  
Item 6  Corrected in Section 6.4.4.7, VL analyses, 3rd paragraph: reference to 
secondary endpoint number  
Item 7  Deleted  in Section 9.3, Enrollment and vaccination visits for Main Coho rt, 
Immediate Vaccination Group  and Section 9.5, Enrollment (visit 2) and 
visit 4 (Month 2) for Main Cohort, Delayed Vaccination Group: sentence 
regarding clinical lab results  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 83 of 166 Item 8  Added in Section 9.15,  Use of electronic Diary (eDiary) for Clinical 
Outc omes Assessments,  and Appendices F through G, Procedures : end of 
study questionnaire regarding COVID vaccines received outside the study  
Item 9  Added in Appendices A, B, and C, Sample informed  consent forms , section 
“Being in the study”: participants will take an end of study questionnaire  
Item 10  Added in Appendix B, Sample informed consent form for Prospective 
Close Contact (PCC) cohort , and Appendix C, Sample informed consent 
form for Case -Ascertained Close Contact (CACC) cohort , section “Being 
in the study”: applicable participants will receive SARS -CoV -2 screening 
at the University about two times per week.  
Item 11  Deleted in Appendices A, B, and C,  Sample informed consents, second 
sentence : reference to alternate study name of “vPROTECT”  
Item 12  Adde d in Appendix A,  Sample informed consent form for the main cohort: 
additional information for participant regarding text or email reminders for 
nasal swabs  
Item 13  Deleted in Appendices A, B and  C, Sample informed consents: reference to 
“electronically” fo r signature  
Item 14  Deleted in Appendices A, B and C, Sample informed consents , signature 
table: column for denoting time of signature  
Item 15  Deleted in Appendix A, Sample informed consent form  for the main cohort , 
section 8: redundant information  
Item 16  Corrected in in Appendix A, Sample informed consent form for the main 
cohort , section10: VAERS reporting requirements  
Item 17  Revised in Appendices F and G: table text and associated footnotes  
Item 18  Revised Appendix H, Visit windows, Case -Ascertained Cl ose Contact 
(CACC) cohort, to include applicable Prospective Close Contact  (PCC) 
participants who test positive for SARS -CoV -2 or whose Main Cohort 
study contact tests positive for SARS -CoV -2 
Item 19  Revised throughout protocol: minor grammatical, editori al, and formatting 
corrections.  
Item 20  Updated Title page, Table of Contents, Section 13, Version history , and 
Appendix I , Protocol signature page : dates, version number, and contents 
of this a mendment  
Date: February 17, 2021  
Protocol version: 1.0 
Protocol modification:  Not applicable  
Original protocol  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 84 of 166 14 Document references (other than literature 
citations)  
Other documents referred to in this protocol, and containing information relevant 
to the con duct of this study, include:  
• Assessment of Understandi ng. Accessible through the  CoVPN  protocol -
specific website.  
• CDC COVID -19 Vaccination Program Provider Requirements and Support . 
Available at https://www.cdc.gov/vaccines/covid -19/vaccination -provider -
support.html  
• CoVPN  Certificate of Confidentiality. Acce ssible through the CoVPN  
website.  
• CoVPN 3006  Study Specific Procedures. Accessible through the CoVPN  
protoc ol-specific website.  
• Dangerous Goods Regulations (updated annual ly), International Air Transport  
Association . Availabl e for purchase at 
https://www.iata.org/publications/dgr/Pages/index.aspx  
• International Council  on Harmonisation  of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) E6  (R2), Guideline for G ood Clinical 
Practice: Section  4.8, Informed consent of trial subjects. Available at 
http://www.ich.org/ page/efficacy -guidelines  
• Laboratory Center assay portfolio  
• Moderna COVID -19 Vaccine  EUA Fact Sheet and Full PI for Vaccination 
Providers . Available at https://www.modernatx.com/covid19vaccine -eua/. 
• Participants ’ Bill of Rights and Responsibilities. Access ible through the 
CoVPN  protocol -specific website.  
• NIH Policy on Reporting Race and Ethnicity Data: Subjects in Clinical 
Research. Availab le at https://gr ants.nih.gov/grants/guide/notice -files/NOT -
OD-01-053.html  
• Title 21, Code of Federal Regulations, Part 50. Available at 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFR
Part=50  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 85 of 166 • Title 45, Code of Federal Regulations, Part 46  (2018 req uirements) . Current 
requirements  available at https://www.hhs.gov/ohrp/regulations -and-
policy/regulations/45 -cfr-46/ind ex.html  
• VAERS , Vaccine Adverse Event Reporting System. Available at  
https://vaers.hhs.gov/reportevent.html  
• VAERS , Vacci ne Adverse Event R eporting System  FAQ . Available at 
https://vaers.hhs.gov/faq.html  
• V-safe After Vaccination Health Checker . Available at 
https://www.cdc.gov/coronavirus/2019 -ncov/vaccines/safety/vsafe.html  
See Section  16 for lite rature cited in the background and statis tics sections of this 
protocol.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 86 of 166 15 Acronyms and abbreviations  
Ab  antibody  
ACIP   Advisory Committee on Immunization Practices  
AE  adverse event  
AUC   area under the curve  
BAMA   binding antibody multiplex assay  
CAB   Comm unity Advisory Board  
CDC   US Centers for Disease Control and Prevention  
CFR   Code of Federal Regulations  
CI  confidence intervals  
COVID -19 Coronavirus disease 2019  
CoVPN   COVID -19 Prevention Network  
CRF   case report form  
CRPMC   NIAID Clinical Research Pro ducts Management Center  
CRS   clinical research site  
DAIDS   Division of AIDS (US NIH)  
DHHS   US Department of Health and Human Services  
EAE   adverse events requiring expedited reporting  
EC  Ethics Committee  
eDiary   Electronic diary  
ELISA   enzyme -linked immu nosorbent assay  
EUA   emergency use authorization  
FAS  Full analysis set  
FDA   US Food and Drug Administration  
Fred Hutch  Fred Hutchinson Cancer Research Center  
GCP   Good Clinical Practice  
GMT   geometric mean titer  
HIPAA   Health Insurance Portability and Acc ountability Act  
HIV  human immunodeficiency virus  
IB  Investigator’s Brochure  
IBC  Institutional Biosafety Committee  
ICH  International Council on Harmonisation  of Technical 
Requirements for Pharmaceuticals for Human Use  
IQR  Interquartile range  
IDMC   Independent Data Monitori ng Committee  
IM  Intramuscular  
IRB  Institutional Review Board  
LC  Laboratory Center  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 87 of 166 LNP   Lipid nanoparticle  
LOC   Leadership and Operations Center  
mRNA   Messenger ribonucleic acid  
nAb  neutralizing antibody  
NHP   nonhuman primate  
NIAID   National Institute o f Allergy and Infectious Diseases (US NIH)  
NIH  US National Institutes of Health  
OHRP   US Office for Human Research Protections  
PCR   polymerase chain reaction  
PI  Principal Investigator  
RE  regulatory entity  
SAP  Statistical Analysis P lan 
SCHARP   Statistical Center for HIV/AIDS Research and Prevention  
SDMC   statistical and data management center  
SSP  Study specific procedures  
SOP  Standard operating procedure  
UW-VL  University of Washington Virology Laboratory  
UW-VSL   University of Wash ington Virology Specialty Laboratory  
VAERS   Vaccine Adverse Event Reporting System  
VE  Vaccine efficacy  
VE I  Vaccine efficacy against infectiousness  
VEs  Vaccine efficacy against susceptibility  
VL  Viral load  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 88 of 166 16 Literature cited  
1. Johns Hopkins Coronavir us Resource Center. 2020 [Available from: 
https://coronavirus.jhu.edu/map.html.  
2. Lipsitch M, Dean NE. Understanding COVID -19 vaccine efficacy. Science. 
2020.  
3. Mehrotra DV, Janes HE, Fleming TR, Annunziato PW, Neuzil KM, Carpp 
LN, et al. Clinical Endpoi nts for Evaluating Efficacy in COVID -19 Vaccine 
Trials. Ann Intern Med. 2020.  
4. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and 
immunological assessment of asymptomatic SARS -CoV -2 infections. Nat 
Med. 2020;26(8):1200 -4. 
5. Salvatore P P, Sula E, Coyle JP, Caruso E, Smith AR, Levine RS, et al. 
Recent Increase in COVID -19 Cases Reported Among Adults Aged 18 -22 
Years - United States, May 31 -September 5, 2020. MMWR Morb Mortal 
Wkly Rep. 2020;69(39):1419 -24. 
6. Boehmer TK, DeVies J, Caruso E , van Santen KL, Tang S, Black CL, et al. 
Changing Age Distribution of the COVID -19 Pandemic - United States, 
May-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(39):1404 -9. 
7. CDC: Centers for Disease Control and Prevention. COVID -19 
Hospitalization and D eath by Age 2020 [Available from: 
https://www.cdc.gov/coronavirus/2019 -ncov/covid -data/investigations -
discovery/hospitalization -death -by-age.html.  
8. Halloran ME, Longini IM, Jr., Struchiner CJ. Design and interpretation of 
vaccine field studies. Epidemiol  Rev. 1999;21(1):73 -88. 
9. Swan DA, Goyal A, Bracis C, Moore M, Krantz E, Brown E, et al. Vaccines 
that prevent SARS -CoV -2 transmission may prevent or dampen a spring 
wave of COVID -19 cases and deaths in 2021. medRxiv. 2020.  
10. Swan DA, Bracis C, Janes H,  Moo re M, Matrajt L, Reeves DB, et al. 
COVID -19 vaccines that reduce symptoms but do not block infection need 
higher coverage and faster rollout to achieve population impact. medRxiv. 
2020.  
11. Datta S, Halloran ME, Longini IM, Jr. Efficiency of estimating  vaccine 
efficacy for susceptibility and infectiousness: randomization by individual 
versus household. Biometrics. 1999;55(3):792 -8. 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 89 of 166 12. Milani GP, Dioni L, Favero C, Cantone L, Macchi C, Delbue S, et al. 
Serological follow -up of SARS -CoV -2 asymptomatic subjec ts. Sci Rep. 
2020;10(1):20048.  
13. Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello 
M, et al. Mapping Neutralizing and Immunodominant Sites on the SARS -
CoV -2 Spike Receptor -Binding Domain by Structure -Guided High -
Resolution Serology . Cell. 2020;183(4):1024 -42 e21.  
14. Vaccines and Related Biological Products Advisory Committee Meeting. 
Sponsor Briefing Document, Moderna COVID -19 Vaccine 2020 [Available 
from: https://www.fda.gov/media/144452/download.  
15. Vaccines a nd Related Biologic al Products Advisory Committee Meeting. 
Sponsor Briefing Document Addendum,Moderna COVID -19 Vaccine 2020 
[Available from: https://www.fda.gov/media/144453/download.  
16. Flood S, King M, Rodgers R, Ruggles S, Warren J. Integrated Public U se 
Microdata Series , Current Population Survey: version 7.0 [dataset]. 2020.  
17. The New York Times. Tracking the Coronavirus at U.S. Colleges and 
Universities 2020 [Available from: 
https://www.nytimes.com/interactive/2020/us/covid -college -cases -
tracker.ht ml. 
18. Business In sider. The 10 biggest coronavirus outbreaks on college campuses 
across the US since the fall semester began 2020 [Available from: 
https://www.businessinsider.com/10 -colleges -with-fall-coronavirus -
outbreaks -1200 -cases -or-more -2020 -9. 
19. Wilson E, Donovan C V, Campbell M, Chai T, Pittman K, Sena AC, et al. 
Multiple COVID -19 Clusters on a University Campus - North Carolina, 
August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(39):1416 -8. 
20. Buitrago -Garcia D, Egli -Gany D, Counotte MJ, Hossmann S , Imeri H, Ipekci 
AM, et al. Occurrence and transmission potential of asymptomatic and 
presymptomatic SARS -CoV -2 infections: A living systematic review and 
meta -analysis. PLoS Med. 2020;17(9):e1003346.  
21. Goyal A, Reeves DB, Cardozo -Ojeda EF, Schiffer JT,  Mayer BT. Wrong 
person, place and time: viral load and contact network structure predict 
SARS -CoV -2 transmission and super -spreading events. medRxiv. 2020.  
22. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics 
in viral shedding and tran smissibility of COV ID-19. Nat Med. 
2020;26(5):672 -5. 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 90 of 166 23. Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, 
et al. Evidence for transmission of COVID -19 prior to symptom onset. Elife. 
2020;9.  
24. Kissler SM, Fauver JR, Mack C, Tai C, Shiu e KY, Kalinich CC, et al. Viral 
dynamics of SARS -CoV -2 infection and the predictive value of repeat 
testing. medRxiv. 2020.  
25. CDC: Centers for Disease Control and Prevention. Scientific Brief: 
Community Use of Cloth Masks to Control the Spread of SARS -CoV-2 2020 
[Available  from: https://www.cdc.gov/coronavirus/2019 -ncov/more/masking -
science -sars-cov2.html.  
26. Jung CY, Park H, Kim DW, Choi YJ, Kim SW, Chang TI. Clinical 
Characteristics of Asymptomatic Patients with COVID -19: A Nationwide 
Cohort Study in S outh Korea. Int J I nfect Dis. 2020;99:266 -8. 
27. Poteat T, Millett GA, Nelson LE, Beyrer C. Understanding COVID -19 risks 
and vulnerabilities among black communities in America: the lethal force of 
syndemics. Ann Epidemiol. 2020;47:1 -3. 
28. Davies NG, Klepa c P, Liu Y, Prem K,  Jit M, group CC -w, et al. Age -
dependent effects in the transmission and control of COVID -19 epidemics. 
Nat Med. 2020;26(8):1205 -11. 
29. Richmond CS, Sabin AP, Jobe DA, Lovrich SD, Kenny PA. SARS -CoV -2 
sequencing reveals rapid transmissi on from college stu dent clusters resulting 
in morbidity and deaths in vulnerable populations. medRxiv. 2020.  
30. Regeneron Pharmaceuticals. Regeneron's REGN -CoV2 antibody cocktail 
reduced viral levels and improved symptoms in non -hospitalized COVID -19 
patients 2020 [Availabl e from: https://newsroom.regeneron.com/news -
releases/news -release -details/regenerons -regn-cov2 -antibody -cocktail -
reduced -viral-levels -and. 
31. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS -
CoV -2 Neutralizing An tibody LY -CoV555 in  Outpatients with Covid -19. N 
Engl J Med. 2020.  
32. Heneghan C, Brassey J, Jefferson T. SARS -CoV -2 viral load and the severity 
of COVID -19. The Centre for Evidence -Based Medicine. 2020.  
33. Pujadas E, Chaudhry F, McBride R, Richter F, Zh ao S, Wajnberg A, e t al. 
SARS -CoV -2 viral load predicts COVID -19 mortality. Lancet Respir Med. 
2020;8(9):e70.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 91 of 166 34. Westblade LF, Brar G, Pinheiro LC, Paidoussis D, Rajan M, Martin P, et al. 
SARS -CoV -2 Viral Load Predicts Mortality in Patients with and witho ut 
Cancer Who Are H ospitalized with COVID -19. Cancer Cell. 2020;38(5):661 -
71 e2.  
35. Letizia AG, Ramos I, Obla A, Goforth C, Weir DL, Ge Y, et al. SARS -CoV -
2 Transmission among Marine Recruits during Quarantine. N Engl J Med. 
2020.  
36. Datta S, Halloran ME , Longini IM, Jr. A ugmented HIV vaccine trial design 
for estimating reduction in infectiousness and protective efficacy. Stat Med. 
1998;17(2):185 -200. 
37. Halloran ME, Struchiner CJ. Causal inference in infectious diseases. 
Epidemiology. 1995;6(2):142 -51. 
38. Yang Y, Longini  IM, Jr., Halloran ME. Design and Evaluation of 
Prophylactic Interventions Using Infectious Disease Incidence Data from 
Close Contact Groups. J R Stat Soc Ser C Appl Stat. 2006;55(3):317 -30. 
39. Klick B, Leung GM, Cowling BJ. Optimal des ign of studies of i nfluenza 
transmission in households. I: case -ascertained studies. Epidemiol Infect. 
2012;140(1):106 -14. 
40. Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, 
Thorpe LE, et al. Hydroxychloroquine as Postexposure Proph ylaxis to 
Prevent S evere Acute Respiratory Syndrome Coronavirus 2 Infection : A 
Randomized Trial. Ann Intern Med. 2020.  
41. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler 
RN, et al. An mRNA Vaccine against SARS -CoV -2 - Preliminary Report. N 
Engl J Med. 20 20. 
42. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene 
M, et al. Safety and Immunogenicity of SARS -CoV -2 mRNA -1273 Vaccine 
in Older Adults. N Engl J Med. 2020;383(25):2427 -38. 
43. Vaccines and Relate d Biological Products Advisory Commi ttee Meeting. 
FDA Briefing Document, Moderna COVID -19 Vaccine 2020 [Available 
from: https://www.fda.gov/media/144434/download.  
44. UNAIDS. Ethical considerations in biomedical HIV prevention trials. 2007 
7/2007.  
45. The National Commission for the Protecti on of Human Subjects of 
Biomedical and Behavioral Research. The Belmont Report: Ethical Principles 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 92 of 166 and Guidelines for the Protection of Human Subjects of Research. 1979 
4/18/1979.  
46. Council for International Organizati ons of Medical Sciences (CIOMS). 
International ethical guidelines for biomedical research involving human 
subjects. Bull Med Ethics. 2002(182):17 -23. 
47. Sun K, Wang W, Gao L, Wang Y, Luo K, Ren L, et al. Transmission 
heterogeneities, kinetics, and control lability of SARS -CoV -2. Science. 
2021;371(6526).  
48. Li F, Li YY, Liu MJ, Fang LQ, Dean NE, Wong GWK, et al. Household 
transmission of SARS -CoV -2 and risk factors for susceptibility and 
infectivity in Wuhan: a retrospective observational study. Lancet Infe ct Dis. 
2021.  
49. Madewell ZJ, Yang Y, Longini IM, Jr, Halloran ME, Dean NE. Household 
Transmission of SARS -CoV -2: A Systematic Review and Meta -analysis. 
JAMA Network Open. 2020;3(12):e2031756 -e. 
50. Kissler SM, Fauver JR, Mack C, Olesen SW, Tai C, Shiue K Y, et al. SARS -
CoV -2 viral dynamics in acute infections. medRxiv. 2020.  
51. Grambsch PM, Therneau TM. Proportional Hazards Tests and Diagnostics 
Based on Weighted Residuals. Biometrika. 1994;81(3):515 -26. 
52. Hernan MA. The hazards of hazard ratios. Epidem iology. 2010;21(1):13 -5. 
53. Follman n D, Huang CY. Incorporating founder virus information in vaccine 
field trials. Biometrics. 2015;71(2):386 -96. 
54. Lin DY. Proportional means regression for censored medical costs. 
Biometrics. 2000;56(3):775 -8. 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 93 of 166 Appendix A  Sample in formed  consent form  for Main 
cohort , Immediate Vaccination and Standard of 
Care Groups  
 
Sponsor / Study Title:  
  National Institutes of Health, “ A randomized controlled study to 
assess SARS CoV -2 infection, viral shedding, and subsequent 
potential transmis sion in individuals  immunized with M oderna 
COVID -19 Vaccine ” 
Protocol Number:  
 CoVPN 3006  
Principal Investigator:  
(Study Doctor)  
 «PiFullName»  
 
Telephone:  
 «IcfPhoneNumber»  
 
Address:  «PiLocations»  
 
 
Thank you for your interest in our research study. It is called CoVPN 3006. This 
informed consent form will tell you more about the study. Please read it carefully 
as you decide if you want to join. If you have  questions, please ask us. At the end, 
we will  ask you to answer  a few questions to make sure you understand the study .  
If you decide to join this study, we will ask you to sign this form. We will offer 
you a copy of this form to keep.  
CoVPN 3006  is a re search study. Research is not the same as medi cal care. The 
purpose of a research study is to answer scientific questions. We hope that what 
we learn will help people in the future.  
Key information  
• Joining this research study is voluntary. It is your choic e. 
• Our scientific questions are: Does the vacc ine protect people from getting 
infected with a coronavirus called SARS -CoV -2? Does the vaccine prevent 
people from transmitting SARS -CoV -2 to others?  
• If you join, your participation in this study will last for  about 5 months.  
• If you join, we will ask you to answer questionnaires, get injections, give 
blood, and take daily swabs of your nose .  
Here are the risks of taking part:  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 94 of 166 • The most common risk is symptoms such as muscle aches or headaches after 
getting the injection . 
• There is a  risk of loss of your personal information .   
• There are other, less serious risks. We will tell you more about them later in 
this consent form.  
About the study  
The COVID -19 Prevention Network (CoVPN) is doing a study to test a vaccine 
against SARS -CoV -2. SARS -CoV -2 is the virus  that causes the disease called 
COVID -19. We want to know if the vaccine is able to protect people from getting 
infected and if getting the vaccine will affect the amount of virus that is in your 
nose. We also wan t to know if getting the vaccine will preve nt transmitting 
SARS -CoV -2 to others.  
Many  young adults  will take part in this study  around the US . This study has 5 
groups . The first 3 groups , called the Immediate Vaccin ation , Standard of Care, 
and Vaccine Dec lined groups , will be in the Main Study.   
• The Immediate Vaccin ation  and Standard of Care groups will have a bout 
12,000 people that will get vaccine injections either immediately or 4 
months later . In this study, “standard of care” refers to all federal, st ate, 
and loca l recommendations regarding COVID -19 prevention, including 
COVID -19 vaccination, masking, social distancing, isolation and 
quarantine.  
• The Vaccine Declined group will have  about 6,000 people who prefer not 
to be vaccinated and will be followed  for 4 months .  
• The last two groups  are close contacts of the Main Study : the Prospective 
Close Contact  (PCC) group will have up to 36,000 people , and the Case -
ascertained Close Contact (CACC) group  will have up to 2250 people . 
These close contact groups w ill help researchers determine if the vaccine 
prevents transmission of the SARS -CoV -2 virus to others. We will explain 
more about this later in this form.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 95 of 166 You have indicated that you are agreeable to getting vaccinated for COVID -19 as 
recommended by the Centers f or Disease Control and Prevention  (CDC)  and have 
no preference as to the timing of vaccination.  
The researcher in charge of this study at this clinic is [Insert name of site PI] . The 
US National Institutes of Health is payin g for thi s study.  
1. This study’s vaccine  has an Emergency Use Authorization (EUA)  for 
individuals 18 and older . 
The vaccine we will use in this study is called the Moderna COVID -19 Vaccine. 
The vaccine has been given to over 15,000 people in other research studies a nd 
over 100 million people under EUA. We will give you the most up -to-date “Fact 
Sheet for Recipients and Caregivers” with more information about the Moderna 
COVID -19 Vaccine. The person giving you the vaccine can answer any questions 
you might ha ve about what is in this fact sheet.  
We already know that the vaccine can prevent serious COVID -19 disease, but we  
do not know if the vaccine will work to prevent SARS -CoV -2 infection  in others.  
That is what we are testing in this study.  

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 96 of 166 The Moderna COVI D-19 Vacc ine is not approved for sale in the United States by 
the US Food and Drug Administration (FDA).  
Although the vaccine is not approved, it has an Emergency Use Authorization 
(EUA) from the FDA based on its success at preventing disease symptoms fro m 
SARS -CoV-2 in other studies to date. During a public health emergency, like the 
COVID -19 pandemic, the FDA can issue an EUA to get vaccines to people faster. 
When the FDA issues an EUA, they continue to monitor safety.  
The vaccine was developed by Moder naTX, Inc. Typical vac cines for viruses are 
made from a weakened or killed virus, but the Moderna COVID -19 Vaccine  is not 
made from the SARS -CoV -2 virus. The vaccine includes a short segment of 
messenger ribonucleic acid (mRNA). The mRNA is a genetic code that tells cells 
how t o make a protein. This mRNA is made in a laboratory. When injected into 
the body, the mRNA vaccine causes some cells to make that viral protein, which 
can trigger the immune system. Your immune system protects you from disease. 
If a p erson is later infecte d, their immune system remembers the protein from the 
vaccine which may help it to fight the virus. It is impossible for the vaccine to 
give you SARS -CoV -2 or COVID -19 infection.  
Risks of the Moderna COVID -19 Vaccine:  
To date, more t han 100 million people  have already received the Moderna 
COVID -19 Vaccine . In clinical trials, most people who got the vaccine had some 
reaction after their injections, especially after the second injection. The reaction to 
the vaccine didn’t affect their daily lives and it wen t away after two or three days. 
Most of these people said they had pain in the arm where they got the injection. 
These people also felt tired, had headaches, muscle and joint pain, and chills. A 
much smaller number of these people sai d they had redness or swelling where the 
needle went in their arm.  Some people had swelling of the lymph nodes in the 
same arm  of the injection . 
The risks of the study vaccine seen so far are the same as what have been seen 
with most vaccines. Generally, v accines can cause fever, chills, rash, aches and 
pains, nausea, headache, dizziness, and feeling tired. Vaccines can also cause 
pain, redness, swelling, or itching where you got the injection. Most people can 
still do their planned activities after getting  a vaccine. Rarely , people have side 
effects that limit their normal activities or make them go to the doctor.  
Rarely, a vaccine can cause you to have an allergic reaction. You might have a 
rash, hives, swelling of your face and throat, a fast heartbeat, d izziness and 
weakn ess, or trouble breathing. Allergic reactions can be life -threatening. Tell us 
if you have e ver had a bad reaction to any injection or vaccine.  
There may be other risks that we don’t yet know about, even serious ones. We 
will tell you if we learn about any  new risks.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 97 of 166 Joining the study  
2. You will receive  the vaccine immediately or later . 
Some people will get the study vaccine immediately. Other people will get the 
study vaccine 4 months later .  
We will compare the results from people who got the vaccine immediately with 
results from people who got the vaccine later. In this way, we will be able to tell if 
the vaccine can prevent SARS -CoV -2 infection.  
You have a 50/50 chance of getting the vaccin e immediately or later. Whether 
you get the vacc ine immediately or a little later is completely random, like 
flipping a coin.  
We have no say in whether you get the vaccine immediately or later.  
3. It is completely up to you whether or not to join this study.  
Take your time in deciding. If it helps, talk t o people you trust, such as your 
doctor, friends , or family . If you decide not to join this study, or if you leave it 
after you have joined, it will not change your healthcare. If you do join, you do 
not give  up your legal rights.  
You cannot be in this st udy while you are in another study where you get a study 
product.  
If you choose not to join this study, you may be able to join another study.   
If you have a preference to be vaccinated immediately, you have  the option to not 
join the study and instead re ceive vaccination outside of the study right away.  
If you have a preference to not be vaccinated at all, you have the option to join the 
“Vaccine Declined” observational group . 
If you are an employee or rela tive of an employee of the study site , you are u nder 
no obligation to participate in this study . You may withdraw from the study at any 
time and for any reason, and your decision will not have any effect on your/your 
family member’s performance appraisal o r employment at the study site . You 
may refuse t o participate or you may withdraw from the study at any time without 
penalty or anyone blaming you.  
If you are a student, your participation will not place you in good favor with the 
study doctor or other f aculty (for example, receiving better grades, 
recommendations, employment). Also, not participating in this study will not 
adversely affect your relationship with the study doct or or other faculty.  
CoVPN 3006  Version  4.0 / May 2 0, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 98 of 166 4. If you want to join this study, after you sign this consent,  you will download 
an electronic diary (eDiary) app and take questionnaires in it.  
We will send you information about how to download the eDiary app onto your 
phone or tablet. We can help you download the  app and show you how to use it.  
To find out if y ou are eligible to join the study, you will answer  questionnaires in 
the eDiary. Some of the questions will ask about your health history, what 
medications you take, your age, r ace, and ethnicity, and where  you live. Your 
answers will tell us about some aspects of your health and if you may be eligible 
to join the study. It should only take about 10 minutes to complete the 
questionnaires.  
Your answers to the questions may show you are not eligible to join th e study, 
even if you want to. We might contact you  to ask some more questions to further 
evaluate wh ether you can join the study.  
In order to use the app you will be asked to agree to t he Terms of Use and Privacy 
Policy which will appear on your mobile de vice’s screen when you first start 
using the app. If you decide that you do not want to agree, then you should not 
participate in the research. While using the app, data about you includ ing personal 
health information, other communication data, and interne t usage will be collected 
and transmitted to the r esearchers and to the app developer. A complete 
description of this data collection and sharing is found in the Privacy Policy. 
Transmission of information via the internet is not completely secure, so ther e is a 
small risk of unintentional release of your  information and safeguards are in place 
to protec t your personal information. While the Terms of Use may include 
statements limiting yo ur rights if you are harmed in this study , you do not release 
the inve stigator, sponsor, institution, or agents from responsibility for mistakes, 
and these statements do not apply to the use of the app in this research study.  
Being in the study  
If you want to join and you are eligible, here is what will happen:  
You will be in the study about 5 months . 
Visits can be done in -person or remotely depending on the type of proced ures that 
need to be done. Visits where you get injections must be done in person.  Remote 
visits will be done whenever possible  to reduce poten tial SARS -CoV -2 exposure.   
You may have to come to the clinic if you have a lab or health issue.  
Site: Insert vi sit lengths.  
Visits can last from [#] to [#] hours.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 99 of 166 At your first visit, we will give you nasal sw ab kits  and instructions  so that you 
can take daily  swabs of your nose. Once you receive your first kit, and for four 
months of the study , you will swab your nose  every day , and you will be 
prompted by text or email to scan the barcode on the swab.  You can  ask us 
questions if you need help . You will return your swabs using drop-off location(s) 
specified by the clinic  or by mail.  
If you are in the immediate vaccination group, we will t ake blood samples in the 
clinic at your first injection visit and 2 more times, two months and four months 
later.  When we take blood, the amount will depend on the lab tests we need to do . 
Each time we take your blood , the total amount we will take will not be more than 
two tablespoons . If for some reason you cannot come t o the clinic, you may be 
asked to self -collect blood using a small device called the Tasso -SST OnDemand.  
Each time you collect your own blood , the amount will be less than one teaspoon.  
We will give you everything you need to take the blood and return it t o us. We 
will be looking at how your body responds to the vaccine and if you been exposed 
to the SARS -CoV -2 virus.   
If you are in the Standard of Care group ( the later vaccination group ), we will t ake 
blood samples in the clinic at the first visit, and 2 more times, two months and 
four months later. Each time we take your blood , the total amount we will take 
will not be more than one teaspoon.  If for some reason you cannot come to the 
clinic, you may be asked to self -collect blood using a small device calle d the 
Tasso -SST OnDemand. Each time you collect your own blood , the amount will be 
less than one teaspoon. We will give  you everything you need to take the blood 
and return it to us. We will be looking to see if you been exposed to the SARS -
CoV -2 virus.   
The self-collection device called the Tasso -SST OnDemand  sticks to the skin with 
a light adhesive. When the button is pr essed, a vacuum forms  and the device will 
prick the surface of the skin. The vacuum draws blood out of the capillaries and 
into a sample pod attached to the bottom of the device.  
You will also take questionnaire s in the eDiary that ask about the results of  any 
SARS -CoV -2 tests  you may have  had. The questionnaires will take about 5 
minutes to complete. You will also take an End of Study questionnaire in the 
eDiary. The eDiary will send your phone or tablet a push notification or you will 
receive a reminder e mail.  
5. We will give yo u the vaccine  on a schedule . 
You will be in one of 2 groups: The Immediate Vaccination group or the Standard 
of Care  group . In the Standard of Care group, you will be offered vaccine at 
Month 4 and 5 if you have not received a vaccine already by then. Rega rdless  of 
which group you are in, you will get 1 injection into your upper arm at 2 separate 
visits during the study.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 100 of 166 We w ill ask you to sign up for v -safe to report any reactions to the study vaccine. 
V-safe is a smartphone -based tool from the Center for Disease Control (CDC) that 
uses text messaging and web s urveys to check in with you after your COVID -19 
vaccination.  
 
 
Procedures for 
Immediate 
Vaccination 
group  Screening 
visit(s)  First 
injection 
visit 1st 
month  2nd 
month  4th 
month  
Injection   √ √   
Medical history 
questionnaire  √ √    
SARS CoV -2 
testing 
questionnaire   About 2x per week  
eDiary app √ About 2x per week  through month 4  
Blood drawn   √  √ √ 
Nasal swab   Daily through month 4  
 
 
 
Procedures for  
Standard of 
Care  group  Screening 
visit(s)  1st 
Day 2nd 
month  First 
injection 
visit (4th 
month)  5th 
month  
Injection     √ √ 
Medical history 
questionnaire  √ √    
SARS CoV -2 
testing 
questionnaire   About 2x per week   
eDiary app √ About 2x per week  through 
month 4  √ 
Blood drawn   √ √ √  
Nasal swab   Daily through month 4   
 
6. We will compensate you for your participation.  
Site: Insert your compensation plan here, e.g. money for number of swabs returned. 
Remember to include any costs to participants.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 101 of 166 7. In addition to giving you the vaccine:  
We wil l ask you to give a referral code to people with whom you expect to be in 
frequent close physi cal proximity during the study, like a roommate or co -worker. 
We want to ask these people to enroll in another part of this study that will help us 
find out if th e vaccine prevents transmission of the SARS -CoV -2 virus. We may 
also ask you to provide us wit h their contact information so that we can reach out 
to them directly . We are calling this group the Prospective Close Contact group or 
PCC.  
As part of their study participation, they will be asked to  complete questionnaires 
like the ones you completed  in the eDiary . If you become infected with SARS -
CoV -2, we will ask you to share your status  with your PCCs. Then  your PCC 
participants will be asked to fill out add itional questionnaire s for 2 weeks  as well 
as take nasal swabs and self-collect blood samples . 
When considering who to ask to be your PCC , you should think about whether 
you feel comfortable or safe  sharing your infection status with  them  if you get 
SARS -CoV-2. If you don’t feel comfortable  sharing this information with them, 
you should not  ask them to participate  as a PCC .  
It is possible that someone you know may also be participating in the Main part of 
the study and might identify you as a close contact . They will not know you are 
also participating in the study unless you choose to tell  them. If someone else 
identifies you as a close contact, they will give you their referral code. It is okay 
to be enrolled in both the Main part of the study and the PCC  group.  
We may also ask you for the name of someone who can tell us how you are doing  
if we can’t reach you or if you are unable to talk. We may contact you after the 
main study ends (for example, to tell you about the study results).  
We will ask you to c ontinue to follow any school  or employer  program for SARS -
CoV -2 testing and contact tr acing , if applicable . If you test positive for SARS -
CoV -2, based on any SARS -CoV -2 testing you receive , please tell us as soon as 
possible.  
8. The CoVPN will test your sampl es to see how your body, including your 
immune system, resp onds to the Moderna COVID -19 vaccine . 
We will send your samples to labs approved by the CoVPN. Your samples will 
not be labeled with your name or other identifying information.  
Researchers may als o do genetic testing related to this study on your samples. 
Your genes are pass ed to you from you r birth parents. Differences in people’s 
genes can help explain why some people get a disease while others do not. The 
genetic testing will only involve some o f your genes, not all of your genes (your 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 102 of 166 genome). The researc hers will study o nly the genes rela ted to the immune system 
and coronavirus, and genes that may affect how people get coronavirus.  
If you get SARS -CoV -2, the researchers may look at all of the v irus’ genes that 
are in your samples. The researchers will use  this information  to learn more about 
SARS -CoV -2 and how the virus is impacted by the study vaccine.  
The tests the researchers do on your samples are for research purposes, not to 
check your hea lth. However, the nasal swab testing you do as part of this study 
may tell us if you are SARS -CoV -2 positive. Nasal swab test results from the 
study will be provid ed to the sites and be made available to you. You may be 
asked to get a confirmatory test. Fo r all other lab tests, we will not provide the 
results to you or the site.  
When your samples are no longer needed for this study, the CoVPN will continue 
to store them . 
9. We will do our best to protect your private information.  
US sites: Check Health Insuran ce Portability and Accountability Act (HIPAA) 
authorization for conflicts with this section.  
We will keep your study records and samples in a secure location. We will label 
all of your samples and most of your records with a code number, not your name 
or other personal information. We will not share your name with anyone who 
does not need to know it.  
Your records may also be reviewed by groups who watc h over this study. These 
groups include:  
▪ Study monitors  
• The CoVPN, people who work for it, and companies th at help it with this 
study  
• Some government agencies:  
o The US National Institutes of Health  
o The US Office for Human Research Protections  
o Any regulatory  agency that reviews research studies  
• Some committees that make sure we protect your rights and keep you sa fe: 
o The Independent Data Monitoring Committee  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 103 of 166 o Advarra Institutional Review Board (IRB)  
o Sites may, but are not required to include:  [Insert name of local IRB/EC]  
o Sites include:  [Insert name of local IBC]  
All reviewers will take steps to keep your records private.  
We cannot guarantee absolute privacy. If you are found to have a medical 
condition that we are required to report by law, then some of your information 
may be shared.  
At this clinic, we have to report the following information:  
Site: Include any public health or legal reporting requirements. Bulleted examples 
should include all appropriate cases (reportable communicable disease, risk of harm 
to self or others, etc.)  
• SARS -CoV -2 
• Pneumonia  
• After receiving the vaccine, we are requir ed to report any of the following that 
may occur to the FDA/CDC Vaccine Adverse Event Reporting System 
(VAERS):  
▪ Vaccine administration errors  
▪ Serious reaction after receiving the vaccine (for exampl e that results in 
death, hospitalization , a life-threatening  reaction, a birth defect, or other 
important medical event ) 
▪ A condition called “Multisystem Inflammatory Syndrome”  
▪ Cases of COVID -19 that r esult in hospitalization  
US sites: Include the following  boxed text. You can remove the box around the text.  
We have a  Certificate of Confidentiality from the US government to help protect 
your privacy. With the certificate, we do not have to release infor mation about 
you to someone who is not connected to the study, such as the courts or police. 
Sometimes we can’t use the certificate. Since the US National Institutes of Health 
funds this research, we cannot withhold information from it.  
The CoVPN may shar e information from this study with  other researchers. 
Researchers may publish the results of this study.  
Site: The text below may not be deleted or changed per FDA requirement. You can 
remove the box.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 104 of 166 A description of this clinical trial will be available  on 
http://www.ClinicalTrials.gov,  as required by U.S. L aw. This Web site will not 
include information that can identify you. At most, the Web site will include a 
summary of the results. You can search this website at any ti me. 
10. We may take you out of the s tudy at any time.  
We may take you ou t of the study if:  
• you do not follow instructions,  
• we think that staying in the study might harm you,  
• the study is stopped for any reason.  
11. If you get COVID -19, we will ask you to do several things.  
If you find out that you have COVID -19, please let us kn ow right away. We wi ll 
ask you to quarantine per local guidelines. By agreeing to join this study, you also 
agree to share any SARS -CoV -2 test results with us.   
We will ask you to tell any one with whom you have recently had close physical 
contact that they  may have been expos ed to COVID -19. We will give you a 
referral code to give to these contacts so that they can decide if they would like to  
join the Case Ascertained Close Contact group (CACC). We may also ask you to 
provide us with their contact information so that we can r each out to them 
directly . You may remember at the beginning of this form that we told you that 
about 2,250  people will be enrolled in the CACC group. The CACC group will 
help us learn if people who got the study vaccine are less likely to give SARS -
CoV -2 to someone else.  When considering who to ask to be your CACC, you 
should think about whether you feel comfortable or saf e sharing your infection 
status with them  if you get SARS -CoV -2. If you don’t feel comfortable sharing 
this information with them, you s hould not ask them to participate as a CACC.  
It is possible that someone you know m ay also be participating in the Main part of 
the study and might identify you as a close contact. They will not know you are 
also participating in the study unless you choos e to tell them. If someone else 
identifies you as a close contact, they will give you their referral code. It is okay 
to be enrolled in both the Main part of the study and the CACC group.  
If you find out that you have COVID -19, you will be directed to con tact the 
clinic, and we will ask you to either come to the clinic to have your blood drawn 
or we will ask you to self-collect  less than one teaspoon of blood and complete 
one additional eDiary questionnaire. It is important that  you give the blood 
sample a s soon as possible after finding out the you have COVID -19. 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 105 of 166 We will ask you to trac k your COVID -19 symptoms using  the eDiary daily for 2 
weeks or until the symptoms go away.  
After you get better, we will  ask you to continue your study participation so that  
we can mo nitor your health and safety for the rest of the study.  
If you are hospi talized, we will pause your pa rticipation. We will ask for your 
medical records and results from tests you might have received at the hospital. It 
is unlikely that you will be hospita lized, but to prepare for this, we will ask you to 
sign and date a medical release of information so we  can get records from your 
doctor or view your hospital records. When you are released from the hospital, 
please let us know. We will ask you t o resume your study participation so that we 
can continue to monitor your health and safety for the rest of the s tudy.  
Site: Modify the following sentence as appropriate.  We will not pay for any of 
your COVID -19 care directly.  
12. If you receive an EUA or lic ensed COVID -19 vaccine outside the study,  we 
will stop your on -study vaccinations but you may continue in the stu dy. 
If you receive an EUA or licensed COVID -19 vaccine outside the study, please let 
us know. We will ask you to tell us what vaccine you recei ved and when you 
received it. You may continue to participate in follow -up visits and procedures 
like swabbing yo ur nose and completing eDiary entries. Your continued 
participation is valuable to help us meet our study goals . 
If you are in the Standard of Care group and  receive COVID -19 vaccination 
outside the study prior to your Month 4 visit, that Month 4 visit will be your last 
visit and can happen remotely . At this visit , we will ask you for a final blood 
sample ( the sample can be self -collected using Tasso-SST OnDemand ) and to 
complete an End of Study questionnaire.  
Other Risks  
13. There are other risks to being in this study.  
This section describes the other risks and restrictions we know about. There may 
also be unknown risks, even serious ones. We will tell you if we learn an ything 
new that may affect your willingness to stay in the study.  
Risks of routine medical procedures:  
In this study, we will do some routine medical procedures. These are taking blood 
and giving injections. These procedures can caus e bruising, pain, faint ing, 
soreness, redness, swelling, itching, a sore, bleeding, and (rarely) muscle damage 
or infection where you got the injection.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 106 of 166 Risks of swabbing your nose:  
The feeling of having a small, soft -tipped swab inserted into your nostril  and 
twirled around may be a little uncomfortable, but it should not be painful. There is 
a small chance there could be some bleeding, but this is unlikely.  
Risks to your personal i nformation:  
We will take several steps to protect your personal informatio n. Although the risk 
is very low, it is possible that your personal information could be given to 
someone who should not have it. If that happened, you could have stress or 
anxiety.  
Risks of genetic testing:  
It is unlikely, but the genetic tests done on y our samples could show you may be 
at risk for certain diseases. If others found out, it could lead to discrimination or 
other problems.  
Risk of anxiety/emotional stress:  
You may feel anxiety or emotional stre ss if you experience any of the risks 
described  here. You may feel worried if tests show that you have SARS -CoV -2. 
Some of the questions we will ask you may make you feel uncomfortable.  
Risk of delaying COVID -19 vaccine:  
COVID -19 vaccines are highly effec tive at preventing COVID -19 illness . The 
Center s for Disease Control and Prevention (CDC) recommend that you receive a 
COVID -19 vaccine  if it is made available to you . By agreeing to potentially del ay 
getting the vaccine you may be at risk for serious illness if you get SARS -CoV -2 
infection.  
Unknown ri sks: 
The vaccine has been shown to prevent adults from getting COVID -19 for at least 
6 months  after their injection, but we do not know if it will prote ct them for any 
longer. If you get COVID -19, we do not know how the vaccine might affect your 
illness. I t is also unknown i f the vaccine will preven t you from giving the virus to 
someone else. If you get COVID -19, we do not know how the vaccine might 
affec t your illness.  
We do no t know if getting this vaccine will affect how you respond to any future 
SARS -CoV-2 vaccines.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 107 of 166 We do  not know if getting the vaccine will affect pregnancy or breastfeeding. If 
you have concerns, we recommend that you discuss this wit h a health care 
provider .  
While you are in this study, you should still follow federal, state , and loca l 
guidelines for SARS -CoV -2 prevention, which may include wearing a mask and 
keeping physical distance from others . If you get sick, you should follow COVID -
19 precautions and isolate or self -quarantine.   
Benefits  
14. This study may not benefit you.  
COVID -19 vaccination helps protect people from getting sick or severely ill with 
COVID -19. This study may help researchers f ind out if the vaccine is able to prevent  
infection with SARS -CoV -2. COVID -19 vaccination is an important tool to help stop the 
COVID -19 pand emic. The CDC recommends you get a COVID -19 vaccine as soon as 
one is available to you.  
If the vaccine later become s approved and sold, there are no plans to share any money 
with you . 
If you decide not to join this study,  you could get the Moderna COVID -19 vaccine or 
another  COVID -19 vaccine in your community . You can also continue to follow federal, 
state, and local guidelines  for SARS -CoV -2 prevention . You do not have to join this 
research study if you don’t want to.  
Your rights and responsibilities  
15. If you join the study, you have rights and responsibilities.  
You have many rights that we will respect . You also have responsibilities. We list 
these in the Bill of Rights and Responsibilities for Research. We will giv e you a 
copy of it.  
Leaving the study  
16. Tell us if you decide to leave the study.  
You are free to leave the study at any time and for a ny reas on. If you want to 
leave, you will need to tell us. Your care at this clinic, your standing at your 
school , and your legal rights will not be affected.  
Previo usly collected information about you will  remain in th e study records and 
will be included in the analysis of results. Your information can not be removed 
from the study records.  
We may ask you to give a final blood sample  or nasal swab .  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 108 of 166 We believe these steps are important to protecting your health, but it is up to you 
whether to complete them.  
Injuries  
Sites: Approval from CoVPN Regulatory Affairs (at CoVPN.core.reg@fredhutch.org) is 
needed for any change (other than those that the instr uctions specifica lly request or those 
previously approved by CoVPN Regulatory Affairs) to the boxed text. You can remove the box 
around the text.  
17. If you get sick or injured during the study, contact us immediately.  
Paragraph below for all sites.   
Your heal th is important t o us. (Sites: adjust the following 2 sentences if 
applicable to the care available at your site)  We will tell you about the care that 
we can give here. For the care that we cannot provide, we will explain how we 
will help you get care else where.  
2 paragra phs below for all sites.   
This research study is covered by a US government program that may provide 
compensation for a serious injury or death. We will give you a handout with more 
information about this program.  The National Institutes of Health (NIH) do es not 
have a mechanism to provide direct compensation for research related injury.  
Some injuries are not physical. For example, you might be harmed emotionally by 
being in this study. Or you might lose wages beca use you cannot go to work. 
However, there a re no funds to pay for these kinds of injuries, even if they are 
study related.  
You always have the right to use the court system if you are not satisfied.  
18. When samples are no longer needed for this study, the C oVPN wants to use 
them in other studies and  share them with other researchers.  
The CoVPN calls these samples “extra samples”. The CoVPN will only allow 
your extra samples to be used in other studies if you agree to this. You will mark 
your decision at the  end of this form.  
Do I have to agree? No. You are free to say yes or no, or to change your mind 
after you sign this form. At your request, the CoVPN will destroy all extra 
samples that it has. Your decision will not affect your being in this study.  
Where  are the samples stored?  Extra samples are stored in a secure central place 
called a repository. Your samples will be stored in the CoVPN repository in the 
United States.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 109 of 166 How long will the samples be stored? There is no limit on how long your extra 
samples  will be stored. [Site: Revise the previous  sentence to insert limits if your 
regulatory authority imposes them.]  
Will I be paid for the use of my samples? No. Researchers may make scientific 
discoveries or products using your samples. If this happens, there is no plan to 
share any money with you.  
Will I benefit from allowing my samples to be used in other studies? Probably not. 
Results from these other stud ies are not given to you, this clinic, or your doctor. 
They may help other people in the future.  
Will the CoVPN sell my samples and informatio n? No, but the CoVPN may share 
your samples with other researchers. Once the CoVPN shares your samples and 
inform ation, it may not be able to get them back.  
What information is shared with researchers? The samples and information will 
be labeled with a cod e number which will not be removed. The key to the code 
will stay at this clinic. However, some information that the CoVPN shares may be 
personal, such as your race, ethnicity, sex, and health information from the study.  
What kind of studies might be done  with my extra samples and information? The 
studies will be related to vaccines, the immune system, coronavirus, and other 
diseases.  Researchers may also do genetic testing on your samples.  
If you agree, researchers may compare all of your genes (your geno me) to the 
genomes of many other people. Researchers look for common patterns of genes to 
help them understand di seases. The researchers may put the information into a 
protected database so that other researchers can access it. Your name and other 
personal  information will not be included.  
Usually, no one could connect your genome to you as a person. There are rules  
against this. It’s also really difficult to do. But there is a risk that someone could 
combine information from your genome and other public i nformation about you 
and identify you. If others found out, it could lead to discrimination or other 
problems. Th e risk of this happening is very small.  
Who will have access to my information in studies using my extra samples?  
People who may see your info rmation are:  
• Researchers who use your extra samples and information for other research  
• Government agencies that f und or monitor the research using your extra 
samples and information  
• The researcher’s Institutional Review Board or Ethics Committee  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 110 of 166 • Any regula tory agency that reviews research studies  
• The people who work with the researcher  
All of these people will do the ir best to protect your information. If they publish 
their research, they will not use your name or identify you personally.  
Questions  
19. Whom to  contact about this s tudy  
During the study, if  you experie nce any medical problems, suffer a research -
related injury, or have questions, concerns , or complaints about the study, please 
contact the study doctor  at the telephone number listed on the first pa ge of this 
consent document. If you seek emergency care, or hospitalization is required, aler t 
the treating physician that you are participating in this research study.  
An institutional review board (IRB) is an independent committee established to help 
protect the rights of research subjects.  
If you have any questions about your rights as a resea rch subject, and/or concerns 
or complaints regarding this research study, contact:  
by mail:  
Study Subject Adviser  
Advarra IRB  
6100 Merriweather Dr., Suite 600 Colum bia, MD 21044  
or call toll free :    877 -992-4724  
or by email :          adviser@advarra.com  
Please reference the following number when contacting the Study Subject 
Adviser: Pro00049375  
US sites may include, but are not required to:  You may also contact the [name of 
local IRB/EC] at [insert contact information].  
Your permission s and signature  
20. In Section 18, w e told you above about possible other uses of your extra 
samples and information outside this study. Please choose only one of the options 
below and wri te your initials in the box next to it. Whatever you choose, the 
CoVPN keeps track of your decision about how your samples and information can 
be used. You can change your mind after signing this form.  
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 111 of 166  I allow my extra samples and information to be used for other studies related to 
vaccines, the immune system, coronavirus, and other diseases. This may include 
genetic testing.  
OR  
 I agree to the option above and also to allow my extra samples and information 
to be used in studies that look at my whole genome.  
OR  
 I do not allow my extra samples to be used in any other studies. This includes 
not allowing genetic testing, or studies that look at my whole genome.   
 
21. If you agree to join this study, you will need to sign below. Before you sign, 
make sure  of the following:  
• You have read this consent form.  
• You feel that you understand what the study is about and what will happen to 
you if you join. You understand what the  possible risks and benefits are.  
• You have had your questions answered and know that yo u can ask more.  
• You agree to join this study.  
• You wi ll not be giving up any of your rights by signing this consent form.  
 
      
Participant’s Name (Print)   Participant’s Signature   Date   
      
Clinic Staff Conducting 
Consent  
Discussion (Print)   Clinic S taff Signature   Date   
 
 
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 112 of 166 Appendix B  Sample informed consent form for Main 
cohort, Vaccine Declined Group  
 
Sponsor / Study Title:  
  National Institutes of Health, “A randomized controlled study to 
assess SARS CoV -2 infection, viral shedding, and subsequent 
potential transmission in individuals  immunized with Moderna 
COVID -19 Vaccine”  
Protocol Number:  
 CoVPN 3006  
Principal Investigator:  
(Study Doctor)  
 «PiFullName»  
 
Telephone:  
 «IcfPhoneNumber»  
 
Address:  «PiLocations»  
 
 
Thank you for your interest in our research study. It is called CoVPN 3006. This 
informed consent form will tell you more about the study. Please read it carefully 
as you decide if you want to jo in. If you have questions, please ask us. At the end, 
we will ask you to answer  a few questions to make sure you understand the study .  
If you decide to join this study, we will ask you to sign this form. We will offer 
you a co py of this form to keep.  
CoV PN 3006  is a research study. Research is not the same as medical care. The 
purpose of a research study is to answer scientific questions. We hope that what 
we learn will help people in the future.  
Key information  
• Joining this r esearch study is voluntary. I t is your choice.  
• Our scientific question s are: Does the vaccine protect people from getting 
infected with a coronavirus called SARS -CoV -2? Does the vaccine prevent 
people from transmitting SARS -CoV -2 to others?  
•  If you join, y our participation in this study will last for about 4-5 months.  
• If you join, we will ask you to answer questionnaires, give blood, and take 
daily swabs of your nose .  
Here are the risks of taking part:  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 113 of 166 • There is a  risk of loss of your personal information .   
• There are other, less serious risks. We will tell you more about them later in 
this consent form.  
About the study  
The COVID -19 Prevention Network (CoVPN) is doing a study to test a vaccine 
against SARS -CoV -2. SARS -CoV -2 is the virus that causes the disea se called 
COVID -19. We want to know if the vaccine is able to protect people from getting 
infected and if getting the vaccine will affect the amount of virus that is in your 
nose. We also want to know if getting the vaccine will prevent transmitting 
SARS -CoV-2 to others.  
Many  young adults  will take part in this study  around the US. This study has 5 
groups. The first 3 groups, called the Immediate Vaccin ation , Standard of Care, 
and Vaccine Declined groups, will be in the Main Study.  
• The Immediate Vaccin ation and Standard of Care groups will have about 
12,000 people that will get vaccine injections either immediately or 4 
months later. In this study, “standard o f care” refers to all federal, state , 
and local recommendations regarding COVID -19 prevention, inc luding 
COVID -19 vaccination, masking, social distancing, isolation and 
quarantine.  
• The Vaccine Declined group will have about 6,000 people who prefer not 
to be vaccinated and will be followed for 4 months.  
• The last two groups are close contacts of the Mai n Study: the Prospective 
Close Contact  (PCC) group will have up to 36,000 people, and the Case -
ascertained Close Contact (CACC) group will have up to 2250 peo ple. 
These close contact groups will help researchers determine if the vaccine 
prevents transmissi on of the SARS -CoV -2 virus to others. We will explain 
more about this later in this form.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 114 of 166  
Because you have indicated that you prefer not to receive a COVID -19 vaccine, 
we are asking you to join the Main part of the study in which people are followed 
for 4 months but do not receive vaccine injections (Vaccine Declined group). If at 
the end of the 4 months you indicate that you prefer to be vaccinated, the 
Mod erna COVID -19 vaccine will be offered to you. If you choose to take up the 
offer of vaccine, you w ill continue in the study another month to receive both 
recommended vaccine doses. The researcher in charge of this study at this clinic 
is [Insert name of site PI] . The US National Institutes of Health is paying for this 
study.  
Joining the study  
1. It is completely up to you whether or not to join this study.  
Take your time in deciding. If it helps, talk to people you trust, such as your 
doctor, friends, or family. If you decide not to join this study, or if you leave it 
after you have  joined, it will not change your healthcare. If you do join, you do 
not give up your legal rights.  

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 115 of 166 You cannot be in this study while you are in another study where you get a study 
product.  
If you choose not to join this study, you may be able to join ano ther study.  If at 
any time you decide you want to get vaccinated, you are fre e to do so . This may 
be in this study (beginning at Month 4) or may be elsewhere at any time. You can  
also get SARS -CoV -2 tested  in your community.  
If you are an employee or relat ive of an employee of a participating site, you are 
under no obligation to pa rticipate in this study. You may withdraw from the study 
at any time and for any reason, and your decision will not have any effect on 
your/your family member’s performance apprai sal or employment at the study 
site. You may refuse to participate or you may withdraw from the study at any 
time without penalty or anyone blaming you.  
If you are a student, your participation will not place you in good favor with the 
study doctor or othe r faculty (for example, receiving better grades, 
recommendations, employment). Also, not participating in this study will not 
adversely affect your relationship with the study doctor or other faculty.  
2. If you want to join this study, after you sign this con sent, you will download 
an electronic diary (eDia ry) app and take questionnaires in it.  
We will send you information about how to download the eDiary app onto your 
phone or tablet. We can help you download the app and show you how to use it.  
To find out i f you are eligible to join the study, you will an swer questionnaires in 
the eDiary. Some of the questions  will ask about your health history , what 
medications you take, your age, race, and ethnicity, and where you live . Your 
answers will  tell us about some  aspects of your health  and if you may be eligibl e 
to join the study . It should only take about 10 minutes to complete the 
questionnaires.  
Your answers to the questions  may show you are not eligible to join the study, 
even if you want to. We might contact you to ask some more questions to further 
evaluat e whether you can join the study.   
In order to use the app you will be asked to agree to the Terms of Use and Privacy 
Policy which will appear on your mobile device’s screen when you first start 
using the ap p. If you decide that you do not want to agree, t hen you should not 
participate in the research. While using the app, data about you including personal 
health information, other communication data, and internet usage will be collected 
and transmitted to th e researchers and to the app developer. A complet e 
description of this data collection and sharing is found in the Privacy Policy. 
Transmission of information via the internet is not completely secure, so there is a 
small risk of unintentional release of y our information and safeguards are in place 
to protect your personal information. While the Terms of Use may include 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 116 of 166 statements limiting your rights if you are harmed in this study, you do not release 
the investigator, sponsor, institution, or agents from responsibility for mistakes, 
and these statements  do not apply to the use of the app in this research study.  
Being in the study  
If you want to join and you are eligible, here is what will happen:  
3. You will be in the study about 4-5 months . 
Visits can be don e in-person or remotely depending on the type of procedures that 
need to be done. If you decide to get vaccine from the study site, v isits where you 
get injections must be done in person. R emote visit s will  be done whenever 
possible to reduce potential SAR S-CoV -2 expo sure.    
You may have to come to the clinic  if you have a lab or health issue.  
Site: Insert visit lengths.  
Visits can last from [#] to [#] hours.  
At your first visit, we will give you nasal swab kits  and instruct ions so that you 
can take daily  swabs of your nose. Once you receive your first kit, and for four 
months of the study, you will swab your nose  every day , and you will be 
prompted  by text or email to scan the barcode on the swab . The questionnai res 
will take about 5 minutes to complete. You can ask us questions if you need help . 
You will return your swabs using drop-off location(s) specified by the clinic  or by 
mail.  
We will t ake blood samples in the clinic at the first visit, and 2 more times, t wo 
months and four months later. Each time we take your blood , the total amount we 
will take will not be more than one teaspoon.  If for some reason you cannot come 
to the clinic, you may be asked to self -collect blood using a small device ca lled 
the Tasso -SST OnDemand. Each time you collect your own blood , the amount 
will be less than one teaspoon. We will give you everything you need to take the 
blood and return it to us. We will be looking to see if you been exposed to the 
SARS -CoV -2 virus.  The self -colle ction device called the Tasso -SST OnDemand  
sticks to the skin with a light adhesive. When the button is pressed, a vacuum 
forms and the device will prick the surface of the skin. The vacuum draws blood 
out of the capillaries and into a sampl e pod attached to the bottom of the device.  
You will also take questionnaire s in the eDiary that ask about the results of any 
SARS -CoV -2 tests you may have had . The questionnaires will take about 5 
minutes to complete. You will also take an End of Study qu estionnaire in the 
eDiary. The eDiary will send your phone or tablet a push notification or you will 
receive a reminder email.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 117 of 166  
Procedures for  
Vaccine Declined 
Group  Screening 
visit(s)  1st 
Day 2nd 
month  4th  
month  
Medical history 
questionnaire  √ √   
SARS -CoV -2 
testing 
questionnaire  About 2x per week  
eDiary app √ About 2 x per week 
through month 4  
Blood drawn   √ √ √ 
Nasal swab   Daily through month 4  
4. At the end of 4 months the study staff will ask you if want to receive the 
Moder na COVID -19 vaccine.  
If you still prefer not to be vaccinated , your study participation will end at Month 
4, which will be the 5th visit.  
If you prefer to be vaccinated, y ou will be consented with a nother  different 
consent form , and your study participati on will last an additional  month .  
5. We will compensate you for your participation.  
Site: Insert your compensation plan here, e.g. money for number of swabs returned. 
Remember to include any costs to partici pants.  
6. We will ask you to refer your close contacts . 
We will ask you to give a referral code to people with whom you expect to be in 
frequent close physical proximity during the study, like a roommate or co -worker. 
We want to ask these people to enroll in another part of this study that will help us 
find o ut if the vaccine prevents transmission of the SARS -CoV -2 virus. We may 
also ask you to provide us with their contact information so that we can reach out 
to them directly . We are calling this group the Pr ospective Close Contact group or 
PCC.  
As part of t heir study participation, they will be asked to complete a weekly 
eDiary that includes questionnaires like the ones you completed. If you become 
infected with SARS -CoV -2, we will ask you to share your stat us with your PCCs. 
Then your PCC participants will be asked to fill out additional questionnaires for 
2 weeks as well as take nasal swabs and self -collect blood samples.  
When considering who to ask to be your PCC, you should think about whether 
you feel co mfortable or safe sharing your infection status wit h them if you get 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 118 of 166 SARS -CoV -2. If you don’t feel comfortable sharing this information with them, 
you should not ask them to participate as a PCC.  
It is possible that someone you know may also be participat ing in the Main part of 
the study and might identif y you as a close contact. They will not know you are 
also participating in the study unless you choose to tell them. If someone else 
identifies you as a close contact, they will give you their referral cod e. It is okay 
to be enrolled in both the Main part of the study and the PCC group.  
We may also ask you for the name of someone who can tell us how you are doing 
if we can’t reach you or if you are unable to talk. We may contact you after the 
main study en ds (for example, to tell you about the study result s). 
We will ask you to c ontinue to follow any school  or employer program for SARS -
CoV -2 testing and contact tracing , if applicable . If you test positive for SARS -
CoV -2, based on any SARS -CoV -2 testing you receive, please tell us as soon as 
possible . 
7. The Co VPN will test your samples to see how your body, including your 
immune system, responds to a potential infection.  
We will send you r samples to labs approved by the CoVPN. Your samples will 
not be labeled with your name or other identifying information.  
Researchers may also do genetic testing related to this study on your samples. 
Your genes are passed to you from your birth parents.  Differences in people’s 
genes can help explain why some people get a disease while others do not. The 
genetic testing will on ly involve some of your genes, not all of your genes (your 
genome). The researchers will study only the genes related to the immun e system 
and coronavirus, and genes that may affect how people get coronavirus.  
If you get SARS -CoV -2, the researchers may loo k at all of the virus’ genes that 
are in your samples. The researchers will use this information to learn more about 
SARS -CoV -2 and how the virus is impacted by the study vaccine.  
The tests the researchers do on your samples are for research purposes, not to 
check your health. However, the nasal swab testing you do as part of this study 
may tell us if you are SARS -CoV -2 positive. Nas al swab test results from the 
study will be provided to the sites and be made available to you. You may be 
asked to get a conf irmatory test. For all other lab tests, we will not provide the 
results to you or the site.  
When your samples are no longer needed  for this study, the CoVPN will continue 
to store them.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 119 of 166 8. We will do our best to protect your private information.  
US sites: Che ck Health Insurance Portability and Accountability Act  (HIPAA ) 
authorization for conflicts with this section.  
We will keep y our study records and samples in a secure location. We will label 
all of your samples and most of your records with a code number, n ot your name 
or other personal information. We will not share your name with anyone who 
does not need to know it.  
Your records may also be reviewed by groups who watch over this study. These 
groups include:  
▪ Study monitors  
• The CoVPN, people who work for it,  and companies that help it with this 
study  
• Some government agencies:  
o The US National Institutes of Health  
o The US Office for Human Research Protections  
o Any regulatory agency that reviews research studies  
• Some committees that make sure we protect your right s and keep you safe:  
o The Independent Data Monitor ing Committee  
o Advarra  Institutional Review Board  (IRB)  
o Sites may , but are not required to include:  [Insert name of local IRB/EC]  
o Sites include:  [Insert name of local IBC]  
All reviewers will take steps to keep your records private.  
We cannot guarantee absolute privacy. If you are found to have a medical 
condition that we are required to report by law, then some  of your information 
may be shared.  
At this clinic, we have to report the following information:  
Site: Include any public health or legal reporting requirements. Bulleted examples 
should include all appropriate cases (reportable communicable disease, ris k of harm 
to self or oth ers, etc.)  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 120 of 166 • SARS -CoV -2 
• Pneumonia  
US sites: Include the following boxed text. You can remove the box around the text.  
We have a Certificate of Confidentiality from the US government to help protect 
your privacy. With the certificate,  we do not have to relea se information about 
you to someone who is not connected to the study, such as the courts or police. 
Sometimes we can’t use the certificate. Since the US National Institutes of Health 
funds this research, we cannot withhold informat ion from it.  
The CoVPN may share information from this study with  other researchers. 
Researchers may publish the results of this study.  
Site: The text below may not be deleted or changed per FDA requirement. You can 
remove the box.  
A description of this clinical trial will be a vailable on 
http://www.ClinicalTrials.gov , as required by U.S. Law . This Web site will not 
include information that can identify you. At most, the Web site will include a 
summary of the results. You can search this website at any time.  
9. We may take you out of the study at any time.  
We may take you out of the study if:  
• you do not follow instructions,  
• we think that staying in the study might harm you,  
• the study is stopped for any reason.  
10. If you get COVID -19, we wi ll ask you to do several things.  
If you find out that you have  COVID -19, please let us know right away.  We will 
ask you to quarantine per local guidelines. By agreeing to join this study, you also 
agree to share any SARS -CoV -2 test results with us.   
We will ask you to tell anyone with whom you have r ecently  had close physical 
contact that they may have been exposed to COVID -19. We will give you a 
referral code to give to  these contacts so that they can decide if they would like to 
join the Case Ascertained Close Contact group (CACC) . We may also ask y ou to 
provide us with their contact information so that we can reach out to them 
directly . You may remember at the beginnin g of this form that we told you that 
about 2250  people will be enrolled in the CACC  group . The CACC group will 
help us learn if peopl e who got the study vaccine are less likely to give SARS -
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 121 of 166 CoV -2 to someone else . When considering who to ask to be your CACC , you 
should think about whether you feel comfortable or safe  sharing your infection 
status with them if you get SARS -CoV -2. If you d on’t feel comfortable sharing 
this information with them, you should not ask them to participate as a CACC.  
It is possible that someone you know may also be participating in the Main part of 
the study and might identify you as a close contact. They will no t know you are 
also participating in the study unless you choose to tell them. If someone else 
identifies you as a close co ntact, they will give you their referral code. It is okay 
to be enrolled in both the Main part of the study and the CACC group.  
If you find out that you have  COVID -19, you will be directed to contact the 
clinic, and we will ask you to either come to the c linic to have your blood drawn 
or we will ask you to self -collect less than one teaspoon of blood and complete 
one additional eDiary questionnaire. It is important that you give the blood 
sample as soon as possible after finding out the you have COVID -19. 
We will ask you to track your COVID -19 symptoms using the eDiary  daily for 2 
weeks or until the symptoms go away.  
After you get bette r, we will ask you to continue your study participation so that 
we can monitor your health and safety for the rest of the s tudy.  
If you are hospitalized, we will pause your participation. We will ask for your 
medical records and results from tests you mig ht have received at the hospital. It 
is unlikely that you will be hospitalized, but to prepare for this, we will ask you to  
sign and date a medical release of information so we can get records from your 
doctor or view your hospital records. When you are re leased from the hospital, 
please let us know. We will ask you to resume your study participation so that we 
can continue to  monitor your health and safety for the rest of the study.  
Site: Modify the following sentence as appropriate.  We will not pay for an y of 
your COVID -19 care directly.  
11. If you receive an EUA or licensed COVID -19 vaccine outside the study, 
please tell us.  
If you receive an EUA or licensed COVID -19 vaccine outside the study, please let 
us know. We will ask you to tell us what vaccine you r eceived and when you 
received it. You may continue to participate in follow -up visits and procedures 
like swabbing your nos e and completing eDiary entries. Your continued 
participation is valuable to help us meet our study goals . 
If you have received COVID -19 vaccination outside the study prior to your 
Month 4 visit, that Month 4 visit will be your last visit  and can happen re motely. 
At this visit, we will ask you for a final blood sample (the sample can be self -
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 122 of 166 collected using Tasso -SST OnDemand) and to co mplete an End of Study 
questionnaire.  
Other Risks  
12. There are other risks to being in this study.  
This section describes the other risks and restrictions we know about. There may 
also be unknown risks, even serious ones. We will tell you if we learn anythin g 
new that may affect your willingness to stay in the study.  
Risks of routine medical procedures:  
In this study, we will do some routine medical procedures. These are taking blood 
and giving injections. These procedures can cause bruising, pain, fainting, 
soreness, redness, swelling, itching, a sore, b leeding, and (rarely) muscle damage 
or infection where you got the injection.  
Risks of swab bing your nose:  
The feeling of having a small, soft -tipped swab inserted into your nostril and 
twirled around may be a  little uncomfortable, but it should not be pai nful. There is 
a small chance there could be some bleeding, but this is unlikely.  
Risks to your personal information:  
We will take several steps to protect your personal information. Although the risk 
is very  low, it is possible that your personal informa tion could be given to 
someone who should not have it. If that happened, you could have stress or 
anxiety.  
Risks of genetic testing:  
It is unlikely, but the genetic tests done on your samples could show you m ay be 
at risk for certain diseases. If others f ound out, it could lead to discrimination or 
other problems.  
Risk of anxiety/emotional stress:  
You may feel anxiety or emotional stress if you experience any of the risks 
described here. You may feel worried if tests show that you have SARS -CoV -2. 
Some of  the questions we will ask you may make you feel uncomfortable.  
Risk of declining  COVID -19 vaccine:  
The Centers for Disease Control and Prevention (CDC) recommend s that you 
receive a COVID -19 vaccine if it is  made available to you. COVID -19 vaccines 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 123 of 166 are highly effective at preventing serious illness. By not getting  the vaccine , you 
may be at risk for serious illness if you get SARS -CoV -2 infection . 
While you are in this stud y, you should still follow federal, state, and local 
guidelines for SARS -CoV -2 prevention, which may include wearing a mask and 
keeping physical distance from others . If you get sick, you should follow COVID -
19 precautions and isolate or self -quarantine.  
Benefits  
13. This study may not benefit you. 
This study may help researchers find out if the vaccine is able to prevent  infection 
with SARS -CoV -2. If the vaccine later becomes approved and sold, there are no 
plans to share any money with you . 
The nasal swab testing you do as part of this study m ay tell us if you are SARS -
CoV -2 positive. Nasal swab test results from the study will be provided to the 
sites and be made available to you. You can still get nasal swab testing for SARS -
CoV -2 at any tim e outside the study.  
Whether or  not you join this s tudy, you could get a COVID -19 vaccine in your 
community. You can also continue to follow local guidelines for SARS -CoV -2 
infection. You do not have to join this research study if you don’t want to.  
Your  rights and responsibilities  
14. If you join the study, you have rights and responsibilities.  
You have many rights that we will respect. You also have responsibilities. We list 
these in the Bill of Rights and Responsibilities for Research. We will give you a 
copy of it.  
Leaving the study  
15. Tell us if you decide t o leave the study.  
You are free to leave the study at any time and for any reason. If you want to 
leave, you will need to tell us. Your care at this clinic , your standing at your 
school,  and your legal rights will not be affected.  
Previously collected info rmation about you will  remain in the study records and 
will be included in the analysis of results. Your  information can not be removed 
from the study records.  
We may ask you to give a f inal blood sample or nasal swab.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 124 of 166 We believe these steps are important  to protecting your health, but it is up to you 
whether to complete them.  
 
Injuries  
Sites: Approval from CoVPN Regulatory Affairs (at CoVPN.core.reg@fredhutch.org) 
is needed for any chan ge (other than those that the instructions specifically request or 
those previously approved by CoVPN Regulatory Affairs) to the boxed text. You can 
remove the box around the text.  
16. If you get sick or injured during the study, contact us immediately.  
Paragr aph below for all sites.   
Your health is important to us. (Sites: adju st the following 2 sentences if 
applicable to the care available at your site)  We will tell you about the care that 
we can give here. For the care that we cannot provide, we will explain how we 
will help you get care elsewhere.  
The National Institutes of Health (NIH) does not have a mechanism to provide 
direct compensation for rese arch related injury.  
Some injuries are not physical. For example, you might be harmed emotionally by 
being in this study. Or you might lose wages because you cannot go to work. 
However, there are no funds to pay for these kinds of injuries, even if they ar e 
study related.  
You always have the right to use the court system if you are not satisfied.  
17. When samples are no longer needed for this study, the CoVPN wants to use 
them in ot her studies and share them with other researchers.  
The CoVPN calls these samp les “extra samples”. The CoVPN will only allow 
your extra samples to be used in other studies if you agree to this. You will mark 
your decision at the end of this form.  
Do I hav e to agree? No. You are free to say yes or no, or to change your mind 
after you sign this form. At your request, the CoVPN will destroy all extra 
samples that it has. Your decision will not affect your being in this study.  
Where are the samples stored?  Extra samples are stored in a secure central place 
called a repository. Y our samples will be stored in the CoVPN repository in the 
United States.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 125 of 166 How long will the samples be stored? There is no limit on how long your extra 
samples will be stored. [Site: Revi se the previous sentence to insert limits if your 
regulatory authority  imposes them.]  
Will I be paid for the use of my samples? No. Researchers may make scientific 
discoveries or products using your samples. If this happens, there is no plan to 
share any m oney with you.  
Will I benefit from allowing my samples to be used in other studies? Probably not. 
Results from these other studies are not given to you, this clinic, or your doctor. 
They may help other people in the future.  
Will the CoVPN sell my samples  and information? No, but the CoVPN may share 
your samples with other researchers. Once the CoVPN shares your samples and 
information, it may not be able to get them back.  
What information is shared with researchers? The samples and information will 
be lab eled with a code number which will not be removed. The key to the code  
will stay at this clinic. However, some information that the CoVPN shares may be 
personal, such as your race, ethnicity, sex, and health information from the study.  
What kind of studie s might be done  with my extra samples and information? The 
studies will be related to vaccines, the immune system, coronavirus, and other 
diseases.  Researchers may also do genetic testing on your samples.  
If you agree, researchers may compare all of your g enes (your geno me) to the 
genomes of many other people. Researchers look for common patterns of genes to 
help them understand diseases. The researchers may put the information into a 
protected database so that other researchers can access it. Your name and  other 
personal  information will not be included.  
Usually, no one could connect your genome to you as a person. There are rules 
against this. It’s also really difficult to do. But there is a risk that someone could 
combine information from your genome and  other public i nformation about you 
and identify you. If others found out, it could lead to discrimination or other 
problems. The risk of this happening is very small.  
Who will have access to my information in studies using my extra samples?  
People who ma y see your info rmation are:  
• Researchers who use your extra samples and information for other research  
• Government agencies that fund or monitor the research using your extra 
samples and information  
• The researcher’s Institutional Review Board or Ethics Commi ttee 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 126 of 166 • Any regula tory agency that reviews research studies  
• The people who work with the researcher  
All of these people will do their best to protect your information. If they publish 
their research, they will not use your name or identify you personally.  
Questions  
18. Whom to  contact about this study  
During the study, if  you experie nce any medical problems, suffer a research -
related injury, or have questions, concerns , or complaints about the study, please 
contact the study doctor  at the telephone number listed on the first pa ge of this 
consent document. If you seek emergency care, or hospitalization is required, alert 
the treating physician that you are participating in this research study.  
An institutional review board (IRB) is an independent committee establi shed to 
help pr otect the rights of research subjects.  
If you have any questions about your rights as a research subject, and/or concerns 
or complaints regarding this research study, contact:  
by mail:  
Study Subject Adviser  
Advarra IRB  
6100 Merriweather Dr.,  Suite 600  
Columbia, MD 2104 4 
or call toll free :    877 -992-4724  
or by email :          adviser@advarra.com  
Please reference the following number when contacting the Study Subject 
Adviser: Pro00049375  
US sites may include , but are not required to:  You may a lso contact the [name of 
local IRB/EC] at [insert contact information].  
Your permissions and signature  
19. In Section 18, we told you above about possible other uses of your extra 
samples and information outside this study. Please choose only one of the optio ns 
below and write your initials in the box next to it. Whatever you choose, the 
CoVPN keeps track of your decision about how your samples and information can 
be used. You can change your mind after signing this form.  
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 127 of 166  I allow my extra samples and informa tion to be used for other studies related to 
vaccines, the immune system, coronavirus, and other diseases. This may include 
genetic testing.  
OR  
 I agree to the option above and also to allow my extra samples and information 
to be used in studies that l ook at my whole genome.  
OR  
 I do not allow my extra samples to be used in any other studies. This includes 
not allowing genetic testing, or studies that look at my whole genome.   
 
20. If you agree to join this study, you will need to sign below. Before you  sign, 
make sure of the following:  
• You have read this consent form.  
• You feel that you understand what the study is about and what will happen to 
you if you join. You understand what the possible risks and benefits are.  
• You have had your questions answered and know that you can ask more.  
• You agree to join this study.  
You will not be giving up any of your rights by signing this consent form.  
 
      
Participant’s Name (Print)   Participant’s Signature   Date   
      
Clinic Staff Conducting 
Consent  
Discussion ( Print)   Clinic Staff Signature   Date   
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 128 of 166 Addendum  Sample informed consent form for Vaccine 
Declined Group participants who decide to take up 
Moderna COVID -19 Vaccine on study  
 
Sponsor / Study Title:  
  National Institutes of Health, “A randomized controlled  study to 
assess SARS CoV -2 infection, viral shedding, and subsequent 
potential transmission in individuals  immunized with Moderna 
COVID -19 Vaccine”  
Protocol Number:  
 CoVPN 3006  
Principal Investigator:  
(Study Doctor)  
 «PiFullName»  
 
Telephone:  
 «IcfPhoneNumber»  
 
Address:  «PiLocations»  
 
Thank you for your interest in getting the Moderna COVID -19 Vaccine through 
the researc h study, CoVPN 3006. Previously you agreed to join this study because 
you did not want to get the vaccine. This informed consent addendum will give 
you more information about getting the Moderna COVID -19 Vaccine. The 
information i n the informed consent you  previously signed still applies. If you 
have questions, please ask us.  
After reviewing this informed consent addendum, if you decide to get the 
Moderna COVID -19 vaccine in this study, we will ask you to sign this form. We 
will o ffer you a copy of this fo rm to keep.  
1. This study’s vaccine has an Emergency Use Authorization (EUA) for 
individuals 18 and older.  
The vaccine we use in this study is called the Moderna COVID -19 Vaccine. The 
vaccine has been given to over 15,000 people in other research studies and  over 
100 million people under EUA. We will give you the most up -to-date “Fact Sheet 
for Recipients and C aregivers” with more information about the Moderna 
COVID -19 Vaccine. The person giving you the vaccine can answer any questions 
you might have about wh at is in this fact sheet.  
We already know that the vaccine can prevent serious COVID -19 disease, but we 
do not know if the vaccine will work to prevent SARS -CoV -2 infection in others. 
That is what we are testing in this study.  
The Moderna COVID -19 Vaccin e is not approved for sale in the United States by 
the US Food and Drug Administration (FDA).  
CoVPN 3006  Version  4.0 / May 20,  2021  
CoVPN 3006_v4.0_Final.docx  / Page 129 of 166 Although t he vaccine is not approved, it has an Emergency Use Authorization 
(EUA) from the FDA based on its success at preventing disease symptoms from 
SARS -CoV -2 in other studies to date. During a public health emergency, like the 
COVID -19 pandemic, the FDA can iss ue an EUA to get vaccines to people faster. 
When the FDA issues an EUA, they continue to monitor safety.  
The vaccine was developed by ModernaTX, Inc. Typical vaccines for viruses are 
made from a weakened or killed virus, but the Moderna COVID -19 Vaccine  is not 
made from the SARS -CoV -2 virus. The vaccine includes a short segment of 
messenger ribonucleic acid (mRNA). The mRNA is a genetic code that tells cells 
how to make a protein. This mRNA is made in a laboratory. When injected into 
the body, the mRNA vac cine causes some cells to make that viral protein, which 
can trigger the immune system. Your immune system protects you from disease. 
If a person is la ter infected, their immune system remembers the protein from the 
vaccine which may help it to fight the v irus. It is impossible for the vaccine to 
give you SARS -CoV -2 or COVID -19 infection.  
Risks of the Moderna COVID -19 Vaccine:  
To date, more than 100 mil lion people have already received the Moderna 
COVID -19 Vaccine. In clinical trials, most people who got t he vaccine had some 
reaction after their injections, especially after the second injection. The reaction to 
the vaccine didn’t affect their daily lives  and it went away after two or three days. 
Most of these people said they had pain in the arm where they got the injection. 
These people also felt tired, had headaches, muscle and joint pain, and chills. A 
much smaller number of these people said they had redness or swelling where the 
needle went in their arm. Some people had swelling of the lymph nodes in th e 
same arm of the injection.  
The risks of the study vaccine seen so far are the same as what have been seen 
with most vaccines. Generally, vaccines can  cause fever, chills, rash, aches and 
pains, nausea, headache, dizziness, and feeling tired. Vaccines can  also cause 
pain, redness, swelling, or itching where you got the injection. Most people can 
still do their planned activities after getting a vaccine.  Rarely, people have side 
effects that limit their normal activities or make them go to the doctor.  
Rarel y, a vaccine can cause you to have an allergic reaction. You might have a 
rash, hives, swelling of your face and throat, a fast heartbeat, dizziness an d 
weakness, or trouble breathing. Allergic reactions can be life -threatening. Tell us 
if you have e ver ha d a bad reaction to any injection or vaccine.  
There may be other risks that we don’t yet know about, even serious ones. We 
will tell you if we learn ab out any new risks.  
Unknown risks:  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 130 of 166 The vaccine has been shown to prevent adults from getting COVID -19 for at least 
6 months after their injection, but we do not know if it will protect them for any 
longer. If you get COVID -19, we do not know how the vaccine  might affect your 
illness. It is also unknown if the vaccine will prevent you from giving the virus to 
someone else. If you get COVID -19, we do not know how the vaccine might 
affect your illness.  
We do no t know if getting this vaccine will affect how you respond to any future 
SARS -CoV -2 vaccines.  
We do  not know if getting the vaccine will affect pregnancy or breastfeeding. If 
you have concerns, we recommend that you discuss this with a health care 
provider.  
While you are in this study, you should still follow federal, state , and local 
guidelines for SARS -CoV -2 prevention, which may include  wearing a mask and 
keeping physical distance from others . If you get sick, you should follow COVID -
19 precautions and iso late or self -quarantine.   
Agreeing to get the v accine  
2. You will receive the vaccine on a schedule.  
If you choose, and if you have not received a vaccine by  your Month 4 study visit 
and choose to be vaccinated , you will get the 1st injection of the vaccine at your 
Month 4 study visit. Study staff will sc hedule you to get your 2nd injection about 4 
weeks  later.  In total, y ou will get 1 injection in your upper arm at 2 separate visits 
during the study.  
We w ill ask you to sign up for v -safe to report any reactions to the study vaccine. 
V-safe is a smartphone -based tool from the Center for Disease Control (CDC) that 
uses text messaging and web surveys to check in with you after your COVID -19 
vaccination.  
3. We will do our best to protect yo ur private information.  
US sites: Check Health Insurance Portability and A ccountability Act (HIPAA) 
authorization for conflicts with this section.  
We will keep your study records and samples in a secure location. We will label 
all of your samples and most of your records with a code number, not your name 
or other personal inform ation. We will not share your name with anyone who 
does not need to know it.  
Your records may also be reviewed by groups who watch over this study. These 
groups include:  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 131 of 166 • Study m onitors  
• The CoVPN, people who work for it, and companies that help it with this  
study  
• Some government agencies:  
▪ The US National Institutes of Health  
▪ The US Office for Human Research Protections  
▪ Any re gulatory agency that reviews research studies  
• Some commi ttees that make sure we protect your rights and  keep you safe:  
▪ The Independent Data Monitoring Committee  
▪ Advarra Institutional Review Board (IRB)  
▪ Sites may, but are not required to include:  [Insert name of local IRB/EC]  
All reviewers will take steps to keep your records private.  
We cannot guaran tee absolute privacy. If you are found to have a medical 
condition that we are required to report by law, then some of your information 
may be shared.  
At this clinic, we have to report the following information:  
Site: Include any public health or legal r eporting requirements. Bulleted examples 
should include all appropriate cases (reportable communicable disease,  risk of harm 
to self or others, etc.)  
• SARS -CoV -2 
• Pneumonia  
• After you receiv e the vaccine, we are required to report any of the following 
to the  FDA/CDC Vaccine Adverse Event Reporting System (VAERS):  
▪ Vaccine administration errors  
▪ Serious reaction after r eceiving the vaccine (for example that results in 
death, hospitalization, a life -threatening reaction, a birth defect, or other 
important medical  event)  
▪ A condition called “Multisystem Inflammatory Syndrome”  
▪ Cases of COVID -19 that result in hospitalization  
US sites: Include the following boxed text. You can remove the box around the text.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 132 of 166 We have a  Certificate of Confidentiality from the US governm ent to help protect 
your privacy. With the certificate, we do not have to release information about 
you to someone who is not connected to the study, such as the courts or police. 
Sometimes we can’t use th e certificate. Since the US National Institutes of Health 
funds this research, we cannot withhold information from it.  
The CoVPN may share information from this study with  other researchers. 
Researchers may publish the results of this study.  
4. It is comple tely up to you whether or not to get the vaccine in  this study.  
Take your time in deciding. If it helps, talk to people you trust, such as your 
doctor, friends, or family. If you decide not to get vaccine in this study, or if you 
decide to get it outside o f this study, it will not change your healthcare.  
If you decide not to get vaccine in this study, you could get the Moderna COVID -
19 vaccine or another COVID -19 vaccine in your community. You can also 
continue to follow local guidelines for SARS -CoV -2 infection. You do not have 
to get vaccine in this stud y if you don’t want to.  
If you are an employee or relative of an employee of the study site, you are under 
no obligation to get vaccine in this study. You may decline to get vaccine from 
the study at any time and for any reason, and your decision will not  have any 
effect on your/your family member’s performance appraisal or employment at the 
study site. If you change your mind  at any time, there will be no penalty, and no 
one will get mad at you.  
If you are a student, your decision to get vaccine in this s tudy will not place you 
in good favor with the study doctor or other faculty (for example, receiving better 
grades, recommendations, employment). Also, not getting vaccine in this study 
will not adversely affect your relationship with the study doctor or o ther faculty.  
5. We will compensate you for getting the vaccine.  
Site: Insert your compensation plan here, e.g. money for number of study visits completed . 
Remember to include any costs to participants.  
Benefits  
6. This study may not benefit you . 
COVID -19 vaccin ation helps protect people from getting sick or severely ill with 
COVID -19. This study may help researchers find out if the vaccine is able to 
prevent  infection with SARS -CoV -2. COVID -19 vaccination is an important tool 
to help st op the COVID -19 pandemic. The CDC recommends you get a COVID -
19 vaccine as soon as one is available to you.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 133 of 166 If the vaccine later becomes approved and sold, there are no plans to share any 
money with you . 
Injuries  
Sites: Approval from CoVPN Regulatory Affairs (at CoVPN.core.reg@fred hutch.org) 
is needed for any change (other than those that the instructions specifically request or 
those previously approved by CoVPN Regulatory Affairs) to the boxed text. You can 
remove the box around the text.  
7. If you get sick or injured during the stud y, contact us immediately.  
Paragraph below for all sites.   
Your health is important to us. (Sites: adjust the following 2 sentences if 
applicable to the care available at your site)  We will tell you about the care that 
we can give here. For the care that w e cannot provide, we will explain how we 
will help you get care elsewhere.  
2 paragraphs below for all sites.   
This research study is covered by a US government program that may provide 
compensation for a serious i njury or death. We will give you a handout  with more 
information about this program. The National Institutes of Health (NIH) does not 
have a mechanism to provide direct compensation for research related injury.  
Some injuries are not physical. For example, you might be harmed emotionally by 
being i n this study. Or you might lose wages because you cannot go to work. 
However, there are no funds to pay for these kinds of injuries, even if they are 
study related.  
You always have the right to use the court syste m if you are not satisfied.  
 
Questions  
8. Whom to contact about this study  
During the study, if you experie nce any medical problems, suffer a research -
related injury, or have questions, concerns, or complaints about the study, please 
contact the study doctor  at the telephone number listed on the fi rst page of this 
consent document. If you seek emergency care, or hospitalization is required, alert 
the treating physician that you are participating in this research study.  
An institutional review board (IR B) is an independent committee established to 
help protect the rights of research subjects.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 134 of 166 If you have any questions about your rights as a research subject, and/or concerns 
or complaints regarding this research study, contact:  
by mail:  
Study Subject Advi ser 
Advarra IRB  
6100 Merriweather Dr., Suite 60 0Columbia, MD 21044  
or call toll free :    877 -992-4724  
or by email :          adviser@advarra.com  
Please reference the following number when contacting the Study Subject 
Adviser: Pro00049375  
US sites may include, but are not required to:  You may also contac t the [name of 
local IRB/EC] at [insert contact information].  
Your permissions and signature  
9. If you agree to join this study, you will need to sign below. Before you sign, 
make sure of the following:  
• You have read this consent form.  
• You feel that you unde rstand what the study is about and what will happen to 
you if you join. Y ou understand what the possible risks and benefits are.  
• You have had your questions answered and know that you can ask more.  
• You agree to join this study.  
• You wi ll not be giving up an y of your rights by signing this consent form.  
 
      
Participant’s Name (Print)   Participant’s Signature   Date   
      
Clinic Staff Conducting 
Consent  
Discussion (Print)   Clinic Staff Signature   Date   
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 135 of 166 Appendix C  Sample informed consent form for 
Prospective  Close Contact  (PCC)  cohort  
 
Sponsor / Study Title:  
  National Institutes of Health, “ A randomized controlled study to 
assess SARS CoV -2 infection, viral shedding, and subsequent 
potential transmission in individuals  immunized with Moderna 
COVID -19 Vaccine ” 
Prot ocol Number:  
 CoVPN 3006  
Principal Investigator:  
(Study Doctor)  
 «PiFullName»  
 
Telephone:  
 «IcfPhoneNumber»  
 
Address:  «PiLocations»  
 
Thank you for your interest in our research study. It is called CoVPN 3006. This 
informed consent form will tell you more about the study. Please read it carefully to help  
you decide if you want to join. If you have questions, please ask us.   
If you decide  to join this study, we will ask you to sign this form. We will offer you a 
copy of this form to keep.  
CoVPN 3006 is a research study. Research is not the same as medical care. The purpose 
of a research study is to answer scientific questio ns. We hope tha t what we learn will help 
people in the future.  
Key information  
• Joining this research study is voluntary. It is your choice.  
• Our scientific question s are: Does the study vaccine protect people from 
getting infected with a coronavirus called SARS -CoV -2? Does the study 
vaccine prevent people from transmitting SARS -CoV -2 to others?  
• If you join, your participation in this study will last for about 5 month s. 
• If you join, we will ask you to answer eDiary  questionnaire s. If you or your 
contact in th e main study group becomes SARS -CoV -2 infected,  then we will 
ask you to  take daily swabs of your nose , answer daily eDiary questionnaire 
for 2 weeks , and give 2 blood samples .  
Here are the risks of taking part:  
• There is a  risk of loss of your personal inf ormation .  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 136 of 166 • There are other, less serious risks. We will tell you more about them later in 
this consent form.  
About the study  
The COVID -19 Prevention Network (CoVPN) is doing a study to test a vaccine 
against SARS -CoV -2. SARS -CoV -2 is the virus that causes the disease called 
COVID -19. We want to know if the vaccine is able to protect people from getting 
infected and if getting the vaccine will affect the amount of virus that is in your 
nose. We also want to know if getting the vaccine will preven t transmitti ng 
SARS -CoV -2 to others.  
We are asking you to join this study because you have been referred as a close 
contact with someone who is in the Main study.  
Many  young adults  will take part in this study  around the US. This study has 5 
groups. The first 3 grou ps, called the Immediate Vaccin ation , Standard of Care, 
and Vaccine Declined groups, will be in the Main Study.  
• The Immediate Vaccin ation  and Standard of Care groups will have about 
12,000 people that will get vaccine injections either immediately or 4 
months later. In this study, “standard of care” refers to all federal, state , 
and local recommendations regarding COVID -19 prevention, inclu ding 
COVID -19 vaccination, masking, social distancing, isolation and 
quarantine.  
• The Vaccine Declined group will have about 6,000 people who prefer not 
to be vaccinated and will be followed for 4 months.  
• The last two groups are close contacts of the Main Study: the Prospective 
Close Contact  (PCC) group will have up to 36,000 people, and the Case -
ascertained Close Contact  (CACC) group will have up to 2250 people. 
These close contact groups will help researchers determine if the vaccine 
prevents transmission  of the SARS -CoV -2 virus to others. We will explain 
more about this later in this form.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 137 of 166 You are being asked to parti cipate in the PCC group. The researcher in charge of 
this study at this clinic is [Insert name of site PI] . The US National Institutes of 
Health is paying for this study.  
Joining the study  
1. It is completely up to you whether  or not t o join this study.  
Take your tim e in deciding. If it helps, talk to people you trust, such as your 
friends or family. If you deci de not to  join this study, or if you leave it after you 
have joined, it w ill not change your healthcare. If you do join, you do  not give up 
your legal rights.  
If you are an employee or relative of an employee of the study site , you are under 
no obligation to participate in this study. You may withdraw from the study at any 
time and for any reason, and your decision will not have any effect on your/your 
family member’s performance appraisal or employment at the study site . You 
may refuse to participate or you may withdraw from the study at any time without 
penalty or anyone blaming you.  

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 138 of 166 If you are a student, your participation will  not place you  in good favor with the 
study doctor or other faculty (for example, re ceiving better g rades, 
recommendations, employment). Also, not participating in this study will not 
adversely affect your relationship with the study doctor or other facult y. 
Being in the study  
If you want to join, here is what will happen:  
We will send you information ab out how to download an electronic diary (eDiary) 
app onto your phone or tablet. We c an help  you download the app and show you 
how to use it. In order to use  the app you will be asked to agree to the Terms of 
Use and Privacy Policy w hich will appear on your  mobile device’s screen when 
you first start using the app. If you decide that you d o not w ant to agree, then you 
should not participate in the research. Wh ile using the app, data about you 
including personal health information, oth er communication data, a nd internet 
usage will be collected and transmitted to the researchers and to the ap p 
devel oper. A complete description of this data collection and sharing is found in 
the Privacy Policy. Transmission of information via the internet  is not completely 
secure, so there is a small risk of unintentional release of your information and 
safegua rds are  in place to protect your personal information. While the Terms o f 
Use may include statements limiting your rights if you are harmed in this study, 
you do not release the investigator, sponsor, institution, or agents from 
responsibility for mistakes , and these statements do not apply to the use of the app 
in this resear ch study.  
Initially, you will answer a 5 -minute questionnaire in the eDiary.  It will ask you 
about things such as your sex, age, race , and ethnicity. During the study, y ou will 
also answer questi onnaires about whether you are sick or if you have tested 
positive for SARS -CoV -2. You will take an End of Study questionnaire in the 
eDiary at your last study visit . If you are a student, you may get SARS -CoV -2 
testing at your school about twice a week. If you have tested positive, you will 
enter  the results of your SARS -CoV -2 tests taken at school  or another location  
into the eDiary . 
If you or your contact in the main study group becomes SARS -CoV -2 infected, 
then we will ask you to take swabs of your nose and answer eDiary questionnaire s 
every day for 2 weeks . You will be prompted by text or email to scan the barcode 
on the swab. You will return your nasal swabs using drop-off location(s) specified 
by the clinic  or by mail.  
We will ask you to self -collect a small amount of your blood twice  using  a small  
device calle d the Tasso -SST OnDemand . You will ta ke the first blood sample as 
soon as possible  once  you begin the daily swabs , and then you will take another 
sample about a month later.  This will be less than one teaspoon of blood taken 
from one of your upper arms usi ng a small device. We will give you everything 
you need to take the  blood  and return it  to us.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 139 of 166 The self -collection device sticks to the skin with a light adhesive. When the 
button is pressed, a vacuum forms , and the device will prick the surface of the 
skin. The vacuum draws blood out of the capillaries and into a sample pod 
attached to the bottom of the device.  
It is important that you continue to follow the federal , state , and local guidelines  
for SARS -CoV -2 prevention, which may include wearing a mask a nd keeping 
physical distance fr om others. If you get COVID -19 and are hospitalized, we will 
pause your participation. We will ask for your medical records and results from 
tests you might have received at th e hospital. It is unlikely that yo u will be 
hospi talized, but to prepare for thi s, we will ask you to sign and date a medical 
release of infor mation so we can get records from your doctor or view your 
hospital records. When you are released from the hospit al, please let us know. We 
will as k you to resume  your study participation so th at we can continue to monitor 
your health and safety for the r est of the study.  
We will not pay for any of your COVID -19 care directly.  
2. The CoVPN will test your samples to see how your body, including your 
immune system, resp onds to the potential infection . 
We will send your samples to labs approved by the CoVPN. You r samples will 
not be labeled with your name or other identifying information.  
Researchers may also do genetic te sting related to this study on you r samples. 
Your  genes are passed to y ou from your birth parents. Differences in people’s 
genes can help expl ain why some people get a disease while others do not. The 
genetic testing will only involve some of your genes, n ot all of your genes (your 
genome) . The researche rs will study only the  genes related to the immune system 
and coronavirus, and genes that may  affect how people get coronavirus.  
If you get SARS -CoV -2, the researchers may look at all of the virus’ genes tha t 
are in your samples. The researc hers will use t his information to lea rn more about 
SARS -CoV -2 and how the virus is impacted by the study vac cine.  
The tests the researchers do on your samples are for research purposes, not to 
check your health. However, t he nasal swab testing you may do a s part of this 
study may tell us if y ou are SARS -CoV -2 positive. Nasal swab test results from 
the study will  be provided to the sites and be made available to you. You may be 
asked to get a confirmatory test. For all other  lab tests, we will not provide th e 
results to yo u or the site.  
When yo ur samples are no longer needed for this study, the CoVPN will continue  
to store them.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 140 of 166 3.  When samples are no longer needed for this study, the CoVPN wants to use 
them in other studies and share them with other researchers.  
The CoVPN c alls these samples “extra samples”. The CoVPN will only allow 
your extra samples to be used i n other studies i f you agree to this. You will mark 
your decision at the end of this form.  
Do I have to agree? No. You are free to say yes or no, or to change you r mind 
after you sign this form. At your request, the CoVPN will destroy all extra 
samples that it has. Your d ecision will not affect your being in this study.  
Where are the samples stored?  Extra samples are stored in a secure central place 
called a reposi tory. Your samples will be stored in the CoVPN repository in the 
United States.  
How long will the samples be s tored? There is no limit on how long your extra 
samples will be stored. [Site: Revise the previous sentence to insert limits if your 
regulatory au thority imposes them.]  
Will I be paid for the use of my samples? No. Researchers may make scientific 
discoveri es or products using your samples. If this happens, there is no plan to 
share any money with you.  
Will I benefit from allowing my samples to be u sed in other studies? Probably not. 
Results from these other studies are not given to you, this clinic, or you r doctor. 
They may help other people in the future.  
Will the CoVPN sell my samples and information? No, but the CoVPN may share 
your samples with  other researchers. Once the CoVPN shares your samples and 
information, it may not be able to get them back.  
What information is shared with researchers? The samples and information will 
be labeled with a code number which will not be removed. The key to t he code 
will stay at this clinic. However, some information that the CoVPN shares may be 
personal, such as you r race, ethnicity, sex, and health information from the study.  
What kind of studies might be done  with my extra samples and information? The 
studies will be related to vaccines, the immune system, coronavirus, and other 
diseases.  
Researchers may also do g enetic testing on your samples.  
If you agree, researchers may compare all of your genes (your genome) to the 
genomes of many other people. Researc hers look for common patterns of genes to 
help them understand diseases. The researchers may put the informati on into a 
protected database so that other researchers can access it. Your name and other 
personal information will not be included.  
CoVP N 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 141 of 166 Usually, no one could connect your genome to you as a person. There are rules 
against this. It’s also really difficult to do. But there is a risk that someone could 
combine information from your genome and other public information about you 
and identify you. If others  found out, it could lead to discrimination or other 
problems. The risk of this happening is very small.  
Who will have access to my information in studies using my extra samples?  
People who may see your information are:  
• Researchers who use your extra samp les and information for other research  
• Government agencies that fund or monitor the research using your extra 
samples and information  
• The researcher’s Institutional Review Board or Ethics Committee  
• Any regulatory agency that reviews research studies  
• The pe ople who work with the researcher  
All of these people will do their best to protect your information. If  they publish 
their research, they will not use your name or identify you personally.  
4. We will  compensate you for your participation.  
Site: Insert your c ompensation plan here, e.g. money for number of swabs returned. 
Remember to include any costs to participants.  
5. We wi ll do our best to protect your private information.  
Site: Check HIPAA authorization for conflicts with this section.  
Your study records and samples will be kept in a secure location. We will label all 
of your samples and most of your rec ords with a code number, not your name or 
other personal information. We will not share your name with anyone who does 
not need to know it.  
Your records may al so be reviewed by groups who watch over this study. These 
groups include:  
• Study monitors  
• The CoVP N, people who work for it, and companies that help it with this 
study  
• Some government agencies:  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 142 of 166 o The US National Institutes of Health  
o The US Office for Human Re search Protections  
o Any regulatory agency that reviews research studies  
• Some committees that make sure we protect your rights and keep you safe:  
o The Independent Data Monitoring Committee  
o Advarra Institutional Review Board (IRB)  
o Sites may but are not require d to include:  [Insert name of local IRB/EC]  
o Sites include:  [Insert name of local IBC]  
All reviewers will take steps to keep your records private.  
Sites: Include the following boxe d text. You can remove the box around the text.  
We have a Certificate of Confidentiality from the US government to help protect 
your privacy. With the certificate, we do not have to release information about 
you to someone who is not connected to the study , such as th e courts or police. 
Sometimes we can’t use the certificate. Since the US National Institutes of Health 
funds this research, we cannot withhold information from it.  
The CoVPN may share information from this study with  other researchers. 
Researc hers may pub lish the results of this study.  
Sites: The text below may not be deleted or changed per FDA requirement. You can 
remove the box.  
A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov, as required by U.S. Law. This Web sit e will not 
include information that can identify you. At most, the Web site will include a 
summary of the results. You can search this website at any time.  
6. We may take you out of the study at any time.  
We may take you out of the study if:  
• you do not follow instructions,  
• we think that staying in the study might harm you,  
• the study is stopped for any reason.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 143 of 166 Risks  
7. There are some risks to being in this study.  
This section describes the risks we know about. There may also be unknown risks, 
even ser ious on es. We will tell you if we learn anything new that may affect your 
willingness to stay in the study.  
Risks of blood draws:  
In this study, we will either take your blood or ask you to self -collect your blood 
with a small device. Taking blood can caus e bruis ing, pain, fainting, soreness, 
redness, and itching.  
Risks of swabbing your nose:  
The feeling of having a small, soft -tipped swab inserted into your nostril and 
twirled around may be a little uncomfortable, but it should not be painful. There is 
a small c hance there could be some bleeding, but this is unlikely.  
Risks to your personal information:  
We will take several steps to protect your personal information. Although the risk 
is very low, it is possible that your personal information could be giv en to 
someone who should not have it. If that happened, you could have stress or 
anxiety.  
Risks of COVID -19:  
While you are in this study, you should still follow federal, state , and local 
guidelines for SARS -CoV -2 prevention, which may include  wearing a m ask an d 
keeping physical distance from others . If you get sick, you should follow COVID -
19 precautions and isolate or self -quarantine.   
Benefits  
8. This study may not benefit you . 
This study may help researchers find out if people who got the vaccine are les s 
likely to give it to people who they have been in close  contact with . If the vaccine 
later becomes approved and sold, there are no plans to share any money with you . 
You do not  have to join this research study if you don’t want to.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 144 of 166 Leaving the study  
9. Tell us if you decide to leave the study.  
You are free to le ave the study at any time and for any reason. If you want to 
leave, you will need to tell  us. Your legal rights will not be affected.  
Previously collected information about you will  remain in the stu dy re cords and 
will be included in the analysis of results. Your  information can not be removed 
from the study records.  
We may ask you to give a final blood sample  or nasal swab .  
We believe these steps are important to protecting your health, but it is up  to you 
whether to complete them.  
Injuries  
Sites: Approval from CoVPN Regulatory Affairs (at CoVPN.core.reg@fredhutch.org) 
is needed for any change (other than those that the instructions specifically request or 
those previously approved by CoVPN Regulator y Affairs) to the boxed text. You can 
remove the box around the text.  
10. If you have a life -threatening medical emergency, call 911 right away or seek 
help immediately.  
We do not expect you to get sick or injured as a result of being in this study. I f 
you get  COVID -19 while you are in the study, please let us know. (Sites: adjust 
the following 2 sentences if applicable to the care available at your site)  We will 
tell you about the care that we can give here. For the care that we cannot provide, 
we wil l explain  how we will help you get care elsewhere. You or your health 
insurance will have to pay for the care you get elsewhere.  
Some injuries are not physical. For example, you might be harmed emotionally by 
being in this study. Or you might lose wages be cause you  cannot go to work. 
However, there are no funds to pay for these kinds of injuries, even if they are 
study related.  
You always have the right to use the court system if you are not satisfied.  
Questions  
11. Whom to contact about this study  
During the study, if  you experie nce any medical problems, suffer a research -
related injury, or have questions, concerns , or complaints about the study, please 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 145 of 166 contact the study doctor  at the telephone number listed on the first page of this 
consent document.  
An institutional  review board (IRB) is a n independent committee established to 
help protect the rights of research subjects.  
If you have any questions about your rights as a research subject, and/or concerns 
or complaints regarding this research study, contac t: 
by mail:  
Study Subject Adviser  
Advarra IRB  
6100 Merriweather Dr., Suite 600  
Columbia, MD 2104 4 
or call toll free :    877 -992-4724  
or by email :          adviser@advarra.com  
Please reference the following number when contacting the Study Subject 
Adviser: Pro00049375  
US sites may include, but are not required to:  You may also contact the [name of 
local IRB/EC] at [insert contact information].  
Your permissions and signature  
12. In Section 3, w e told you above about possible other uses of your extra 
samples and information o utside this study. Please choose only one of the options 
below and write your initials in the box next to it. Whatever you choo se, the 
CoVPN keeps track of your decision about how your samples and information can 
be used. You can change your mind after sig ning this form.  
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 146 of 166  I allow my extra samples and information to be used for other studies related to 
vaccines, the immune system,  coronavirus, and other diseases. This may include 
genetic testing.  
OR  
 I agree to the option above and also to allow my extr a samples and information 
to be used in studies that look at my whole genome.  
OR  
 I do not allow my extra samples to be used in any other studies. This includes 
not allowing genetic testing, or studies that look at my whole genome.   
 
13. If you agree to jo in this study, you will need to sign below. Before you sign, make 
sure of the following:  
• You have read this consent form.  
• You feel that you understand what the study is about and what will happen to 
you if you join. You understand what the possible risks a nd benefits are.  
• You agree to join this study.  
You will not be giving up any of your rights by signing this consent form.  
 
      
Participant’s Name (Print)   Participant’s Signature   Date   
      
Clinic Staff Conducting 
Consent  
Discussion (Print)   Clinic Staff Signature   Date   
 
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 147 of 166 Appendix D  Sample informed consent form for Case -
Ascertained Close Contact  (CACC)  cohort  
 
Sponsor / Study Title:  
  National Institutes of Health, “ A randomized controlled study to 
assess SARS CoV -2 infection, viral shedding, and subsequent 
potential transmission in individuals  immunized with Moderna 
COVID -19 Vaccine ” 
Protocol Number:  
 CoVPN 3006  
Principal Investigator:  
(Study Doctor)  
 «PiFullName»  
 
Telephone:  
 «IcfPhoneNumber»  
 
Address:  «PiLocations»  
 
Thank you for your interest in our research study. It is called CoVPN 3006. This 
informed consent form will tell you more about the study. Please read it care fully 
to help you d ecide if you want to join. If you have questions, please ask us.  
If you decide  to join this study, we will ask  you to sign  this form. We will offer 
you a copy of this form to keep.  
CoVPN 3006 is a research study. Research is not the sa me as medical care.  The 
purpose of a research study is to answer scientific questions. We hope tha t what 
we learn will help people in the futu re. 
Key information  
• Joining this research study is voluntary. It is your choice.  
• Our scientific question s are: Does the study vaccine protect people from getting 
infected with a coronavirus called SARS -CoV -2? Does the study vaccine prevent 
people from transmitting SARS -CoV -2 to others?  
• If you join, your participation in this study will last for about 1 month.  
• If you j oin, we will ask you to answer questionnaire s, give blood, and take daily 
swabs of your nose f or 2 weeks.  
Here are the risks of taking part:  
• There is a  risk of loss of your personal information .  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 148 of 166 • There are other, less serious risks. We will tell you more about them later in this 
consent form.  
About the study  
The COVID -19 Prevention Network (CoVPN) are doing a study to test a vaccine 
against SARS -CoV -2. SARS -CoV -2 is the virus that causes the disease called 
COVID -19. We are asking you to join this study bec ause you recently had close 
physical contact with someo ne who is in the Main study and who got infected 
with SARS -CoV -2. We want to find out if the person you had close physical 
contact might have transmitted SARS -CoV -2 to you.  
Many  young adults  will take  part in this study  around the US. This study has 5 
groups. The first 3 groups, called the Immediate Vaccin ation , Standard of Care, 
and Vaccine Declined groups, will be in the Main Study.  
• The Immediate Vaccin ation  and Standard of Care groups will have abo ut 
12,000 people that will get vaccine injections eithe r immediately or 4 
months later. In this study, “standard of care” refers to all federal, state , 
and local recommendations regarding COVID -19 prevention, including 
COVID -19 vaccination, masking, social  distancing, isolation and 
quarantine.  
• The Vaccine Decl ined group will have about 6,000 people who prefer not 
to be vaccinated and will be followed for 4 months.  
• The last two groups are close contacts of the Main Study: the Prospective 
Close Contact  (PCC)  group will have up to 36,000 people, and the Case -
ascertained Close Contact (CACC) group will have up to 2250 people. 
These close contact groups will help researchers determine if the vaccine 
prevents transmission of the SARS -CoV -2 virus to others. We wil l explain 
more about this later in this form.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 149 of 166 You are being asked to participate in the CACC group. The researcher in charge 
of this study at this clinic is [Insert name of site PI] . The US National Institutes of 
Health is paying f or this study.  
Joining the study  
1. It is complete ly up to you whether or not to join this study.  
Take your time i n deciding. If it helps, talk to people you trust, such as your 
friends or family. If you decide not to join t his study, or if y ou leave it afte r you 
have joined, it will not change your healt hcare. If you do join, you do not give up 
your legal rights.  
If you are an employee or relative of an employee of the study site , you are under 
no obligation to participate in this study. You may withdraw fr om the study at any 
time and for any reason, and  your decision will not have any effect on your/your 
family member’s performance appraisal or employment at the study site . You 
may refuse to participate or you may withdraw from the study at any time without  
penalty or anyone blaming you.  
If you are a stu dent, your participation will not place you in good favor with the 
study doctor or other faculty (for example, receiving better grades, 

CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 150 of 166 recommendations, employment). Also, not part icipating in this study will  not 
adversely affect your relationship with the  study doctor or other faculty.  
Being in the study  
If you want to join , here is what will happen:  
We will send you information about how to download an electronic diary (eDiary) 
app onto your phone or tablet.  We can help you download the app and show you 
how to use it. In order to use the app you will be asked to agree to the Terms of 
Use and Privacy P olicy which will appear on your mobile device’s screen when 
you first start using the app. If you decide that you do not want to agree, then  you 
should not participate in the research. While using the app, data about you 
includi ng personal health informati on, other communication data, and internet 
usage will be collected and transmitted  to the researchers and to t he app 
developer. A complete d escription of this data collection and sharing is found in 
the Privacy Policy. Transmiss ion of information via the i nternet is not completely 
secure, so there is a small risk of unintentional releas e of your information and 
safeguards are in place to prote ct your personal information. While the Terms of 
Use may include statements limiting you r rights if you are harmed i n this study, 
you do not release the investigator, sponsor, institution, or agents  from 
responsibility for mis takes, and these statements do  not apply to the use of the app 
in this research study.  
You will take a 5 -minute questi onnaire in the eDiary. It wi ll ask you about your 
contact with the person who tested positive for SARS -CoV -2, as well as other 
things such  as your sex, age, race , and ethnicity.  You will also take an End of 
Study questionnaire in the eDiary. If you have t ested positive for SARS -CoV -2, 
you will enter the results of your SARS -CoV -2 tests taken at school  or another 
location  into the eDiary.  
If you are affiliated with a school that provides SARS -CoV -2 testing , you may get 
tested  about twice a week . 
We will ask you to take daily swabs of both of your nostrils  and track your 
COVID -19 symptoms in the eDiary daily for two weeks . You will be prompted 
by text or email to scan the barcode on the swab. You will return your nasal 
swabs using drop-off location (s) specified by the clinic or by mail.  
We will also ask you  to collect a small amount of blood from one of your upper 
arms twice during the study  using a small device called the Tasso -SST 
OnDemand . This will be less than one teaspoon of blood taken from one of your 
upper arms using a small device. You will take the first blood sample as soon as 
possible, and then you will take another sample about a mo nth later.  We will give 
you everything you need to take these samples and return them  to us.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 151 of 166 The se lf-collection device sticks to the skin with a light adhesive. When the 
button is pressed, a vacuum forms , and the device will prick the surface of the 
skin. The vacuum draws blood out of the capillaries and into a sample pod 
attached to the bottom of the device.  
It is important that you continue to follow the federal, state , and local guidelines 
for SARS -CoV -2 prevention, which may include  wearing a mask and  keeping 
physical distance from others.  
If you are hospitalized, we will pause your participation. We will ask for your 
medical records and results from tests you might have received at the hospital. It 
is unlikely that you will be hospitalized, but to pr epare for this, we will ask you to 
sign and date a medical release of information so we can get reco rds from your 
doctor or view your hospital records. When you are released from the hospital, 
please let us know. We will ask you to resume your study partic ipation so that we 
can continue to monitor your health and safety for the r est of the study.  
2. The CoV PN will test your samples to see how your body, including your 
immune system, resp onds to the potential infection . 
We wil l send your samples to labs approve d by the CoVPN. Your samples will 
not be labeled with your name or other id entifying information.  
Researchers may also d o genetic testing related to this study on your samples. 
Your genes are passed to you from your birt h parents. Differences in people’s 
genes can help explain why some people get a disease while others do not. T he 
genetic testing will only involve some of y our genes, not all of your genes (your 
genome). The researchers will study only the genes related to  the immune system 
and coronavirus,  and genes that may affect how people get coronavirus.  
If you get SARS -CoV -2, the researchers may look at all of the viru s’ genes that 
are in your samples. The researchers will use this information to learn more about 
SAR S-CoV -2 and how the virus is impact ed by the study vaccine.  
The tests the researchers do on your samples are f or research purposes, not to 
check your health . However, the nasal swab testing you do as part of this study 
may tell us if you are SARS -CoV -2 positive. Nasal swab test results from  the 
study will be provided to the sites and be made available to you. You may be 
asked to get a confirmatory test. For a ll other lab tests, we will not provide the 
results to you or the site.  
When your samples are no lo nger needed for this study, the CoV PN will continue 
to store them.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 152 of 166 3. When samples are no longer needed for this study, the CoVPN wants to use 
them in other studies and share them with other researchers.  
The CoVPN calls these samples “extra samples”. The CoV PN will only allow 
your extra sampl es to be used in other studies if you agree to this. You will mark 
your dec ision at the end of this form.  
Do I have to agree? No. You are free to say yes or no, or to change your mind 
after you sign this form. At your request, the CoVPN will destroy all e xtra 
samples that it has. Your decision will not affect your being in this study.  
Where are the samples stored?  Extra samples are stored in a secure central place 
called a repository. Your samples will be stored in the CoVPN repository in the 
United States . 
How long will the samples be stored? There is no limit on how long your extra 
samples will be stored. [Site: Revise the previous sentence to insert limits if your 
regulatory authority imposes them.]  
Will I be paid for the use of my samples? No. Researche rs may make scientific 
discoveries or products using your samples. If this happens, there is no plan to 
share a ny money with you.  
Will I benefit from allowing my samples to be used in other studies? Probably not. 
Results from these other studies are not g iven to you, this clinic, or your doctor. 
They may help other people in the future.  
Will the CoVPN sell my sam ples and information? No, but the CoVPN may share 
your samples with other researchers. Once the CoVPN shares your samples and 
information, it may  not be able to get them back.  
What information is shared with researchers? The samples and information will 
be labeled with a code number which will not be removed. The key to the code 
will stay at this clinic. However, some information that the CoVPN sha res may be 
personal, such as your race, ethnicity, sex, and health information from the study.  
What kind of st udies might be done  with my extra samples and information? The 
studies will be related to vaccines, the immune system, coronavirus, and other 
diseases.  
Researchers may also do genetic testing on your samples.  
If you agree, researchers may compare all of yo ur genes (your genome) to the 
genomes of many other people. Researchers look for common patterns of genes to 
help them understand diseases. The r esearchers may put the information into a 
protected database so that other researchers can access it. Your name  and other 
personal information will not be included.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 153 of 166 Usually, no one could connect your genome to you as a person. There are rules 
against this . It’s also really difficult to do. But there is a risk that someone could 
combine information from your genome  and other public information about you 
and identify you. If others found out, it could lead to discrimination or other 
problems. The risk of thi s happening is very small.  
Who will have access to my information in studies using my extra samples?  
People wh o may see your information are:  
• Researchers who use your extra samples and information for other research  
• Government agencies that fund or monito r the research using your extra 
samples and information  
• The researcher’s Institutional Review Board or Ethics Committee  
• Any regulatory agency that reviews research studies  
• The people who work with the researcher  
All of these people will do their best to pr otect your information. If they publish 
their research, they will not use your name or identify you per sonally.  
4. We will  compensate you for your participation.  
Site: Insert your compensation plan here, e.g. money for number of swabs returned. 
Remember to in clude any costs to participants.  
5. We will do our best to protect your private information.  
Site: Check HIPAA authorization for conflicts with this section.  
Your study records and samples will be kept in a secure location. We will label all 
of your samples a nd most of your records with a code number, not your name or 
other personal information. We will  not share your name with anyone who does 
not need to know it.  
Your records may also be reviewed by groups who watch over this study. These 
groups include:  
• Study monitors  
• The CoVPN, people who work for it, and companies that help it with this 
study  
• Some go vernment agencies:  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 154 of 166 o The US National Institutes of Health  
o The US Office for Human Research Protections  
o Any regulatory agency that reviews research studies  
• Some co mmittees that make sure we protect your rights and keep you safe:  
o The Independent Data Monitorin g Committee  
o Advarra Institutional Review Board (IRB)  
o Sites may but are not required to include:  [Insert name of local IRB/E C]  
o Sites include:  [Insert name of local IBC]  
All reviewers will take steps to keep your records private.  
Sites: Include the following boxed text. You can remove the box around the text.  
We have a Certificate of Confi dentiality from the US government to help protect 
your privacy. With the certificate, we do not have to release information about 
you to someone who is not connected to the study, such as the courts or police. 
Sometimes we can’t use the certificate. Since the US National Inst itutes of Health 
funds this research, we cannot withhold information from it.  
The CoVPN may share information from this study with  other researchers. 
Researchers may publish the results of this study.  
Sites: The text below may not be deleted or changed p er FDA requirement. You can 
remove the box.  
A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov, as required by U.S. Law. This website will not 
include information that can identify you. At most, the website will include  a 
summary of the results. You can search this website at any time.  
6. We may take you out of the study at any time.  
We may take you out of the study if:  
• you do not follow instructions,  
• we think that staying in the study might harm you,  
• the study is stopped for any reason.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 155 of 166 Risks  
7. There are some  risks to being in this st udy.  
This section describes the risks we know about. There may also be unknown 
risks, even serious ones. We will tell you if we learn anything new that may affect 
your willi ngness to st ay in the study.  
Risks of blood draws:  
In this study, we will either take your blood or ask you to self -collect your blood 
with a small device. Taking blood can cause bruising, pain, fainting, soreness, 
redness, and itching.  
Risks of swabbing your nose:  
The feeling of having a small, soft -tipped swab inserted into your nostril and 
twirled around may be a little uncomfortable, but it should not be painful. There is 
a small chance there could be some bleeding, but this is unlikely.  
Risks to your  personal in formation:  
We will take several steps to protect your personal information. Although the risk 
is very low, it is possible that your personal information could be given to 
someone who should not have it. If that happened, you could have stress o r 
anxiety.  
Risks of COVID -19:  
While you are in this study, you should still follow federal, state , and local 
guidelines for SARS -CoV -2 prevention, which may include  wearing a mask and 
keeping physical distance from others . If you get sick, you should fol low COVID -
19 precautions and isolate or self -quarantine.   
Benefits  
8. This study may not benefit you.  
This study may help researchers find out if people who got the vaccine and later 
got infected with SARS -CoV -2 are less likel y to giv e it to people who they have 
been in close contact with . If the vaccine later becomes approved and sold, there 
are no plans to share any money with you . 
You do not have to join this research study if you don’t want to.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 156 of 166 Leaving the study  
9. Tell us if  you decide to leave the study.  
You are free to leave the study at any time and for any  reason. If you want to 
leave, you will need to  tell us. Your legal rights will not be affected.  
Previously collected information about you will  remain in the study records and 
will be included in the analysis of results. Your  information can  not be removed 
from the study records.  
We may ask you to give a final blood sample  or nasal swab .  
We believe these steps are important to protecting your he alth, but it is up to you 
whether to complete them.  
Injur ies 
Sites: Approval from CoVPN Regulatory Affairs (at CoVPN.core.reg@fredhutch.org) 
is needed for any change (other than those that the instructions specifically request or 
those previously approved by CoVPN Regulatory Affairs) to the boxed text. You can 
remove the box around the text.  
10. If you have a life -threatening medical emergency, call 911 right away or seek 
help immediately.  
We do not expect you to get sick or injured as a result of being in this study. If 
you get COVID -19 while you are in the study, p lease let us know.  (Sites: adjust 
the following 2 sentences if applicable to the care available at your site)  We will 
tell you about the care that we can give here. For the care that we cannot pr ovide, 
we will explain how we will help you get care elsewher e. You or your health 
insurance will have to pay for the care you get elsewhere.  
Some injuries are not physical. For example, you might be harmed emotionally by 
being in this study. Or you might lose wages because you cannot go to work. 
However, there are no funds to pay for these kinds of injuries, even if they are 
study related.  
You always have the right to use the court system if you are not satisfied.  
Questions  
11. Whom to contact about this stud y 
During the study, if  you experie nce any medical problems, s uffer a research -
related injury, or have questions, concerns , or complaints about the study, please 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 157 of 166 contact the study doctor  at the telephone number listed on the first page of this 
consent docum ent.  
An institutional review board (IRB) is a n independent c ommittee established to 
help protect the rights of research subjects.  
If you have any questions about your rights as a research subject, and/or concerns 
or complaints regarding this research stud y, contact:  
by mail:  
Study Subject Adviser  
Advarra IRB  
6100 M erriweather Dr., Suite 600  
Columbia, MD 2104 4 
or call toll free :    877 -992-4724  
or by email :          adviser@advarra.com  
Please reference the following number when contacting the Study Subject 
Adviser: Pro00049375  
Sites may include, but are not required to: You may also contact the [name of 
local IRB/EC] at [insert contact information].  
Your permissions and signature  
12. In Section 3, we told you above about possible other uses of your extra 
samples and information outside this study. Please choose only one of the options 
below and write your initials in the box next to it. Whatever you choo se, the 
CoVPN keeps track of your decision about how your samples and information can 
be used. You can change your mind after signing this form.  
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 158 of 166  I allow my extra samples  and information to be used for other studies related to 
vaccines, the immune system,  coronavirus, and other diseases. This may include 
genetic testing.  
OR  
 I agree to the option above and also to allow my extra samples and information 
to be used in st udies that look at my whole genome.  
OR  
 I do not allow my extra samples to be used in any other studies. This includes 
not allowing genetic testing, or studies that look at my whole genome.   
 
13. If you agree to join this study, you will need to sign below . Before you sign, 
make sure of the following:  
• You have read this consent form.  
• You feel that you understand what the study is about and what will happen to 
you if you join. You understand what the possible risks and benefits are.  
• You agree to join this st udy. 
You will not be giving up any of your rights by signing this consent form.  
 
      
Participant’s Name (Print)   Participant’s Signature   Date   
      
Clinic Staff Conducting 
Consent  
Discussion (Print)   Clinic Staff Signature   Date   
 
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 159 of 166 Appendix E  Procedures for Main Cohort , Immediate 
Vaccination Group  
 
Visit:  011 022 03 04 05 06 
Day:   D1 D29 D57 D113  D141  
Week:   W0 W4 W8 W16  W20  
Month:   M0 M1 M2 M4 M5 
Procedure  Scr. VAC1  VAC2     
Study procedures        
Screening consent (if used)  ✓ – – – – – 
Assessment of un derstanding  ✓ – – – – – 
Protocol consent (eConsent)  ✓ – – – – – 
Medical history questionnaire3 ✓ ✓ – – – – 
SARS -CoV -2 infection risk 
assessment3 ✓ Weekly   
COVID -19 symptom surveillance3 – Weekly starts at week 2, not during week 5   
Confirm eligibilit y ✓ – – – – – 
Obtain demographics3 ✓ – – – – – 
Randomize  – ✓ – – – – 
SARS -CoV -2 testing  questionnaire3 – approximately 2x per week   
End of study questionnaire3 – – – – ✓ – 
Research Samples4       
Serum for Immunogenicity Assays 
and Storage  – ✓ – ✓ – – 
Serum for SARS -CoV -2 clinical 
serology5 – ✓6 – ✓6 ✓ – 
Nasal swab  – Daily7 – 
Vaccination procedures        
COVID -19 symptom check8 – ✓ ✓ – – – 
Vaccination  – ✓ ✓ – – – 
 
Greyed out visit column does not apply to this group.  
1 Screening may occur over the course of several contacts/visits up to and including day 
1, prior to vaccination.  
2 Blood draw s required at vaccination visit s must be performed prior to vaccination . 
3 Results from screening at school, if applicable, or at other locations  will be cap tured via 
eDiary, please see Section  9.16. 
4 From screening to the final study visit, the total blood vo lume to be collected from each 
participant will be approximately 40 mL (maximum) with a maximum of approxima tely 
17 mL collected in a single visit .  
5 For blood self -collected by a participant the maximum volume will be less than 1 mL  in 
a single collection . 
6 SARS -CoV -2 clinical serology testing may be performed on leftover blood from 
samples collected for immu nogenicity assays. No separate blood sample  is needed.  If a 
Main cohort  participant is also in the Prospective Close Contact ( PCC ) cohort  related to 
CoVPN 3006  Version  4.0 / May 20, 2 021 
CoVPN 3006_v4.0_Final.docx  / Page 160 of 166 an index case  or in the Case -ascertained Close Contact  (CACC)  cohort , one additional 
blood collection (self -collection) will be performed ( see table below  ). 
7 Daily swabs will be collected from  vaccination through D113. Swabs will be returned 
via drop-off location(s) specified by the clinic or through the mail.  
8 COVID -19 Symptom Check to be performed within 2 4 hours prior to vaccination.  
 
The following additional  procedures will occur f or Main cohort , immediate  vaccination 
participants , who fall under any of the following categories:  
•  tested positive for SARS -CoV -2 from enrollment through Month 4  (see Section  9.7) 
•  enrolled also in the  PCC cohort and are related to an index case  (see Section  9.8) 
•  enrolled also in the  CACC  cohort  (see Section 9.9) 
 
Day relative to notification o f infection:  D1-14 
Study procedures   
Symptom tracking  via eDiary  daily  
Research Samples   
Serum for SARS -CoV -2 clinical serology1  ✓2 
1 For blood self-collected by a participant the maximum volume will be less than 1 mL in a 
single collection.  
2 Sample  for serology will be collected as soon as possible following  report of  positive 
SARS -CoV -2 test . 
 
In addition, we ma y ask participants  to sign a rele ase to allow us to review their COVID -19 
related  medical records .  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 161 of 166 Appendix F  Procedures for Main Cohort, Standard of  
Care  and Vaccine Declined Group s 
 
Visit:  011 02 03 04 05 06 
Day:   D1 D29 D57 D113  D141  
Week:   W0 W4 W8 W16  W20  
Month:   M0 M1 M2 M4 M5 
Procedure  Scr.    VAC1  VAC2  
Study procedures        
Screening consent (if used)  ✓ –  – – – 
Assessment of understan ding ✓ –  – – – 
Protocol consent (eConsent)  ✓ –  – – – 
Medical history questionnaire2 ✓ ✓  – – – 
SARS -CoV -2 infection risk 
assessment2 ✓ Weekly  – 
COVID -19 symptom surveillance2 – Weekly  – 
Confirm eligibility  ✓ –  – – – 
Obtain demographics2 ✓ –  – – – 
Randomize , Standard of Care Group 
only  – ✓  – – – 
SARS -CoV -2 testing  questionnaire2 – approximately 2x per week  – 
End of study questionnaire2 – –  – ✓7 ✓ 
Research Samples        
Serum for SARS -CoV -2 clinical 
serology3 – ✓  ✓ ✓ – 
Nasal swab  – Daily4 – 
Vaccination procedures6       
COVID -19 symptom check5 – –  – ✓ ✓ 
Vaccination  – –  – ✓ ✓ 
Greyed out visit does not apply to this group.  
1 Screening may occur over the course of several contacts/visits up to and 
including day 1, prior to randomization.  
2 Results from screening at school, if applicable, or at other locations w ill be 
captured via  eDiary, please see Section 9.16. 
3 From screening to the final study visit, the total blood volume to be collected 
from each participant will be app roximately 15 mL (maximum) with a 
maximum of approximately 5 mL collected in a single visit. For blood self -
collected by a participant the maximum volume will be less than 1 mL in a 
single collection.  If a Main cohort partici pant is also in the Prospective  Close 
Contact (PCC) cohort related to an index case or in the Case -ascertained Close 
Contact (CACC) cohort, one additional blood collection (self -collection) will be 
performed (see table below) . 
4 Daily swabs will be collect ed from D1 through D113. Swabs will be returned 
via drop-off location(s) specified by the clinic or through the mail.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 162 of 166 5 COVID -19 Symptom Check to be performed within 24 hours prior to 
vaccination.  
6 Vaccination procedures  only appl y to participants who hav e not received 
COVID -19 vaccine outside the study and for participants in the Vaccine 
Declined Group who request to be vaccinated.  
7 Only applies  to participants who are not  receiving  vaccination on study, ie, 
who have already recei ved COVID -19 vaccine out side the study or who have 
declined vaccination  (Visit 5 will be the last study visit for these participants) . 
The following additional  procedures will occur  for Main cohort, standard of care  and 
vaccine declined  participants , who fall under any of the fol lowing categories:  
• tested positive for SARS -CoV -2 from enrollment through Month 4  (see 
Section 9.7) 
• enrolled also in the PCC cohort and are related to an index case (see Section  
9.8) 
• enrolled also in the CACC cohort (see Section 9.9) 
 
Day relative to notification of infection:  D1-14 
Study procedures   
Symptom tracking  via eDiary  daily  
Research Samples   
Serum for SARS -CoV -2 clinical serology1  ✓2 
1For blood self-collected  by a participant the maximum volume will be  less than 1 mL 
in a single collection.  
2 Sample for serology will be collected as soon as possible following report of 
positive SARS -CoV -2 test  
 
In addition, we may ask participants to sign a release to  allow us  to review their 
COVID -19 related medical records.  
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 163 of 166 Appendix G  Procedures for Prospective Close Contact 
(PCC) c ohort  
 
Visit:  100 101 
Day:  D1 D113 
Month:  M0 M4 
 Enrollment  Follow -up 
Study procedures    
Protocol consent (eConsent)  ✓ – 
Obtain demographics1  ✓ – 
SARS -CoV -2 testing  questionnaire1 approximately 2x per week  
End of study questionnaire1 – ✓ 
1 Results from screening at school, if applicable, or at other locations w ill be captured via  
eDiary, please see Section 9.16. 
 
If a PCC participant (or their Main study  contact ) tests positive for SARS -CoV -2, the 
following additional  procedures will occur:  
Day relative to notification of 
infection:  D1 D29 
Study procedures    
Report of exposure1 ✓  
Symptom tracking1 Daily for 14 
days – 
Research Samples    
Serum for SARS -CoV -2 clinical 
serology2  ✓ ✓ 
Nasal swab3 Daily for 14 
days – 
1 Will be captured via eDiary , please see Section 9.16. 
2For blood self-collected by a particip ant the maximum volume will be  less than 1 mL 
in a single collection . Sample for serology will be collected as soon as possible 
following report of positive SARS -CoV -2 test.  
3Swabs will be returned via drop-off location(s) specified by the clinic or throug h the 
mail.  Nasal swabs  will be collected as soon as possible following report of positive 
SARS -CoV -2 test.  
 
In addition, we may ask participants to  sign a release to allow us to review their 
COVID -19 related medical records.  
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 164 of 166 Appendix H  Procedures for Case -Ascertain ed Close 
Contact Cohort  
 
Visit:  200 201 202 
Day:  D1 D1-D3 D29 
Month:  M0 M0 M1 
 Enrollment  Initial specimen 
collection  Follow -up 
Study procedures     
Protocol consent (eConsent)  ✓ – – 
Collection of demographic 
information1 ✓ – – 
Report of exposure1 ✓ – – 
Symptom tracking1  Daily for 14 days  – 
SARS -CoV -2 testing questionnaire1 approximately 2x per week  
End of study questionnaire1 – – ✓ 
Research Samples     
Serum for SARS -CoV -2 clinical 
serology2   ✓ ✓ 
Nasal swab3   Daily for 14 days  – 
1Results fro m screening at school, if applicable, or at other locations w ill be captured 
via eDiary , please see Section 9.16. 
2 For blood self -collected by  a participant the maximum volume will be  less than 1 
mL in a single collection . Sample for se rology will be collected as soon as possible 
following report of positive SARS -CoV -2 test  (ie, as early as Day 1 ). 
3Swabs will be returned via drop-off location(s) specified by the clinic  or through the 
mail.  Nasal swabs  will be co llected as soon as possible following report of positive 
SARS -CoV -2 test  (ie, as early as Day 1 ). 
 
In addition, we may ask participants to sign a release to allow us to review their 
COVID -19 related medical records.  
 
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 165 of 166 Appendix I  Visit windows  
Main Cohort , Immediate V accination,  Visit Windows  
Visit 
Number  Visit Type  Lower 
Allowable 
Window  Lower 
Target Day Target 
Day1 Upper 
Target Day Upper Allowable 
Window   
01.0 Screening  -56 -  - 0 
02.0 Enrollment /Randomization
2 - - 1 - - 
03.0 Vaccination 2  - -3 293 +7 +14 
04.0 Month 2 Follow -up  - -7 57 +7 +14 
05.0 Month 4 Follow -up  -13 -7 113 +14 +56 
1.Target dates are relative to Visit 2.0  (Enrollment /Randomization ), except for cases described in footnote 3. 
2. Completion of post en rollment activities may occur  up to approxi mately 7 days post enrollment  (see Section  9.3) . 
3. In the event that Vaccination 1 occur s on a different day  than Visit  2.0 (Enrollment/Randomization) , Visit 3.0  target dates are 
relative to date of Vaccination 1 .   
Main Cohor t, Standard of Care and Vaccine Declined , Visit Windows  
Visit 
Number  Visit Type  Lower 
Allowable 
Window  Lower Target 
Day Target 
Day1 Upper Target 
Day Upper Allowable 
Window   
01.0 Screening  -56 -  - 0 
02.0 Enrollment /Randomizatio n2 - - 1 - - 
04.0 Month 2 Follow -up  - -7 57 +7 +14 
05.0 Vaccination 13  -13 -7 113 +14 +28 
06.0 Vaccination 21, 3  - -3 141 +7 +14 
1. Target dates are relative to Visit 2.0  (Enrollment /Randomization ), except visit 06.0, which is relative to visit 05.0.   
2. Completion o f post enrollment activities may occur up to approximately 7 days post enrollment (see Section  9.5) . 
3. Vaccination visits only apply to participants who have not received COVID -19 vaccine outside the study and for participants  in 
the Vaccine Declined Group who request to be vaccinated.  
Case-Ascertained Close  Contact  (CACC) Cohort and applicable Prospective Close 
Contact (PCC) participants1, Visit Windows  
Visit 
Number  Visit Type  Lower 
Allowable 
Window  Lower Target 
Day Target 
Day2 Upper Target 
Day Upper Allowable 
Window   
200.0 Enrollment - - 1 - - 
201.0 Initial blood specimen 
collection   -2 3 +1 +4 
202.0 Day 2 9 Follow -up  - -7 29 +14 +28 
1. Applicable to PCC participants when they (or their Main study contact) tests positive  for SARS -CoV-2. 
2. Target dates are relative to Visit 200.0 (Enrollment).   
CoVPN 3006  Version  4.0 / May 20, 2021  
CoVPN 3006_v4.0_Final.docx  / Page 166 of 166 Appendix J  Protocol Signature Page  
 
A randomized controlled study to assess SARS CoV -2 infection, viral shedding, 
and subsequent potential transmission in individuals immunized with Moderna 
COVID -19 Vaccine  
I will conduct the study in accordance with the provisions of this protocol and all 
applicable protocol -related documents. I agree to conduct this study in 
compliance with United States (U .S.) Health and  Human Service regulations (45 
CFR 46); applicable U.S. Food and Drug Administration regulations; standards of 
the International Council for Harmonisation of T echnical Requirements for 
Pharmaceuticals for Human Use (ICH)  Guideline for Good Clinical Practic e (E6)  
(R2); Institutional Review Board/Ethics Committee determinations; all applicable 
in-country, state, and local laws and regulations; and other applicable  
requirements ( eg, U.S. National Institutes of Health, Division of AIDS) and 
institutional polici es. 
 
 
 
 
     
Investigator of Record  Name  (print)   Investigator of Record  Signature   Date  
 
 
Protocol Number: CoVPN 3006  
Protocol Version: Version 4.0  
Protocol Date: May 20, 2021  
 